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Abstract 
The most common cancer in women is breast cancer with approximately 1 in 8 women 
developing this disease in their lifetime. Clinically, breast cancer can be divided into distinct 
subtypes based on the presence or absence of hormone receptors such as estrogen receptor (ER), 
progesterone receptor (PR) and expression of the HER2 gene. In this project, one of the most 
difficult to treat subclasses - triple-negative (ER-/PR-/HER2-) breast cancer (TNBC) is studied. 
Until now, very limited drug treatment strategies are available for TNBCs because of a lack of 
hormone receptors as potential drug targets. Thus, it is a matter of urgency to seek specific 
treatment tailored to TNBC patients. This raises the prospect that antiretroviral drugs might be 
able to repurpose as anticancer drugs for TNBCs. In the mid-1990s, the incidence of the AIDS-
related cancers was greatly reduced in the HIV patients due to the introduction of antiretroviral 
therapy to the HIV patients. It has been suggested that a direct inhibitory effect of antiretroviral 
drugs on the reverse transcriptase activity of long interspersed nuclear element 1 (LINE-1) in 
tumour cells could be a crucial factor. LINE-1 is the most important transposon with 
autonomous retro-transposition ability in humans. It can alter gene regulations and cause 
somatic mutations. Since LINE-1 has the potential to adversely affect individuals, it is silenced 
in differentiated tissues by diverse endogenous mechanisms. Nonetheless, LINE-1 is highly 
expressed in many cancers, especially in breast carcinomas. Therefore, it is worth examining 
whether antiretroviral drugs can be repurposed as anticancer drugs for treating TNBCs and to 
further understand the relationship between LINE-1 and TNBCs. Antiretroviral drug-induced 
anticancer effects may be relevant to down-regulation of the fatty acid metabolism pathway. In 
this project, two antiretroviral drugs - Efavirenz and SPV122, had been shown to cause cell 
death and cell proliferation retardation, thus, effectively eliminating cancer cells in a range of 
TNBC cell lines. Additionally, LINE-1 suppression had been observed in the antiretroviral 
drugs-treated breast cancer cell lines implying a potential link between LINE-1 and TNBCs. 
Whole-genome RNA sequencing data further highlighted the possible mechanisms involved in 
this anticancer process. It seemed the fatty acid metabolism pathway could be a key regulator 
in this anticancer process. Many key genes involved in fatty acid metabolism were down-
regulated after drug treatments. However, the antiretroviral drugs-treated MCF10AT and 
MCF10CA1α cells were found to present some mesenchymal markers which are often 
characteristic signs of poor prognostic outcomes thereby highlighting the complexity of TNBCs. 
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The RNA sequencing data also strongly implied that cancer stem cells (CSCs) could play a role 
in these confusing results. CSCs are a small group of cancer cells with stem cell-like abilities, 
and they are thought to be responsible for drug resistance, cancer metastasis, and cancer 
recurrence. Interestingly, in a series of experiments, different groups of CSCs showed various 
responses to a range of drugs. ALDHhigh epithelial-type CSCs were significantly reduced after 
antiretroviral drug treatment; whereas, CD44+/CD24- mesenchymal-type CSCs were increased 
after treatment. These results highlighted the importance of CSC heterogeneity and implied that 
mesenchymal-type CSCs have greater resistance to the drugs than other cancer cells. Finally, 
the functional CSC assay demonstrated that CSCs can be eliminated by the antiretroviral drugs 
indicating that Efavirenz and SPV122 might be able to target both non-CSCs and CSCs. To 
combine all the results together, Efavirenz and SPV122 could potentially be valid anticancer 
drugs for treating TNBCs by regulating cancer fatty acid metabolism. Follow-up experiments 
are necessary to further understand how antiretroviral drugs impact anticancer processes.
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Chapter 1 General introduction  
1.1 Introduction  
Breast cancer is the most common cancer diagnosed in Australian women (AIHW, 2017) with 
incidences predicted to rise worldwide in the coming decades (WHO, 2014). Although its early 
detection and new therapeutic strategies have increased the survival rate of breast cancer 
patients (AIHW, 2017), approximately 10% of patients still die within five years of diagnosis 
(AIHW, 2017). The increase in breast cancer mortality depends on many factors including 
cancer metastasis, cancer recurrence, and the origin of the cancer, all of which are challenging 
for the design of future breast cancer therapeutics. Current therapeutic treatments have 
unpleasant side effects which may impact patients’ daily lives. Thus, the goal for breast cancer 
researchers is to develop novel cancer therapies which increase both the survival rate and the 
quality of life for breast cancer patients.  
In this introduction, I will focus on breast cancers, retrotransposons, and antiretroviral drugs. 
More specifically, I will describe triple-negative breast cancers (TNBCs); the role of cancer 
stem cells (CSCs) in cancer biology; the characteristics of different types of transposons and 
their function in the human genome. The utility and mechanisms of antiretroviral drugs will be 
detailed since they appear promising candidates as anti-breast cancer drugs. This will be 
followed by current evidence and hypotheses about the influence of transposons, in particular, 
long interspersed nucleotide element 1 (LINE-1), in epithelial cancers. This introduction should 
help readers to understand the relationships between LINE-1, antiretroviral drugs, and novel 
TNBC treatments. Furthermore, it explains how the cancer field may benefit from these 
findings. 
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1.2 Breast cancer 
‘Cancer is a disease that results from the successive accumulation of genetic and epigenetic 
alterations in oncogenes and tumour-suppressor genes, leading to uncontrolled cell growth’ 
(Virani et al., 2012). 
Breast cancer continues to be a growing public health concern worldwide. According to a recent 
Australian government report, breast cancer transcends colon cancer and became the most 
common cancer in females (AIHW, 2017). The last few decades have seen a growing trend in 
the increased incidence of breast cancer, possibly due in part to an increase in life expectancy 
and an improvement in breast cancer detection techniques (WHO, 2014). On average, around 
50 people are diagnosed with breast cancer every day in Australia (AIHW, 2017). It is the fourth 
leading cause of cancer-related deaths in females in Australia (AIHW, 2017). Thus, developing 
more effective treatment strategies for breast cancer patients is an urgent priority.  
Table 1-1 Staging of breast cancer 
Stage  Description  
Stage 0 Carcinoma in situ 
Stage I Early-stage, non-invasive, no metastasis, size < 1cm 
Stage II Early-stage, non-invasive or slightly invasive, no metastasis, larger size 
Stage III Advanced breast cancer, invasive, no metastasis, larger size or any size with 
ulceration or skin nodules 
Stage IV Advanced breast cancer, invasive, metastasis, any size 
Breast Cancer Treatment. (2019, January 31). Retrieved February 8, 2019, 
from https://www.cancer.gov/types/breast/hp/breast-treatment-pdq#link/_695_toc) 
 
 
 
 
 
Figure 1-1 Different stages of breast cancer 
The numbers represent breast cancer stages; the red shadows represent spreading areas of breast 
cancer in different stages.  
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Breast cancer treatment strategies depend on the type of breast cancer and the stage of the 
disease upon detection. There are five major stages for describing the progression of breast 
cancer (Table 1-1 and Figure 1-1). Stage 0 describes non-invasive breast cancers; stage I 
describes slightly invasive breast cancers of smaller size; stage II describes more invasive breast 
cancers of larger sizes which can affect surrounding lymph nodes; stage III describes larger 
tumours affecting many lymph nodes; and Stage IV describes invasive and metastatic breast 
cancers with the worst prognostic outcomes (NIH, 2018). Breast cancers detected in the early 
stages are generally much easier to treat than breast cancers detected in later stages; however, 
the type of breast cancer is also important in determining the prognostic outcome.   
There are many subclasses of breast cancers identified by their characteristics and gene 
expression. Despite the monoclonal origins of solid tumours, they are composed of a 
heterogeneous population of cells with different proliferative, differentiate, and tumour-
initiating potential (Virani et al., 2012). One of the most recognised and accepted classification 
methods uses hormone receptor identification. From an immunohistochemical perspective, 
breast cancer can be separated into four major groups: the luminal A breast cancers, the luminal 
B breast cancers, the human epidermal growth factor receptor 2 positive (HER2+) breast cancers, 
and the triple-negative breast cancers (TNBCs) (Onitilo et al., 2009). While the luminal and the 
HER2+ breast cancers are usually treated by specifically targeting their hormone receptors, 
systemic chemotherapies or radiotherapies are more often used for eliminating TNBC tumour 
tissues (Denkert et al., 2017).  
Targeted therapy is a fundamental and indeed a commonly used approach for treating cancers: 
chemotherapy and radiotherapy being the most potent anticancer strategies employed. However, 
quite a few side effects including vomiting, nausea, and hair loss have been reported after such 
treatments (Coates et al., 1983). Moreover, although the success rate of chemotherapies is high 
in eliminating TNBCs, some patients can relapse within three years of the primary treatment 
(Foulkes et al., 2010, Hudis and Gianni, 2011). One of the greatest challenges for treating breast 
cancers is determining how to target TNBCs since current targeted therapy methods depend 
upon the presence of hormone receptors. Novel therapies which specifically target TNBC tissue, 
while avoiding normal tissues, are needed to increase the quality of life for patients. 
Chapter 1 
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1.2.1 Triple-negative breast cancers  
Triple-negative breast cancer refers to breast cancers lacking the estrogen receptor (ER), the 
progesterone receptor (PR) and Her2/neu expression (Collignon et al., 2016). They account for 
a significant percentage (15% to 25%) of breast cancer cases (Reddy, 2011). Treatment of 
TNBCs is more challenging than non-TNBCs because current hormone-based therapies mainly 
target receptors which are either absent or poorly expressed. Moreover, TNBCs are often 
characterised by less differentiation, higher proliferation rates, and larger tumour sizes than 
non-TNBCs. Therefore, more TNBCs are identified as invasive ductal carcinomas and 
frequently metastasise (Kalimutho et al., 2015). Furthermore, TNBCs can be particularly 
aggressive and are more likely to recur in the early stages than other breast cancer subtypes 
(Foulkes et al., 2010). Patients with TNBC have a lower five-year survival rate than the average 
breast cancer five-year survival rate (Foulkes et al., 2010, Hudis and Gianni, 2011). During 
TNBC treatment, prevention of cancer recurrence and cancer metastasis have become central 
issues in the maintenance of patients’ cancer-free status. There is an increasing concern that 
some traditional therapies are ineffective when dealing with metastatic cancers (Zeichner et al., 
2016). Thus, improved diagnosis and therapeutic approaches for TNBCs are urgently needed. 
Currently, TNBC patients are disadvantaged due to limited treatment options. As observed by 
Kalimutho et al. (2015), the lack of causally proven, high-frequency oncogenic drivers for 
targeting is a crucial challenge for TNBC treatment. This means that very few drugs can target 
TNBCs sufficiently. There are some TNBC drugs in the development phase which act by 
inhibiting epidermal growth factor receptor (EGFR), mammalian target of rapamycin (mTOR), 
phosphoinositide 3-kinase (PI3K), and Janus kinase. Alternative targets are other 
molecules/signalling pathways which may affect TNBC development (Kalimutho et al., 2015). 
However, to date, none of them has passed phase III clinical trials (Denkert et al., 2017). 
Moreover, until very recently, Atezolizumab (Roche) and Nanoparticle albumin-bound-
paclitaxelis (Celgene) co-treatment has been approved as the first immunotherapy strategy for 
treating advanced or metastatic PD-L1-positive TNBC by the US Food and Drug 
Administration (FDA)(Schmid et al., 2018).  
A significant number of patients (6%) will present with de novo metastatic disease, and 10% to 
40% of patients with localised breast cancer will relapse systemically  (Zeichner et al., 2016). 
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Only a few treatments are available for treating metastatic TNBC, most of which use single-
agent chemotherapy such as microtubule inhibitors, anthracyclines, and antimetabolite agents 
(Zeichner et al., 2016). The poor drug efficacy and the occurrence of frequent visceral or central 
nervous system metastases result in a lower overall survival rate for metastatic TNBC patients 
(Zeichner et al., 2016).  
There are many reasons why the development of TNBC-specific targeted therapies is proving 
challenging to researchers. For example, the targeted pathways might be regulated by other 
genes and pathways and therefore the target sites cannot be fully inhibited in humans. TNBCs 
were originally considered to be a homogeneous group of breast cancers sharing similar genetic 
backgrounds and lacking hormone receptors. Recently, however, researchers have found 
heterogeneity exists within the group and that many different subclasses of TNBCs can be 
classified. Some studies in the field of cancer biology have focused only on the general 
characteristics of TNBCs; however, heterogeneity should be considered since cancer cells with 
different genetic backgrounds may respond differently to different treatments (Lehmann et al., 
2011). There are now many new techniques to help us identify the different subclasses of 
TNBCs, the latest of which was defined by Lehmann and his colleagues (Lehmann et al., 2011). 
TNBCs can be separated into basal-like 1, basal-like 2, immunomodulatory (IM), 
mesenchymal-like, mesenchymal-stem like, luminal androgen, and other TNBCs (Lehmann et 
al., 2011). Every subclass uses different signalling pathways, and therefore, may respond 
differently to drug treatments (Chen et al., 2012b). It is now possible to improve our 
understanding of how different subclasses of TNBCs might respond to various drugs, to make 
prognostic predictions, and to find novel targets for treating TNBCs.    
An alternative explanation for the difficulties experienced by researchers in developing valid 
anti-TNBC drugs is therapeutic resistance. Evidence suggests that therapeutic resistance may 
be associated with the existence of cancer stem cells (CSCs) (Kai et al., 2010). If the treatments 
cannot effectively eliminate CSCs in addition to other cancer cells, the tumours may reappear 
rapidly after treatment (Rodriguez Salas et al., 2010). 
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1.2.2 Cancer stem cells  
Cancer stem cells (CSCs) are cancer cells with stem cell-like abilities. This type of cancer cell 
has captured the attention of cancer clinicians and may be one of the key factors associated with 
their difficulty in treating cancers. Ever since CSCs were reported in leukaemia two decades 
ago, they have been attracting a lot of interest; however, many details are still under debate 
(Simard and Engels, 2010). CSCs are also called cancer-initiating cells because when injected 
into immunodeficient mice, they can generate tumours (Charafe-Jauffret et al., 2009). 
Numerous studies suggest that the eradication of CSCs could be among the most important 
strategies for developing successful cancer treatments because they impact upon cancer self-
renew, cancer metastasis, drug resistance, and are responsible for tumour recurrence (Liu et al., 
2015, Kai et al., 2010, Boyle and Kochetkova, 2014, Charafe-Jauffret et al., 2009). Under most 
conditions CSCs are quiescent, but they can be triggered to induce self-renewal activities and 
to reproduce progenitor cells (Chen et al., 2016). Clearly, the existence of CSCs is a major 
problem in treating cancers. Researchers have recently shown that if anti-cancer drugs kill only 
non-CSCs, CSCs will rapidly induce further cancer growth. Thus, by targeting CSCs, the issues 
of cancer metastasis and cancer recurrence might be addressed, and patients’ lives might be 
extended. The discovery of CSCs has provided an insight into why cancer is sometimes very 
difficult to treat and eliminate. Cancer treatment regimens need to be devised to overcome 
technical challenges.  
CSCs are difficult to characterise because there does not appear to be a universal CSC marker 
(Moghbeli et al., 2014, Snyder et al., 2018). Typically, different markers identify different 
groups of CSCs with very little overlap (Liu et al., 2014a). In breast cancer, there are several 
frequently used CSC markers, including CD44/CD24, ALDH, CD133, CD49f in vitro with 
more markers identified in clinical samples (Moghbeli et al., 2014). However, no universal 
marker represents all breast CSCs. 
At least three different cellular markers and one functional assay are commonly used to identify 
breast CSCs (BCSCs) in breast cancer cell lines (Figure 1-2A). Mesenchymal-type CSC, also 
known as CD44+/CD24- CSC, is one of the most well-known: high levels of expression of 
surface marker CD44 and low or no expression of surface marker CD24 characterise this kind 
of CSC. Epithelial-type CSC or ALDHhigh CSC is also commonly recognized. It has high 
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aldehyde dehydrogenase (ALDH) activity which can catalyse the oxidation of aldehyde readily. 
By using the ALDEFLOUR assay (Stemcell technology), epithelial-type CSC can be detected 
using flow cytometry. The side population (SP) is another group of less promising CSCs which 
use many ATP-binding cassette (ABC) transporters to pump cytotoxic materials out of the cells. 
Some researchers believe this allows the cells to survive in extreme conditions. These cells can 
be identified using Hoechst staining and flow cytometry because the levels of Hoechst 
remaining in SP cells are lower than other cells, allowing them to be separated from the whole 
population. Tumorsphere formation is used to identify another group of CSCs. Some cancer 
cells are able to form spheres when cultured in three-dimensional conditions of low-nutrition 
and are considered to be cells with CSC potential. These cells have been reported to form 
tumours from very small tumorspheres. Unfortunately, there is no conclusive evidence to 
indicate which one of these different types of CSCs is the correct definition of CSCs, and these 
different types of CSCs only overlapped with each other in a quite small amount. Therefore, 
research to date has not yet identified valid drugs for targeting CSCs and only a limited number 
of potential anti-CSC drugs has been investigated. More studies are therefore necessary to 
increase our understanding of CSCs before they can be eliminated from cancer patients.  
 
 
Figure 1-2 Relationships among different types of BCSCs and CSC plasticity  
(A) According to various CSC identification methods, there are at least three different types of BCSCs 
which have very limited overlap. (B) Some non-CSC and CSC may transit their status in between non-
CSC and CSC because of many different stimulations.       
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Another difficulty faced by researchers trying to target CSCs relates to their plasticity (Figure 
1-2B). There are many studies reporting that some cancer cells can switch between non-CSCs 
and CSCs (Liu et al., 2014a); however, there is very little known about the factors affecting 
CSC plasticity. This process may be caused by environmental changes or epigenetic regulation 
(Chen et al., 2016). Thus, while drugs may target existing CSCs, subsequently some non-CSCs 
might switch to CSC status and regenerate cancers. Therefore, a drug which can eradicate both 
non-CSCs and CSCs together could be the next generation anti-cancer drug for improving 
breast cancer prognostic outcomes.  
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1.3 Drug repurposing 
Drug repurposing is an area of drug therapeutics which is currently generating significant 
interest in the field of cancer biology. It is attractive since reducing the possibility of wasting 
time and money, and it may build up a baseline before further drug investigation. New drugs 
face a high failure rate, mainly because the in vitro conditions are very different from in vivo 
conditions (Sleire et al., 2017). However, if the drug of interest has previously been used in 
clinical trials for another purpose, scientists already have some baseline information for the 
repurposed drugs, such as possible side effects, minimal dosage, and potential drug-drug 
interactions which can shorten the drug discovery process (Sleire et al., 2017). One of the most 
successful cases of drug repurposing for treating breast cancers is Metformin (Zi et al., 2018). 
Metformin is a type II diabetes drug that can inhibit the mTOR pathway and can also induce 
cancer cell apoptosis (Zi et al., 2018).  
1.3.1 Antiretroviral drugs 
Retroviruses are a class of RNA virus, which use reverse transcriptase (RT) to insert their own 
sequence into the host DNA in order to replicate themselves using the host replication 
machinery. The human immunodeficiency virus (HIV) is the most well-known retrovirus, 
causing acquired immune deficiency syndrome or AIDS. Even though the incidence of AIDS 
is increasing, the mortality rate is decreasing because of the widespread use of antiretroviral 
drugs (Simard and Engels, 2010).  
The anticancer potential of antiretroviral drugs has been the subject of research since the 1990s 
when scientists realised the incidence of AIDS-related cancers was dramatically reduced after 
treatment with antiretroviral drugs (Simard and Engels, 2010). About two decades ago, highly 
active antiretroviral therapy (HAART) was introduced to HIV-infected patients resulting in the 
reduced motility rate of AIDS-related cancers (Simard and Engels, 2010). It was considered a 
great success in the treatment of AIDS patients and the virus was no longer able to 
induce AIDS-related cancers. However, several researchers believe this success resulted from 
the inhibition of endogenous reverse transcription in cancers (Simard and Engels, 2010), 
activity which was derived from long interspersed nucleotide element 1 (LINE-1), a highly 
mobile transposable element within the human genome. 
Chapter 1 
10 
 
 
Figure 1-3 The mechanisms of RT inhibitors for treating AIDS  
(A) The mechanism of NRTIs is to terminate virus DNA replication. Management of NRTI treatment. (B) 
The mechanism of NNRTIs is to block the function of RT and stop DNA synthesis.  
 
RT inhibitors are the most widely used antiretroviral agents, and many of them are highly 
effective at stopping HIV amplification. Furthermore, they have been extensively used for 
treating many kinds of epithelial cancers, including acute myeloid leukaemia (AML) and 
prostate cancers in cell culture (Sciamanna et al., 2005). Two major groups of RT inhibitors are 
well-studied in HIV treatment: one group being nucleoside RT inhibitors (NRTIs), and the other 
being non-nucleoside RT inhibitors (NNRTIs). NRTIs are nucleoside analogues which can act 
as terminators of growing DNA strands (Figure 1-3A); whereas, NNRTIs can bind to a ‘pocket’ 
of RT causing conformational changes in the RT, thus inhibiting RT function (Figure 1-3B) 
(Bastos et al., 2016). 
LINE-1 inhibition has been studied by many researchers using a retrotransposition assay (Dai 
et al., 2011, Peddigari et al., 2013, Heras et al., 2013). In most of the retrotransposition studies 
in bacterial models, some NRTIs and NNRTIs can effectively inhibit LINE-1 expression (Dai 
et al., 2011). There is evidence to suggest that NRTIs can more efficiently inhibit LINE-1 
expression than NNRTIs in the retrotransposition assay (Jones et al., 2008); although the effects 
might differ depending on the cell line. Although some of these antiretroviral drugs have been 
confirmed to operate as LINE-1 inhibitors, their precise effects and their mechanisms of action 
remain unclear.    
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1.4 Transposable elements 
Transposable elements (TEs or transposons) are a group of genes which can alter their own 
location in the genome and may play substantial roles in human development and evolution. 
TEs were previously considered as non-functioning ‘junk genes’ (Burns, 2017). Recently, 
however, there has been renewed interest in these ‘junk genes’, because scientists have noticed 
that they make up a large proportion of the human genome. The Human Genome Project 
identified more than 45% of the human genome as comprising TEs (Sachidanandam et al., 
2001). Since the proportion of TEs is greater than the protein-coding genes (~2%), scientists 
thus anticipated that TEs could play a critical role in the human genome (de Koning et al., 2011). 
Subsequently, TEs have been a topic of great interest in a wide range of fields. Therefore, the 
significance of TEs in human development and evolution is a hot-button topic in the field of 
biology. To further understand each type of TE and their influence in humans, I describe the 
different types in the following sections.  
1.4.1 DNA transposons  
One of two major classes of TEs is the DNA transposon. In humans, DNA transposons are 
believed to employ a ‘cut and paste’ mechanism for mobilization in the genome by using their 
own encoded transposase. DNA transposons might therefore be cut from their original location 
in the chromosomal DNA and then be inserted into a new genetic location. Little is known 
about DNA transposons because only 2.8% of inactive DNA transposons are present in the 
human genome and only a small amount of their remnants have been found in the germline 
(Evsikov and Marin de Evsikova, 2016). However, scientists believe DNA transposons were 
active 37 million years ago and could be a driving force in human evolution (Cordaux and 
Batzer, 2009). Since DNA transposons are more like molecular fossils, appearing to play no 
current role in the human genome, this review will focus more on retrotransposons. 
1.4.2 Retrotransposons 
Retrotransposons are widespread endogenous gene fragments residing in the genome with 
mobility (Farkash et al., 2006). They can ‘copy and paste’ themselves to new genomic positions 
via RNA-mediated reverse transcription (Cordaux and Batzer, 2009). Retrotransposons 
comprise approximately 42% of the human genome, including 8.3% of long terminal repeat 
(LTR) elements and 33.7% of non-long terminal repeat (non-LTR) elements (Sachidanandam 
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et al., 2001). In contrast to DNA transposons, some active retrotransposons still have the ability 
to move within the genome, in particular, non-LTR  elements (Cordaux and Batzer, 2009).  
1.4.3 Long Terminal Repeat (LTR) elements 
Endogenous retroviruses (ERVs) are the major group of LTR elements in humans and can be 
historically traced back to retroviral-associated infections in the genome. Their name indicates 
their main characteristics, and they are the remnants of ancient retroviral infections (Seifarth et 
al., 2005). Similar to retroviruses, they are supposed to be able to copy themselves back into 
new genetic locations with long terminal repeat ends; however, they have lost part of their 
sequence and hence their jumping function (Evsikov and Marin de Evsikova, 2016). They have 
also been identified as inactive TEs and exert limited influence on the human genome (Cordaux 
and Batzer, 2009). Some other LTR elements such as mammalian apparent LTR 
retrotransposons (MaLR) are considered as active ‘jumping genes’ in certain rodents; however, 
there is no evidence to suggest that MaLR elements appear in the human genome (Evsikov and 
Marin de Evsikova, 2016). In comparison with LTR elements, there are more copy numbers of 
non-LTR elements in the human genome, implying that non-LTR are more important than LTR 
elements. 
1.4.4 Non-Long Terminal Repeat (non-LTR) elements 
To date, the only TEs identified in humans, as being currently active, are non-LTR elements. 
Hence they are the only transposons which may have the ability to impact the human genome. 
Non-LTR elements, including the non-autonomous short interspersed nuclear element (SINE) 
and the autonomous long interspersed nuclear element (LINE), have been reported to move 
within the human genome (Kroutter et al., 2009). SINEs are relatively short non-autonomous 
sequences relying on the reverse transcription function of LINEs to assist their insertions; 
whereas, LINEs are much longer sequences than SINEs and can insert themselves at new gene 
locations autonomously (Koito and Ikeda, 2013). Embryogenesis and cell development are 
heavily involved in these non-LTR elements. Many non-LTR element insertions have also been 
confirmed as potential resources in several genetic disorder diseases (Kroutter et al., 2009).  
1.4.5 Long interspersed nucleotide element 1 (LINE-1)  
Long interspersed nuclear element 1 (LINE-1) is one of the most common and active 
autonomous retrotransposons in the human genome, comprising approximately 17% of the 
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genomic sequence. LINE-1 is encoded as a 40kDa RNA binding protein ORF1p and a 150kDa 
protein ORF2p, with the latter possessing endonuclease and reverse transcriptase activity 
(Figure 1-4) (Sciamanna et al., 2014). Because of its ‘copy and paste’ ability in the human 
genome, it impacts gene structure and gene expression (Koito and Ikeda, 2013). It is now well 
established that LINE-1 can impair the stability of the genome and is thought to be responsible 
for gene damage, gene insertion, and gene breakdown (Beck et al., 2010). LINE-1 reverse 
transcription activities can be extremely harmful to human beings, and the human body has 
developed many different mechanisms for preventing LINE-1 from jumping within the genome 
(Rodić and Burns, 2013). LINE-1 is rarely expressed in normal healthy differentiated tissues 
(Rodić and Burns, 2013), although LINE-1 expression has been associated with some diseases 
that are caused by DNA mutagenesis and instability of LINE-1 elements (Zhang et al., 2014).  
   
 
Figure 1-4 The structure and the ‘copy and paste’ mechanism of LINE-1 
The picture on the top depicts the structure of LINE-1. It encodes an ORF1 protein and an ORF2 protein-
containing endonuclease (EN) and reverse transcriptase (RT) regions. The picture on the bottom 
depicts the process of LINE-1 insertion.   
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1.4.6 LINE-1 in Cancer  
The expression of the LINE-1 element is highly consistent with the occurrence of several human 
neoplasms, specifically lung, prostate, ovarian carcinoma as well as breast cancer (Rodić and 
Burns, 2013). While the mechanisms that underpin LINE-1 expression in many cancers are not 
fully understood, it is considered to be a potential biomarker for many epithelial cancers due to 
its distinct patterns of expression in cancer tissues and patients (Houédé et al., 2014, Houédé et 
al., 2018, Hecht et al., 2018). Normally, elements are not expressed in healthy differentiated 
tissues because of genome defence mechanisms such as DNA methylation and RNA interferons 
(Harris et al., 2010). In contrast, levels of LINE-1 are particularly high in cancer tissues, in 
tumour microvesicles, as well as in the plasma of breast cancer patients. LINE-1 may act to 
modify normal cells in the tumour microenvironment thus making them more amenable to 
tumour growth (Chen et al., 2012a).  
Interestingly, LINE-1-encoded proteins display alternative patterns of expression in different 
kinds of breast cancer cell lines. The expression patterns of LINE-1 differ in non-invasive and 
invasive cancer cells (Chen et al., 2012a). This suggests that detecting LINE-1 expression could 
be useful for distinguishing the various subtypes and clinical stages of cancer cells. Moreover, 
survival rates of patients with a particular subclass of invasive breast cancer correlated with 
detection of LINE-1-encoded ORF1p and ORF2p in the nucleus but not in the cytoplasm (Chen 
et al., 2012a). These studies indicate that LINE-1-encoded proteins have the capability to 
become biomarkers for prognostic prediction in breast cancer, which may allow us to predict 
which patients will end up in high-risk categories. However, at present, the molecular and 
signalling pathway changes that occur during LINE-1 expression remain unclear. The impact 
of LINE-1 on epithelial cancers remains undefined in relation to their mechanism of action. 
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1.5 LINE-1, antiretroviral drugs, and cancers  
Repurposing antiretroviral drugs as anticancer drugs using LINE-1 inhibition could be a 
potential therapeutic pathway for treating breast cancer patients. LINE-1 encodes an RT 
enzyme that may have a key role in tumorigenesis (Patnala et al., 2014). In biochemical analyses, 
several antiretroviral drugs have been shown to inhibit the RT activity of LINE-1. In 
retrotransposition assays, they have been observed to reduce the number of L1 
retrotransposition events (Dai et al., 2011). Recent studies have revealed that antiretroviral 
drugs may effectively reduce cancer cell proliferation in prostate and pancreatic cancer (Houédé 
et al., 2014, Hecht et al., 2018). Inhibition of LINE-1 RT activity has also been shown to 
promote differentiation in several progenitors and transformed cell types (Spadafora, 2004). 
Some researchers have been attempting to find a link between LINE-1 RT inhibition and cancer 
elimination. It is now well established that LINE-1 is expressed in tumour tissues but not in 
normal tissues; however, the influence of LINE-1 inhibition on cancer treatment remains ill-
defined.  
LINE-1 inhibition is associated not only with oncogene expression (Patnala et al., 2014) but 
also with the regulation of certain small non-coding RNAs (Ohms and Rangasamy, 2014) which 
may be involved in regulating cancer progressive protein expression (Xue and He, 2014). 
According to a recent paper (Patnala et al., 2014), inhibiting the function of LINE-1 with 
Efavirenz, an antiretroviral drug, reduces the expression of some well-known oncogenes in 
breast cancer including EGFR, erythroblastosis leukemia viral oncogene homolog (ERBB4) 
and others. On the other hand, silencing LINE-1 mRNA with a specific endo-siRNA (endo453) 
in the T47D breast cancer cell line increases a group of tumour suppressor miRNAs. These 
miRNAs are known for their ability to down-regulate many cancers as well as for their 
involvement in cell differentiation and tumorigenesis (Boyerinas et al., 2010). Therefore, LINE-
1 is likely to play a principal role in cancer cell regulation and could be a novel breast cancer 
targeting site.  
In vitro studies have shown epithelial cancer cells can be successfully eliminated by some 
antiretroviral drugs. Evidence suggests that Abacavir and Efavirenz are effective anti-cancer 
drugs in vitro in prostate cancer cell lines (Carlini et al., 2010, Sciamanna et al., 2005). 
Additionally, Nevirapine is considered to be a potent anticancer drug in terato-, colon-, and 
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lung carcinomas. Moreover, both Efavirenz and Nevirapine can reduce the growth of melanoma 
(Houédé et al., 2014). However, previous studies dealing with the repurposing of antiretroviral 
drugs as anti-cancer drugs have not dealt with TNBCs. Also, there has been little discussion 
about the signalling pathways affected by antiretroviral drugs in relation to their anti-cancer 
activity. Hence, in this study, we have focused on repurposing antiretroviral drugs for the 
treatment of TNBCs, and we have studied potential anti-cancer mechanisms associated with 
inhibiting LINE-1 expression in TNBCs. 
Solid evidence suggests some antiretroviral drugs can effectively eliminate different epithelial 
cancers in vitro. However, further research needs to be done to prove the effectiveness of these 
drugs in vivo. One possible explanation is that the drug dosage for treating retrovirus is not 
sufficient for treating cancers. (Houédé et al., 2014, Hecht et al., 2015). Houédé’s group (2018) 
suggests a sufficient dosage for treating metastatic Castration-resistant prostate cancer could be 
around 1,200-3,000 mg/day (current dosage in clinical trial: 600 mg/day); Hecht’s group (2015) 
suggests that only 1.5% of patients in clinical trial have received sufficient drugs doses above 
the in vitro toxic EC50 of Efavirenz. Alternatively, the microenvironment and gene regulation 
are complicated in the human body. In addition, the existence of CSCs can contribute to drug 
resistance, thereby reducing the anti-cancer effects of certain antiretroviral drugs.  
To date, there has been no study focusing on CSC elimination by antiretroviral drugs. If 
antiretroviral drugs are only able to eradicate the non-CSCs and not the CSCs, it is likely that 
cancers will relapse rapidly. Thus, it is critical to investigate whether antiretroviral drugs can 
eliminate both classes of CSCs. If antiretroviral drugs are indeed effective in treating CSCs, 
this class of drug should be considered as a valid anticancer treatment aimed at improving breast 
cancer prognostic outcomes and prolong cancer-free survival for the patients.  
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1.6 Hypotheses 
The main purpose of this study is to examine whether antiretroviral drugs can be repurposed as 
anticancer drugs to be used against TNBCs. Antiretroviral drugs have been used for treating 
HIV infections for decades, and recent evidence suggests that they have potential as anticancer 
drugs given their effectiveness at eliminating certain types of cancer cell (Houédé et al., 2014). 
Recently, studies of anti-breast cancer effects of antiretroviral drugs have been limited to 
luminal-type breast cancers including T47D and MCF7 (luminal A) cell lines; however, very 
little anticancer effects of antiretroviral drugs have been observed in TNBCs which are viewed 
as the worst type of breast cancers (Patnala et al., 2014). Heterogeneity among breast cancer 
subtypes may explain why they respond differently to different drugs and different drug 
concentrations. Additionally, previous studies have failed to consider the effects of drugs on 
CSCs which are linked to many unfavourable prognostic outcomes. Therefore, this study 
focuses on the responses of TNBCs and BCSCs to antiretroviral drugs. 
The major aim of this study is to explore the efficacy of antiretroviral drugs and their underlying 
mechanisms for causing the blockade of LINE-1-RT in a range of breast cancers, particularly 
TNBCs. The other aim of this study is to investigate whether antiretroviral drugs can eliminate 
CSCs and reduce cancer metastasis and recurrence rates. 
In summary, the hypotheses of this study are:   
• LINE-1 plays a key role in tumorigenesis in TNBCs. 
• Antiretroviral drugs can effectively block LINE-1 expression in TNBCs. 
• Antiretroviral drugs can treat TNBCs. 
• Antiretroviral drugs can reduce the numbers of CSCs in TNBCs. 
To the best of my knowledge, this is the first study to investigate the anticancer effects of 
antiretroviral drugs in TNBCs. A systematic understanding of how antiretroviral drugs 
contribute to the anticancer processes in TNBCs is essential for further improving TNBC 
treatment. Moreover, a thorough examination of the role of LINE-1 in the context of TNBCs 
could potentially contribute to the field of cancer drug development and treatment. An improved 
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understanding of the possible links between LINE-1 inhibition and its anti-cancer effects in 
TNBCs may help us to improve cancer early detection and aid in the valid selection of 
treatments. It is also anticipated that this research will provide an important opportunity to 
advance our understanding of CSCs.  
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1.7 Thesis overview 
This chapter briefly summarised the background relating to breast cancers, transposons, and 
antiretroviral drugs, and it highlighted some of the key questions in the field. 
The second chapter describes the materials and methods used in this project. 
The third chapter examines whether antiretroviral drugs can affect TNBC cell growth and alter 
their phenotype. In addition, it investigates whether LINE-1 is involved in the drugs’ 
mechanism of action.  
The fourth chapter investigates the role of gene regulation in antiretroviral drug activity.  
The fifth chapter tests whether antiretroviral drugs can also be effective at eliminating CSCs 
and thus reduce the potential for metastasis and patient relapse.  
The last chapter analyses and discusses the results, as well as the limitations of our findings. 
Finally, it examines how these discoveries can improve our knowledge of cancer biology.
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Chapter 2 Materials and Methods  
2.1 Materials 
2.1.1 Chemicals 
All chemicals used in this thesis project were of the highest analytical grade unless otherwise 
specified. 
2.1.2 Buffers and solutions 
Table 2-1 Buffers and solutions being used in this thesis project 
Buffer name Formula 
Phosphate buffered saline 
(PBS) buffer (1X) 
0.137 M NaCl/0.0027 M KCl/0.01 M Na2HPO4/0.0018 M 
KH2PO4 in Milli-Q™ water, pH 7.4 
Tris-buffered saline (TBS) 
buffer (1X) 
50 mM Tris-Cl/150 mM NaCl in Milli-Q™ water, pH 7.5 
TBST 0.05% Tween 20 in TBS 
LB broth medium 1% Bacto-tryptone/0.5% Yeast extract/1% NaCl in Milli-Q™ 
water, pH 7.0 
WB transfer buffer 25 mM Tris-base/192 mM Glycine/20% Methanol in Milli-Q™ 
water 
WB blocking buffer 5% non-fat milk or 3% bovine serum albumin (BSA) in TBST 
IF fixation solution 2-4% Paraformaldehyde dissolved in PBS 
IF blocking buffer 5% BSA/0.3% Triton™ X-100 in PBS 
IF antibody dilution buffer 1% BSA/0.3% Triton™X-100 in PBS 
PI staining solution 20 µg/ml PI + 0.1% Triton-X 100 in DPBS 
Annexin-binding buffer 10 mM HEPES/140 mM NaCl/2.5 mM CaCl2 in Milli-Q™ water, 
pH 7.4 
Crystal violet solution 0.5% Crystal violet in 25% Methanol 
(WB: western blot; IF: immunofluorescence; PI: propidium iodide)  
 
2.1.3 Antibiotics 
Table 2-2 Antibiotics being used in this thesis project 
Antibiotic name Brand  Cat# 
Ampicillin Sigma-Aldrich A1593 
Kanamycin sulfate Sigma-Aldrich 60615 
Penicillin -Streptomycin Gibco™ 15140122 
Geneticin™ (G418) Gibco™ 10131035 
Puromycin  InvivoGen ant-pr 
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2.1.4 Kits 
QIAGEN plasmid Mini and Midi Purification Kits (QIAGEN) 
PureLink® RNA Mini Kit (Invitrogen™) 
mirVana™ miRNA Isolation Kit (Invitrogen™) 
TURBO DNA-free™ Kit (Invitrogen™) 
SuperScript® IV First‐Strand cDNA Synthesis Reaction (Invitrogen™) 
PowerUp™ SYBR® Green PCR Master Mix (2X) (Applied Biosystems) 
Pierce™ BCA Protein Assay Kit (Thermo Scientific™)  
Pierce™ ECL Western Blotting Substrate (Thermo Scientific™) 
Cell Line Nucleofector® Kit V (Lonza) 
TaqMan® Advanced miRNA cDNA Synthesis Kit (Applied Biosystems™) 
TaqMan® Fast Advanced Master Mix (2x) (Applied Biosystems™) 
TaqMan® Advanced MicroRNA Assays (Applied Biosystems™) 
XTT Cell Viability Kit (Cell Signaling) 
AlamarBlue™ Cell Viability Assay (Invitrogen™) 
CellTrace™ CFSE Cell Proliferation Kit (Invitrogen™) 
FITC Annexin V/Dead Cell Apoptosis Kit with FITC Annexin V and PI, for Flow Cytometry 
(Invitrogen™) 
NuPage™ 4%-12% Bis-Tris Protein Gel Kit (Invitrogen™) 
ALDEFLUOR™ Kit (STEMCELL Technologies) 
MammoCult™ Human Medium Kit (STEMCELL Technologies) 
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2.1.5 Antibodies 
All the antibodies being used in this study (Table 2-3) are commercially available except anti-
human-(LINE-1) ORF1p and anti-human-(LINE-1) ORF2p. These two antibodies were 
generated in rabbits by IMVS Pathology, Australia.  
Table 2-3 Antibodies being used in this thesis project 
Name  Brand  Cat# Application  Dilution  
Anti-DDX5 Abcam Ab21696 WB 1:1000 
Anti-Human Vimentin antibody BD AF2105 WB 1:800 
Purified Mouse anti-CDC42 BD 610929 WB 1:500 
Anti-phospho-p53 Ser15 Invitrogen 700439 WB 1:200 
Anti-HIV-1 RT Fitzgerald 20-000511 WB 1:1000 
Anti-Human-(LINE-1) ORF1p IMVS AB3412 WB 1:1500 
Anti-Human-(LINE-1) ORF2p IMVS AB4213 WB 1:2000 
Anti-β-actin Sigma A5441 WB 1:10000 
Anti-E-cadherin CST 3195S WB, IF 1:800, 1:200 
Anti-pH2A.X (Ser139) Millipore 05-636-I WB, IF 1:500, 1:200 
Anti-SNAI2/SLUG BD  564614 WB, IF 1:1000, 1:250 
Anti-α-tubulin antibody Sigma T9026 WB, IF 1:10000, 1:500 
Goat anti-Rat IgG H&L HRP Abcam Ab97057 WB 1:2000-
1:10000 
Goat anti-Mouse IgG (H+L) HRP Invitrogen 626520 WB 1:2000-
1:10000 
Goat anti-Rabbit IgG (H+L) HRP Invitrogen 656120 WB 1:2000-
1:10000 
Anti-CD24 antibody (FITC) Abcam Ab30350 IF 1:50 
PE-Cy7™ Anti-CD24 BD  561646 FC 1:50 
Alexa Fluor® 647 anti-CD24 BD  561644 FC 1:50 
Alexa Fluor® 647 anti-Ki-67 BD 561126 FC 1:50 
Alexa Fluor® 488 anti-Annexin V Invitrogen V13241 FC 1:20 
CD133/1 (AC133)-APC Miltenyi 
Biotec 
130-090-
827 
FC 1:20 
FITC-Goat anti-Rabbit IgG (H+L) Invitrogen 65-6111 IF 1:500 
Cy5 Goat anti-mouse IgG (H+L)  Invitrogen A10524 IF 1:500 
Rat IgG (Alexa Fluor 647) Abcam Ab150159 IF 1:500 
Anti-Mouse Alexa 488 CST 4408 IF 1:500 
Anti-Rabbit Alexa 555 CST 4413 IF 1:500 
(WB: western blot; IF: immunofluorescence; FC: flow cytometry) 
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2.1.6 Oligonucleotides 
The primers being used in the general quantitative real-time polymerase chain reaction (qRT-
PCR) were all synthesised by Sigma-Aldrich Pty Ltd. The primer sequences were listed below 
(Table 2-4). 
Table 2-4 Primers being used in qRT-PCR 
Name Sequence Tm°C %GC size  product 
PUM1-2-F CATGGGTCCAGATTCATTCAG 59.4 47.6 21 mer 82 mer 
  PUM1-2-R CCTGGAGGATTTCATTGAAGAC 60.3 45.5 22 mer 
ORF1-1-F TCAAAGGAAAGCCCATCAGACT 61.1 43.5 22 mer 74 mer 
  ORF1-1-R TTGGCCCCCACTCTCTTCT 58.4 61.1 19 mer 
ORF2-EN-F CCCATCAGTGTGCTGTATTC 58.4 50 20 mer 87 mer 
  ORF2-EN-R TGGTAGATCTTCCTCCATCC 58.4 50 20 mer 
ORF2-RT-F ACTGGAAGCATTCCCTTTGAA 57.4 42.9 21 mer 89 mer 
  ORF2-RT-R TGGCCAGAACTTCCAACACT 58.4 50 20 mer 
(Tm: melting temperature) 
 
The TaqMan™ Advanced MicroRNA assays being used in the microRNA qRT-PCR were all 
purchased from Thermo Fisher Scientific. The target microRNA sequences were listed below 
(Table 2-5). 
Table 2-5 Mature miRNA sequence of the target miRNAs being used in microRNA qRT-PCR  
Target microRNA Assay ID Mature miRNA sequence  
miR-21 rno481342_mir UAGCUUAUCAGACUGAUGUUGA 
miR-182 477935_mir UUUGGCAAUGGUAGAACUCACACU 
let-7a 478575_mir UGAGGUAGUAGGUUGUAUAGUU 
miR-423 478090_mir UGAGGGGCAGAGAGCGAGACUUU 
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2.1.7 Plasmid DNA constructs 
2.1.7.1 pmaxGFP® control plasmid DNA for Nucleofection® 
pmaxGFP® (Figure 2-1) which is a positive control plasmid of Nucleofection® is provided in 
the Amaxa® Cell Line Nucleofector® V Kit (Lonza). This plasmid can express Green 
Fluorescent Protein (GFP, from Pontellina p.) in successfully transfected cells. Transfection 
efficiency can vary depending on different batches of experiments. Therefore the transfection 
efficiency of Nucleofection® should be analysed and monitored by observing the pmaxGFP 
transfected control cells in each experiment.   
 
  
Figure 2-1 The plasmid DNA map of pmaxGFP positive control plasmid of Nucleofection®  
(Referring from Olmedillas López et al. (2016)) 
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2.1.7.2 pBS-L1-PA1-mneo plasmid DNA 
pBS-L1-PA1-mneo plasmid was used for simulating retrotransposition activity of LINE-1 in 
mammalian cells (Wagstaff et al., 2011). This plasmid contains an optimised LINE-1 sequence 
(with ~75% similarity to the original LINE-1 sequence) driven by the CMV promoter and a 
neol indicator (Figure 2-2). The neol indicator includes a reversed neomycin resistant sequence 
without any function because of intron disruption, only if retrotransposition happens due to the 
function of LINE-1, there is a chance that a functional neomycin resistance gene which is driven 
by the SV40 promoter can be expressed. With the neomycin resistant ability, the transfected 
cells can survive in the Geneticin-containing medium (Geneticin is a neomycin analogue for 
treating mammalian cells).   
 
 
Figure 2-2 The plasmid DNA map of pBS-L1-PA1-mneo plasmid.  
The plasmid map is created by SnapGene® Viewer, the sequence is cited from Addgene (n.d.) pBS-L1-
PA1-mneo (Plasmid #51288). Retrieved from: https://www.addgene.org/51288/  
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2.1.7.3 pSM2 and pUTR plasmid DNA 
Arrest™ pSM2 control vector (OpenBiosystems, Cat# RHS1704, Figure 2-3), a pSHAG-
MAGIC2 plasmid without short hairpin RNA (shRNA) insertion is a negative control of any 
shRNA expressed by the Expression Arrest™ shRNA system (Paddison et al., 2004). The 
shRNA insertion site of pSM2 can be replaced by a designed shRNA, and this designed shRNA 
can adapt a hairpin formation that degrades later to small interfering RNA (siRNA). The siRNA 
expresses its function of RNA interference, inhibiting target gene expression (Paddison et al., 
2004). The Expression Arrest™ shRNA system can be an effective tool for knocking-down 
target genes. pUTR is a previously designed LINE-1 inhibiting plasmid utilising the Expression 
Arrest™ shRNA system and can specifically target the LINE-1 promoter. The sense and 
antisense sequences of the Expression Arrest™ shRNA plasmids used in this thesis are listed 
in Table 2-6.   
 
Figure 2-3 The plasmid DNA map of Arrest™ pSM2 empty vector  
Cited from: OpenBiosystems (n.d.) Expression Arrest™ pSM2 empty vector. Retrieved from 
http://www.pages.drexel.edu/~bio/cores/Documents/Protocols/(Prot%204).pdf 
 
Table 2-6 The sequences of shRNAs in pSM2 vector shRNA insertion site 
pSM2 
Sense (mir5’)  UUCUCCGAACGUGUCACGUdTdT  
Anti-sense (mir 3’)  ACGUGACACGUUCGGAGAAdTdT  
pUTR 
Sense (mir 5’)  TTTACCTAAGCAAGCCTGGGC  
Anti-sense (mir 3’)  TGCCCAGGCTTGCTTAGGTAAA 
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2.1.8 Cell lines 
The cell lines used in this thesis project include two luminal types of breast cancer cell lines – 
T47D, MCF7, six triple-negative breast cancer (TNBC) cell lines – MCF10AT, MCF10CA1α, 
MDA-MB-231, MDA-MB-436, BT-549, BT-20, and a non-tumorigenic epithelial cell line – 
MCF10A; all of which are listed in Table 2-7 with their classifications. All cell lines mentioned 
were purchased from the American Type Culture Collection (ATCC) unless otherwise specified.  
MCF10A, MCF10AT, and MCF10CA1α are a breast cancer model system that represents breast 
cancer progression within these cell lines. (Lim et al., 2015). MCF10A is a non-cancerous control 
cell line; MCF10AT is a premalignant cell line which is derived from MCF10A; and MCF10CA1α 
is a fully malignant cell line which is derived from MCF10AT (Imbalzano et al., 2009). With these 
cell lines, the net influence of cancer development can be studied since these cell lines are from the 
same origin and therefore have a similar genetic background. 
Table 2-7 Cell lines being used in this thesis project 
Cell line Receptors  Molecular type TN subtype Pathology  
MCF10A ER-/PR-/HER2- TN N/A Fibrocystic 
disease 
MCF10AT ER-/PR-/HER2- TN Unknown - 
MCF10CA1α ER-/PR-/HER2- TN Unknown  - 
MDA-MB-231 ER-/PR-/HER2- TN  MSL AC 
MDA-MB-436 ER-/PR-/HER2- TN MSL AC 
BT-549 ER-/PR-/HER2- TN M IDC 
BT-20 ER-/PR-/HER2- TN Unclassified IDC 
T47D ER+/PR+/HER2- Luminal A N/A IDC 
MCF7 ER+/PR+/HER2- Luminal A N/A IDC 
(ER: Estrogen receptor; PR: progesterone receptor; HER: human epidermal growth factor receptor 2; TN: triple-
negative; M: mesenchymal-like; MSL: mesenchymal stem-like; AC: adenocarcinoma; IDC: invasive ductal 
carcinoma; N/A: not applicable) (Holliday and Speirs, 2011, Dai et al., 2017) 
 
2.1.9 Other materials 
All the schematic diagrams were created by BioRender online software (https://biorender.com/) 
unless otherwise specified.  
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2.2 Methods 
2.2.1 Mammalian cell culture 
2.2.1.1 Traditional two-dimensional cells  
MCF10A, MCF10AT, and MCF10CA1α cultured in the complete DMEM/F-12 medium 
(Gibco™, Cat# 10565018) with 5% horse serum (Gibco™, Cat# 16050122), 10 µg/ml Insulin 
(Sigma-Aldrich, Cat# I882), 20 ng/ml Epidermal Growth Factor (Sigma-Aldrich, Cat# E4127), 
0.5 µg/ml Hydrocortisone (Sigma-Aldrich, Cat# H0888), and 100  ng/ml Cholera toxin (List 
Biological Laboratories, Cat# 101B). T47D, MCF7, MDA-MB-231, MDA-MB-436, and BT-
549 cells were cultured in the complete DMEM medium (Gibco™, Cat# 11965118) with 10% 
foetal bovine serum (FBS) (Thermo Scientific, Cat# SH30071.03). And BT-20 was cultured in 
the complete RPMI 1640 medium (Gibco™, Cat# 61870127) with 10% FBS. All cell lines were 
cultured in a 37°C incubator with 5% CO2 supply. Cells were subcultured every two to four 
days contingent upon cell proliferation rates and experimental designs. Cell cultures were 
regularly observed and monitored under a CK2 Microscope (Olympus). A haemocytometer and 
a microscope were employed for calculating cell number as needed. Most of the cell culture 
experiments in this study were performed under traditional two-dimensional cell culture 
conditions unless otherwise specified.  
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2.2.1.2 MammoCult™ tumorsphere formation three-dimensional cell culture 
MammoCult™ Human Medium Kit (STEMCELL technologies, Cat# 05620) had been utilised 
in many breast cancer cell lines and primary breast cancer tissues for generating tumorspheres 
and have been recognised to represent the cells with stem cell-like characteristics. After 
harvesting and counting cells from a traditional two-dimensional culture, 2x104 cells were 
seeded into an individual well of an Ultra-Low Adherent Suspension Culture plate (Corning, 
Cat# 3471) and were then cultured in the completed serum-free MammoCult™ medium with 4 
µg/mL Heparin (STEMCELL technologies, Cat# 07980) and 0.48 µg/mL Hydrocortisone for 
three to seven days in order to observe tumorsphere formation with/without drug treatment 
(Figure 2-4). The number and size of tumorspheres in each well were measured for further 
analysis.  
Figure 2-4  MammoCult™ 
tumorsphere formation  
Harvested cells from 2D culture 
are seeded in a 6-well plate and 
cultured by completed 
MammoCult™ medium. After 
three to five days, some 
tumorspheres can be formed 
depending upon the different 
characteristics of cell lines. These 
tumorspheres are observed by 
an Olympus IX 81 microscope, 
and the number and size are 
measured by Image J software. 
 
 
 
2.2.1.3 Drug treatment 
Tested drugs were all dissolved in dimethyl sulfoxide (DMSO) to make 100 mM stock and 
were stored in -20°C for long term storage. When performing drug treatment experiments, 
appropriate concentrations of drugs (EC50 value for each cell line) were mixed with the cell 
culture medium, and the pre-seeded cells were incubated with the drug-contained medium for 
a certain period of time (four days for the traditional two-dimensional culture; seven days for 
the MammoCult™ tumorsphere three-dimensional culture) in a 37°C incubator with 5% CO2 
supply. The drug-contained medium was replaced by the fresh drug-contained medium every 
48 hours unless otherwise specified.  
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2.2.2 Mammalian cell transfection 
2.2.2.1 Plasmid amplification and purification 
The frozen glycerol stocks of E. coli containing target plasmids were firstly cultured for 16 
hours in 5 ml LB broth medium (mentioned in section 2.1.2.) with an appropriate amount of 
antibiotics. 100 µl of the primary-cultured E. coli were then cultured in 200 ml LB broth 
medium with an appropriate amount of antibiotics for four to eight hours depending on the 
speed of bacteria growth. The plasmids within E. coli were amplified with bacterial 
amplification and were further isolated by a Plasmid Purification Kit (QIAGEN, Cat# 12943) 
following the given protocol. After collecting cell suspension of the cultured E.coli in the 
centrifugal vessel, the bacterial cells were spun down by centrifugation. The bacterial pellet 
was then resuspended in 4 ml of P1 buffer. 4 ml of P2 buffer was also mixed with the mixture 
followed by gentle mixing of the vessel. An extra 4 ml of P3 buffer was mixed with bacteria-
P1-P2-mixture and further incubated on ice for 15 minutes. The sample was then spun down at 
4°C for at least 30 minutes to remove the residual precipitate. The supernatant containing target 
plasmids was passed through a column which was designed to bind plasmid DNA. Later, 3.5 
ml of isopropanol and 70% ethanol was added to the column orderly so as to precipitate plasmid 
DNA. The final DNA precipitate was resuspended in 50-100 µl of autoclaved water for further 
experiments. 
2.2.2.2 Nucleofection® 
Nucleofection® can be a powerful tool for cell transfection. All the cell transfection experiments 
in this study were conducted by Nucleofection®. Nucleofector® I machine (Lonza) and Cell 
Line Nucleofection® Kit V (Lonza, Cat# VVCA-1003) were utilised for transfecting plasmid 
DNA into certain types of mammalian cells. First, target cells were cultured for two to three 
days to approximately 80% confluency. The cells were then harvested and approximately a 
million cells were collected and mixed with 100 µl Nucleofector® reagent and 5 µl plasmid 
DNA. The mixture was transferred into a Nucleofector® cuvette, which was then placed into a 
Nucleofector® I machine. After applying for a suitable Nucleofection® programme with the 
cells based on previous experiments (X-05 program for T47D cell lines; T-20 program for 
MCF10A, MCF10AT, and MCF10CA1α), the operated cells were transferred into the pre-
warmed cell culture medium. 24 to 48 hours later, the normal cell culture medium was 
exchanged with the transfection selection medium, which contains antibiotics such as 
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Puromycin and Geneticin™, to eliminate non-transfected cells and allowing only successfully 
transfected cells to survive.  
2.2.3 Protein detection  
2.2.3.1 Western blotting 
Western blotting is a commonly used method for detecting relative protein expression among 
samples. The protocol of western blotting used in this project was described as following. 
Samples were harvested from tissue culture flasks and then were lysed by using a 
Radioimmunoprecipitation (RIPA) assay protein extraction buffer (Sigma, Cat# R0278) laud 
with an appropriate amount of protease inhibitors (Roche, Cat# 11836170001) for preventing 
protein digestion. Afterwards, proteins in the samples were separated according to their 
molecular weights through a NuPAGE 4-12% Bis-Tris Protein Gel (Thermo Fisher Scientific, 
Cat# NP0321), followed by transfer to a pre-soaked nitrocellulose membrane (Bio-rad, Cat# 
14024) within a Bio-Rad Mini Trans-Blot® system (Bio-rad, Cat# 1703930) containing WB 
transfer buffer. A protein ladder was used (Novex Sharp Pre-stained protein standard (Thermo 
Fisher Scientific, Cat# LC5800)). Subsequently, the transferred membrane was incubated with 
targeted primary antibodies such as anti-HIV-1 RT antibodies (for detecting ORF2p), anti-
ORF1, anti-β-actin, anti-α-tubulin (as a loading control), anti-fibronectin, anti-E-cadherin, anti-
SLUG, or other relevant primary antibodies diluted in the WB blocking buffer. This process 
was followed by incubating appropriate types and amount of secondary antibodies such as anti-
Rabbit-HRP (horseradish peroxidase), anti-Rat-HRP, anti-Goat-HRP, and anti-Mouse-HRP. 
The details of these antibodies were listed in Table 2-3. After incubating the stained membranes 
with enhanced chemiluminescent substrates (ECL) (ThermoFisher, Cat# 32109), these stained 
membranes were exposed in a GE LAS4000 Fluoimager for detecting relative HRP activities 
among samples. Results were exported from the software for further analysis. 
2.2.3.2 Immunofluorescence (IF) 
Immunofluorescence (IF) is a common method for detecting protein expression patterns within 
cells or on the cell surface. Several different cell markers including CD24, E-cadherin, 
Fibronectin, and SLUG were investigated by IF experiments in order to understand possible 
cell molecular and morphological changes under alternative treatment conditions. These 
markers were directly targeted by specific antibodies which were listed in section 2.1.3. The 
protocol of IF being used in this project is described below (Figure 2-5).  
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Cells were seeded on a 12 mm Poly-D-lysine coating glass coverslip (for enhancing cell 
adhesion to glass surface) (Neuvitro, Cat# GG-12-1.5-PDL) in a 24-well plate for one day until 
the cells attached to the coverslip surface. These cells were then treated with drugs or DMSO 
(control) for another four days. Before staining, cells were washed with PBS for three times, 
and these cells were fixed on coverslips by IF fixation solution (mentioned in section 2.1.2) for 
15 minutes. Afterwards, the cells were permeabilised by 0.25% Triton X-100 for 10 minutes 
followed by incubating with IF blocking buffer for at least 1 hour. The permeabilised cells then 
were incubated with 1 in 200 to 500 IF antibody dilution buffer diluted primary antibodies for 
16 hours in a 4°C cold room with continuously gentle rotation. Subsequently, the cells were 
washed with PBS followed by incubating with 1 in 500 IF antibody dilution buffer diluted 
secondary antibodies if applicable (some primary antibodies are conjugated with fluorescent 
dyes, secondary antibodies are unnecessary for them). Finally, the coverslip with stained cells 
was mounted with ProLong™ Gold /Diamond Antifade Mountant with DAPI (nucleus 
indicator) (Molecular Probes®, Cat# P36930/P36961). The coverslips were observed under a 
Leica SP5 confocal microscope after 24 hours incubation with the mounting buffer in room 
temperature protecting from lights. The fluorescent signals of the IF samples can be 
maintained for several months.  
 
Figure 2-5 Schematic diagram for the process of immunofluorescence 
Cells are seeded on a coverslip which is covered with the complete culture medium. These cells are 
treated by the drugs once they attached to the coverslip. After a treating period, cells on the coverslip 
are stained with fluorescent antibodies which can target specific cell markers. The stained samples are 
mounted on a microscope slide and are observed under a confocal microscope.   
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2.2.4 RNA detection 
2.2.4.1 RNA isolation 
Total RNA extraction was basically based on the protocol of PureLink® RNA mini Kit 
including the following steps: 
Lysis and homogenisation: Samples were washed with PBS, and then lysed in lysis buffer (2-
mercaptoethanol was added freshly before use). After collecting all of the lysates, a 
homogeniser was used with RNase-free autoclaved tips to homogenise the lysate for at least 1 
minute. The homogenised lysate then was centrifuged at 2600 xg for 5 minutes, and the 
supernatant was transferred to a new clean tube.  
Binding and washing: Equal amount of 70% ethanol was mixed with cell lysate, and the 
mixture was passed through a spin column by centrifuge. After that, the column was washed 
with Wash Buffer I by centrifuge. 
Removing DNA and elution: The column was incubated with 60 µl of TURBO DNA-free 
(Life Technologies) mixture (6 µl 10x DNase Buffer and 4 µl DNase diluted in 50 µl Nuclease-
free water) at room temperature for 30 minutes, and then the column was consequently washed 
with Wash Buffer I and II. Finally, RNA was eluted with nuclease-free water and the quality of 
the RNA was assessed using an Aglient 2100 bioanalyzer (Aglient technologies).  
The method used for extracting microRNA was similar to the total RNA extraction method, but 
a different kit (mirVana™ miRNA isolation kit) was utilised as a pre-requisite requirement for 
TaqMan® Advanced microRNA assays used in microRNA experiments. Basically, a Phenol: 
Chloroform extraction step was added in between homogenisation and RNA binding steps, and 
the flow-through was collected in the first filter step in order to accumulate microRNA and 
reduce the influence from mRNA. After complete washing and elution, isolated miRNAs were 
then quantified using a Nanodrop.   
2.2.4.2 Complementary DNA (cDNA) synthesis  
SuperScript® IV First-Strand cDNA Synthesis Reaction was used for synthesising cDNA from 
target RNA. In this assay, the SuperScript® IV was mainly used for general Quantitative real-
time PCR (qRT-PCR) in LINE-1 expression experiments, the protocol was as follows. For each 
sample, 5 µg RNA template was mixed with 1 µl Random hexamers (50 µM), and 1µl dNTP mix 
(10 mM), and made up to a total volume of 13 µl by adding DEPC-treated water in an Eppendorf 
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tube. The mixtures were incubated at 65°C for 5 minutes for RT primer annealing and incubated on 
ice for 1 minute. Afterwards, the annealed RNA was mixed with 4 µl 5x SSIV buffer, 1 µl 100 mM 
DTT, 1 µl RNaseOUT™ RNase Inhibitor, and 1 µl SuperScript® IV RT (200 U/µl). This reaction 
mixture was incubated at 23°C for 10 minutes for reverse transcription and cDNA synthesis, 
followed by an inactivation step at 80°C incubation for 10 minutes. The RNA-cDNA mixture was 
then incubated with 1 µl RNase H (2 U/µl) at 37°C for 20 minutes for reducing RNA contamination 
for the following experiments. The synthesised cDNA was stored at -20°C until further use or its 
concentration determined by a NanoDrop™ machine (Thermo Scientific™) for directly conducting 
qRT-PCR experiments. 
TaqMan® cDNA synthesis assay was used for microRNA studies. This assay can be separated 
into four major parts including the polyadenylation (poly (A)) tailing reaction, the adaptor 
ligation reaction, the RT reaction, and the miR-Amp reaction. For elongating poly (A) tail to 
microRNA, 10 ng of total RNA (made up to 2 µl) was mixed with 0.5 µl poly (A) buffer (10x), 
0.5 µl ATP, and 0.3 µl poly (A) Enzyme in a tube, and the total volume was made up to 5 µl. 
The mixture was then incubated at 37°C for 45 minutes for polyadenylation, followed by a 
reaction termination step at 65°C for 10 minutes. The poly (A) reaction product was then 
incubated with 3 µl DNA Ligase buffer (5x), 4.5 µl 50% PEG 8000, 0.6 µl ligation adaptor 
(25x), 1.5 µl RNA ligase, and 0.4 µl RNase-free water at 16°C for 1 hour in order to complete 
the ligation step. Afterwards, the adaptor ligation reaction product was mixed with RT reaction 
mix containing 6 µl RT buffer (5x), 1.2 µl dNTP mix (25 mM), 1.5 µl universal RT primer 
(20x), 3 µl RT enzyme mix (10x), and 3.3 µl RNase-free water. The mixture was incubated at 
42°C for 15 minutes followed by 85°C for 5 minutes for completing reverse transcription. The 
RT reaction product needs a further step, miR-Amp reaction, before performing the real-time 
PCR (RT-PCR). This reaction can uniformly increase the amount of cDNA for miRNAs. 5 µl 
of RT reaction product was mixed with 25 µl miR-Amp Master Mix (2x), 2.5 µl miR-Amp 
Primer Mix (20x), and 17.5 µl RNase-free water. This mixture was placed into a PCR machine, 
and the cDNA was amplified by following steps: an enzyme activation step (95° for 5 minutes), 
14 cycles of denature/anneal/extend cycle steps (95°C for three seconds followed by 60°C for 
30 seconds), and a stop reaction step (99°C for 10 minutes). The product then can be directly 
used for further RT-PCR experiments or be stored at -20°C for long term storage.   
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2.2.4.3 General quantitative real-time PCR (qRT-PCR) 
qRT-PCR is a technique which is widely used for quantifying relative RNA levels between 
samples. Principally, the more PCR cycles being detected in a sample mean the lower amount 
of cDNA is contained in this sample, vice versa. The details of the qRT-PCR protocol being 
used in this project were described below.  
96-well qRT-PCR plates (Applied Biosystems) were used in this study. One well contained one 
sample per reaction. Each reaction included 10 µl Power SYBR Green PCR Master Mix (2x) 
(Applied Biosystems), 0.5 µl forward primer (100 mM), 0.5 µl reverse primer, and 10 ng 
corresponding sample cDNA, the total volume was made up to 20 µl. The sample loaded-plate was 
then covered and sealed with an adhesive cover and was centrifuged to ensure the sample containing 
the same amount of reagents. The qRT-PCR was operated StepOnePlus™ RT-PCR instrument 
through accompanying software - the ExpressionSuite™ software. The setting of the thermal 
program for the qRT-PCR included a 10 minutes enzyme activation step (at 95°C), and 40 PCR 
cycle (denature at 95°C for 15 seconds and anneal/extend at 60°C for 1 minute). The comparative 
Ct (ΔΔCt) was used to perform the relative quantification of the qRT-PCR results. These results 
were then imported to GraphPad Prism 6 for further graphical analysis. 
2.2.4.4 microRNA qRT-PCR 
The principle of microRNA qRT-PCR is similar to general qRT-PCR, however, because of low 
copy numbers and a relatively small amount of microRNAs compared with mRNAs, another 
qRT-PCR system was used with different types of indicators and primers with the general qRT-
PCR. TaqMan® Advanced microRNA assay; (Applied Biosystems™) which contains PCR 
reagents, reaction buffer, and primers are sensitive to small amounts of sample, and it can 
measure mature microRNAs from less than 10 ng of the total RNA sample.  
In this assay, the total RNAs was prepared by mirVana™ miRNA Isolation kit in order to enrich 
small RNAs. The next step was to synthesise cDNA by the TaqMan® Advanced miRNA cDNA 
Synthesis Kit. Afterwards, 5 µl of one in ten diluted cDNA templates were mixed with 10 µl 
TaqMan® Fast Advanced Master Mix (2X), 1 µl TaqMan® Advanced miRNA assay (20X), 
and 4 µl RNase-free water. The mixture was then transferred into a 96-well PCR plate and 
measured by the StepOnePlus™ RT-PCR instrument (Applied Biosystems). The PCR reactions 
were set as one enzyme activation step (95°C, 20 seconds) and 40 cycles of denature step (95°C, 
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one second) and anneal/extend step (60°C, 20 seconds). The ExpressionSuite™ software was 
used for analysing the results by comparing the relative quantification ΔΔCt values among 
samples. All the samples had four technical replicates to ensure consistency.   
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2.2.5 Cell viability and cell proliferation assay 
2.2.5.1 Crystal violet cell viability assay 
Crystal violet (Sigma-Aldrich, Cat# C0775), a dark-purple colour dye, can stain proteins and 
DNA, thus it can be used as a cell indicator. Crystal violet assay is a quick screening method 
for indirectly determining relative numbers of adherent cells on the same size of cell culture 
plates since dead adherent cells detach from the plate but live adherent cells remain on the plate. 
The violet assay as described below. 
The cultured cells in 25 cm2 flasks are gently washed with water until no red-colour medium 
can be seen and the remaining liquid is aspirated by filter papers. Afterwards, an appropriate 
amount of Crystal violet solution (mentioned in section 2.1.2) is added to the flasks and covers 
the cell-attached surface of the flasks. The solution is incubated with the cells for 20 minutes 
with gentle shake following by another washing step for excluding redundant crystal violet 
solution. The washed flasks are then air-dried for 24 hours. Subsequently, 500 µl of methanol 
is added to the flasks and incubated with the stained purple-colour cells for at least 30 minutes 
until the cells become transparent. The de-stained methanol buffers are measured by 
SmartSpec™ 3000 (BIO-RAD) at OD570 nm, and the relative cell viability of each treating 
conditions can be calculated.  
This method is inexpensive and can roughly quantify cell viability of large-scale of adherent 
cells; however, the accuracy might be lower than other methods which can directly measure 
enzyme activities within the cells. Thus, additional cell viability assays were used for further 
studying drug responses of the cells. 
2.2.5.2 XTT cell viability assay 
2,3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-carboxanilide (XTT) cell viability 
assay (Cell Signaling, Cat# 9095) is a commonly used colourimetric assay. It has been utilised 
in both cell viability and proliferation experiments. Dissolved XTT is a slightly yellow reagent; 
whereas, the colour of XTT changed to bright orange when it is reduced by dehydrogenase 
enzymes. The N-Methylphenazonium methyl sulfate in the XTT solution can enhance XTT 
reduction, thus the colour change can be violent. These dehydrogenase enzymes lose their 
functions immediately after cell death; therefore, measuring the intensity of reagent colour can 
identify the relative numbers of viable cells among treatments.  
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The XTT assay is conducted by the following steps. After mixing XTT reagent and electron 
coupling solution (50:1 ratio), 50 µl of the complete XTT detection reagent is added to each 
testing well of 96-well plates, then the plates are incubated for 4 hours in a 37°C incubator for 
an enzyme reaction. Finally, the absorbance of each well is measured at 450 nm using an ELISA 
reader, and then the data is analysed by Prism software. For cell viability experiment, testing 
cells are treated with different concentrations of drugs (0 µM, 10 µM, 20 µM, 30 µM, 40 µM, 
and 50 µM, separately) in order to calculate proper 50% effective cytotoxic concentration 
(EC50) values of the drugs for further experiments; For cell proliferation experiments, cells are 
treated with DMSO-untreated-control, Efavirenz (EFV) at EC50 concentration, and SPV122 
(SPV) at EC50 concentration for 24 hours, 48 hours, 72 hours, and 96 hours to observe changes 
in cell proliferation between cells with/without drug treatment.  
2.2.5.3 AlamarBlue™ Cell Viability Assay 
The functions of alamarBlue™ Cell Viability Reagent (Thermo Fisher Scientific, Cat# 
DAL1100) are similar to the XTT assay which are used for observing cell viability and cell 
proliferation. The alamarBlue™ cell viability assay could be better than the XTT cell viability 
assay since it is less toxic to cells. The principle of the alamarBlue™ cell viability assay is that 
the blue-colour and non-fluorescent resazurin, the major component of alamarBlue™ reagent, 
can be reduced to resorufin within live cells, and then the red-colour high-fluorescent resorufin 
can be measured either by absorbance at 570 nm or fluorescence at 590 nm (excitation at 530 
nm to 560 nm). The readout of absorbance or fluorescence can be calculated and therefore the 
relative cell viability of each well can be determined. The major difference between alamarBlue 
assay and XTT assay is that after incubating with alamarBlue reagent, the cells could still 
survive and grow. This assay was conducted to partially replace XTT assay in later of this study.  
2.2.5.4 CellTrace™ CSFE cell proliferation assay 
Unlike XTT and alamarBlue™ assays, CellTrace™ 5(6)-Carboxyfluorescein N-
hydroxysuccinimidyl ester (CSFE) Cell Proliferation Assay (Thermo Fisher Scientific, Cat# 
C34554) is an assay specifically for detecting cell division (Figure 2-6). CSFE is a non-
fluorescent cell-permeant compound, thus it can pass through cell membrane when incubated 
with cells. The acetate group is then cleaved by enzymes in the cell cytoplasm, thus the remnant 
green-fluorescent carboxyfluorescein is locked within the cell. When the succinimidyl ester 
group couple with intracellular free amines, the cell can be detected as a green fluorescent cell 
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for quite a long term by flow cytometry FITC filter. When cell division is occurring, the green 
fluorescence is divided into two daughter cells, and therefore the brightness of green 
fluorescence is reduced to half-way of the original brightness. The brightness of CSFE-tracking 
cells is inversely related to the frequency of cell division and cell proliferation, therefore the 
brighter cells have relatively lower cell division rate.  
             
Figure 2-6 Principle of CellTrace™ cell proliferation assay 
In CellTrace™ assay, the parent cells are stained with non-toxic CSFE which can be activated its green-
fluorescence and be implemented to the cell membrane after enzyme digestion within cells. Therefore, 
the brightness of green-fluorescence within the cell can only be diluted during cell division. The 
daughter cells contain about half of the original green-fluorescent compounds. Continuously, the 
younger generation of cells contain less green-fluorescence. Because of this, the relative cell division 
rate can be monitored and be compared between different treatments.   
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2.2.6 Cell physiological and morphological change   
2.2.6.1 Cell cycle analysis 
Propidium iodide (PI) (Sigma-Aldrich, Cat# P4170), a nucleic acid fluorescent indicator, is 
commonly used for cell cycle analysis owing to the diverse amount of DNA in different cell 
stages. DNA variation in cells appears in distinct cell interphase stages of the cell cycle, and 
this can be detected by PI staining. PI can bind proportionately to the amount of DNA 
presenting in the cell. In a human cell, DNA synthesis occurs in synthesis (S) phase thus the 
amount of DNA of S phase cell should be in between of Gap 0 and Gap 1 (G0/G1) phase cell 
and Gap 2 (G2) phase cell; while the cell contains a double amount of DNA in the G2 phase 
than those cells in the G0/G1 phase. Therefore, PI staining for the cells in S phase is brighter 
than the cells in G0/G1 phase but darker than the cells in G2 phase; whereas, the cells in G2 
phase are approximately twice as bright as cells in G0/G1 phase. This feature can identify the 
cells in different cell cycle stages.   
This cell cycle experiment was conducted with the following steps. After harvesting drug-
treated and untreated cells, the cells were fixed in pre-chilled 70% ethanol prepared in 
Dulbecco’s Phosphate-buffered Saline (DPBS) (Gibco™, Cat# 14190250) for 2 to 24 hours 
(the fixed cells can be stored for 1 month). The next step was to wash the fixed cells with DPBS 
for three times, and then to stain the cells with PI staining solution (mentioned in the section 
2.1.2) with 0.2 mg/ml RNase A which can reduce RNA contamination in cell cycle experiment 
for at least 15 minutes. Finally, the stained samples were analysed through flow cytometry 
Fortessa (BD) at the fluorescence emission at 575 nm to observe the percentages of the cells in 
different interphase stages.  
SubG1 detection is a branch of the cell cycle study. The small fragment of DNA is considered 
as the products of apoptosis, thus the cell with DNA fragment smaller than a normal cell (in G0 
or G1 phase) is defined as an apoptotic cell. Through a fluorescence-activated cell sorting 
(FACS) analysis, the proportion of apoptotic cell in the entire population can be observed. 
However, because the subG1 population may include cell debris, the exact apoptotic cells might 
be less than predicted.  
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2.2.6.2 Cell apoptosis 
One of the most popular methods for detecting apoptotic and necrotic cells is the FITC Annexin 
V/Dead Cell Apoptosis Kit (Invitrogen™, Cat# V13242). In this study, PI was used to stain 
DNA, and Annexin V was used for phosphatidylserine staining. PI failed to enter live or early 
apoptotic cells because of the protection of cell membrane, but PI was able to stain late 
apoptotic and necrotic cells due to the loss of membrane integrity. Annexin V labelled cells 
externalised phosphatidylserine on the cell surface in both apoptotic and necrotic cells. Thus, 
apoptotic cells and necrotic cells could be distinguished. The whole process is listed below: (1) 
harvested 1x106 cells, (2) stained the cells in 100 µl of Annexin-binding buffer (mentioned in 
section  2.1.2) with 5 µl of FITC Annexin V solution, 2 µg/ml PI, and 50 µg/ml RNase A in 
dark environment for 30 minutes, (3) washed the stained cells three times for washing out 
redundant staining solution, and (4) analysed the stained cells through flow cytometry Fortessa 
with the fluorescence emission at 530 nm (for detecting FITC signal) and 575 nm (for detecting 
PI signal) immediately after staining completed. The cells can be separated into three major 
groups – live cells (Annexin V-/PI-), early apoptotic cells (Annexin V+/PI-), and late apoptotic 
and necrotic cells (Annexin V+/PI+) according to the FACS analysis results (Figure 2-7).  
 
 
 
 
Figure 2-7 Three major cell status being 
identified by Annexin V/ PI staining 
Based on Annexin V/PI staining, cells in 
different status can be separated by flow 
cytometry according to their fluorescent 
patterns. The cells located in Annexin V-/PI- 
region are live cells; the cells located in 
Annexin V+/PI- region are early apoptotic 
cells; the cells located in Annexin V+/PI+ 
region are late apoptotic and necrotic cells.   
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2.2.6.3 Cell morphology detection 
Cell morphology detection experiments were conducted by Phalloidin staining. Phalloidin, a 
natural toxin from Amanita Phalloides, has high-affinity to eukaryote-enriched filamentous 
actin (F-actin), which is an essential element for cytoskeleton. With Phalloidin staining, the 
entire cell shape and stress fibres within the cell can be clearly observed. Phalloidin staining in 
this experiment was a modified IF staining, the details of are described below.   
Firstly, cells were seeded on 12 mm Poly-D-lysine coating glass coverslips in a 24-well plate 
for one day until the cells attached to the coverslip surface and then treated these cells with the 
drugs or DMSO-control for four days. Before staining, cells were washed with PBS for three 
times, and these cells were fixed on coverslips by IF fixation solution for 15 minutes. 
Afterwards, the cells were permeabilised and stained simultaneously by 0.25% Triton X-100 
with 1 in 250 diluted Phalloidin staining solution for 1 hour in room temperature with light 
protection. Subsequently, the cell-attached coverslip was washed with PBS and then was 
mounted with ProLong™ Gold /Diamond Antifade Mountant with DAPI. The cells on the 
coverslip were observed under a Leica SP5 confocal microscope after 24 hours incubation 
with mounting buffer. The fluorescent signals of the IF samples can be maintained for several 
months.  
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2.2.7 Cancer stem cells (CSCs) study 
Different CSC identifying methods which point out various CSC characteristics have been 
developed over the decades. In breast cancer studies, quite a few methods have been recognised 
as CSC identifying methods. Three commonly used FACS methods including CD44 and CD24 
cell surface antigens, aldehyde dehydrogenase (ALDH) activity, and cell efflux ability (Figure 
2-8) and a functional CSC accumulation assay (mentioned in the section 2.2.1.2) (Kai et al., 
2010) were utilised in this study. The CSC research in this project was mainly based on the 
results of FACS analysis unless otherwise specified. 
 
 
Figure 2-8 Three commonly used FACS-based BCSC identifying methods 
The first commonly used method (on the top) is CD44/CD24 cell surface antigens staining method, cells 
are stained with CD44 and CD24 antibodies and then identified by flow cytometry, the cells with 
CD44+/CD24- features are recognised as the mesenchymal-like CSCs. The second commonly used 
method (in the middle) is ALDH functional assay, cells with higher ALDH activities (green cells) can be 
identified by flow cytometry and are considered as the epithelial-like CSCs. The third commonly used 
method (on the bottom) is cell efflux ability assay, cells with great dye efflux capabilities can also be 
identified by flow cytometry and are considered as the side population cells.   
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2.2.7.1 CD44+/CD24- mesenchymal-like CSCs 
The existence of CD44 and CD24 antigens on the cancer cell membrane has been employed as 
a valid CSC indicator for a long time. The exact function of CD24 has not been determined; 
whereas, CD44 has been linked with some unfavourable outcomes in cancers such as cancer 
metastasis and cancer proliferation (Hu et al., 2018). Evidence suggested that breast cancer cells 
with low CD24 and high CD44 expression can initiate tumour in immunodeficient mice 
(Velasco-Velazquez et al., 2012) which is a typical CSC characteristic.  
For identifying the expression of CD44 and CD24 on the cell surface, the harvested cells were 
stained by an anti-CD44 antibody conjugated with PE fluorescence and anti-CD24 antibody 
conjugated with PE-Cy7™ or Alexa Fluor® 647 fluorescence depending on the fluorescent 
signals of the co-stained antibodies. The sample was incubated with the target antibodies in a 
4°C fridge protecting from light for 30 minutes, followed by gentle wash steps. After a complete 
residue dye wash, the sample was passed through and detected by a flow cytometry BD Fortessa. 
The data was collected by the machine and was further analysed by Flowjo software version X. 
2.2.7.2 High ALDH activity epithelial-like CSCs 
Cancer cells with high ALDH activity have been recognised as CSCs and have been widely 
used in many studies. These cells also can initiate tumour in immunodeficient mice as 
CD44+/CD24- cells do (Ginestier et al., 2007). A commercially available functional CSC assay 
has been established by STEMCELL technologies named ALDEFLUOR® Kit for stem cell 
identification (Cat# 01700). The ALDH substrates expressed green fluorescence while the 
substrates were digested by ALDH. For identifying the cancer cells with high ALDH activity, 
the harvested cells were incubated with an appropriate amount of pre-mixed activated 
ALDEFLUOR® substrate in ALDEFLUOR® buffer for 30 to 40 minutes in a 37°C incubator to 
let ALDH digest the substrates. In the meantime, the same amount of cells were incubated with 
ALDEFLUOR® substrate within similar conditions to the test cells apart from the addition of 
N, N-diethylaminobenzaldehyde (DEAB) for blocking ALDH function. After incubation, the 
test sample and control cells were detected by a flow cytometry BD Fortessa. The data was 
collected by the machine and further being analysed by Flowjo software version X. The high 
ALDH activity cells were gated based on the ALDH inhibition control. Cells brighter than the 
ALDH inhibition control were considered as high ALDH activity cells.  
                                                                                                                                                Materials and Methods 
45 
 
2.2.7.3 Side population 
Side population describes a small among of cancer cells having strong efflux ability associating 
with ABC transporters and maybe one of the causes of cancer drug resistance (Moserle et al., 
2010). However, increasing evidence suggests that the side population might be unable to 
determine CSC and might only be responsible for a part of drug resistance (Britton et al., 2012). 
For determining side population, the harvested cells were incubated with Hoechst 33342 
(Sigma-Aldrich, Cat# B2261) at a final concentration of 5 µg/ml for 90 minutes in a 37°C 
incubator for cells to be stained and/or efflux Hoechst dye. Afterwards, the sample was washed 
with DPBS buffer to remove the residue Hoechst dye followed by adding PI as an indicator of 
dead cells. Finally, the sample was passed through and detected by a flow cytometry BD 
Fortessa with dedicated settings that detect blue and red fluorescence of Hoechst dye. The data 
was collected and further being analysed by Flowjo software version X. Cells with a greater 
efflux ability can be identified from the major population, and these cells were considered as 
side population. 
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2.2.8 RNA sequence (RNA-Seq) analysis 
The entire RNA-Seq process includes sample import and data export as depicted in Figure 2-9. 
Details of RNA-Seq preparation and preliminary data analysis was described below.   
 
Figure 2-9 RNA-Seq process 
High-quality total RNA extracted from samples are reverse transcribed to cDNA. RNA-Seq libraries are 
established based on these cDNA. A sequencer exports the RNA-Seq results after analysing the RNA-
Seq libraries. The results are then further analysed by ANOVA analysis followed by STRING-DB analysis 
or network analysis in order to acquire potential molecular or pathways which may be involved in drug 
responses.    
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2.2.8.1 RNA-Seq preparation  
RNA-Seq preparation can be separated into two major parts, one is sample preparation, and the 
other is sequencing and preliminary analysis.  
The sample preparation of RNA-Seq requires high-quality total RNA as shown in Table 2-8 
and Figure 2-10, the steps of total RNA isolation was described in section 2.2.7.1. 
Table 2-8 The quality of total RNA for RNA sequencing 
Sample RIN value 28s/18s ratio 
MCF10A DMSO 9.5 2.0 
MCF10A EFV 9.0 2.2 
MCF10A SPV 9.6 2.2 
MCF10AT DMSO 8.7 2.3 
MCF10AT EFV 8.5 2.1 
MCF10AT SPV 8.9 2.2 
MCF10CA1a DMSO 9.2 2.2 
MCF10CA1a EFV 8.9 2.3 
MCF10CA1a SPV 9.2 2.3 
MDA-MB-231 DMSO 9.1 2.2 
MDA-MB-231 EFV 10 2.6 
MDA-MB-231 SPV 10 2.7 
MCF7 DMSO 9.7 2.1 
MCF7 EFV 9.9 2.1 
MCF7 SPV 9.9 2.2 
 
 
Figure 2-10 The quality of total RNA analysed by Aglient 2100 bioanalyzer for RNA sequencing 
The top bands represent 28S RNA; the second bands represent 18S RNA; the third bands represent 
RNA fragments around 100 nt; the last green bands represent the bioanalyzer marker. Two clear and 
sharp bands (28S and 18S RNA) and a light band can be detected in a non-degraded pure total RNA 
sample.  
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After collecting high-quality total RNA, the RNA-Seq libraries were made using the Truseq 
stranded mRNA library kit. When the instrument presented all the gene reads for the entire 
human genome from different samples, the reads were mapped with a standard pipeline based 
on Ensembl database version 72 using Tophat-2.0.12-1 software. The raw mapped read counts 
were then converted into Fragments per Kilobase Million (FPKM) values by the cufflinks-2.2.1 
programme in order to make further comparisons. Following mapping, FPKM values were 
imported into Partek Genomics Suite version 6.3 (Partek, St Louis, Missouri, USA) using the 
log(x + 1) transformation to convert all FPKM values to logged values for further analysis. 
2.2.8.2 ANOVA analysis 
After the RNA-Seq data was collected, many methods can be used to analyse the data. The first 
method we used was the analysis of variance (ANOVA) analysis. ANOVA analysis is the most 
widely used method to compare the variance to calculate whether the gene displays a significant 
difference. The experiment was analysed in Partek Genomics Suite using a 2-way ANOVA 
model based on the method of moments (Eisenhart, 1947). The cell type factor had 5 levels 
(MCF10A, MCF10AT, MCF10CA1α, MDA-MB-231, and MCF7) and the treatment factor 
also had 3 levels (EFV, SPV, and DMSO-control). The contrasts EFV-treated cells versus 
DMSO-untreated-control cells and the SPV-treated cells versus DMSO-untreated-control cells 
contrasts were calculated based on the principles of data analysis (Tamhane and Dunlop, 2000) 
by Dr Stephen Ohms.  
Typically in an ANOVA analysis, a p-value less than 0.05 is considered as showing a significant 
difference. However, for the multigene analysis, the cut-off for a significant difference needs 
to be corrected, otherwise, the power could be too low to identify the truly significant genes. 
As such, the optimised p-value, q-value, was used for determining significant genes in this 
study. Q-value takes into consideration the false discovery rate (FDR) and has a higher chance 
of detecting significant differences (Li et al., 2007). A gene with a q-value less than the set cut-
off was considered as a gene with significant change and can be further analysed by the 
STRING-DB pathway searching software version 10.5. 
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2.2.8.3 Network analysis 
Network analysis for RNA-Seq results is based on interpreting the ANOVA results. The 
principle of this method is to gather the genes with a similar trend to a module. This module 
may contain some relevant genes since they have a similar expression pattern in different 
conditions. Thus, when analysing these genes by the STRING-DB pathway searching tool, 
there is a chance of finding genes which are correlated with each other. 
The preliminary RNA-Seq data analysis including ANOVA analysis and network analysis was 
done by Dr Stephen Ohms. We sincerely appreciate his assistance and cooperation.  
 
Statistical analysis 
The data obtained from each experiment (immunofluorescence, western blot, RT-PCR, cell 
proliferation assay, cell cycle assay, CSC assays, and others) were expressed as the mean ± SD 
of three independent experiments with each experiment performed in triplicate. A student’s t-
test was used to estimate statistical significance using Prism software (GraphPad Software, San 
Diego, CA). P < 0.05 was accepted as statistically significant. If not, need to amend in each 
section where relevant  
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Chapter 3 The effects of antiretroviral drugs on triple-negative 
breast cancer cell lines  
3.1 Introduction   
Breast cancer is one of the most common and lethal diseases worldwide, however, some of its 
causes and regulatory pathways involved are beyond our understanding. On average, more than 
50 people are diagnosed with breast cancer daily in Australia, most are women older than 50 
years old (AIHW, 2017). In Australia, one in seven women has a chance of being diagnosed 
with breast cancer in her lifetime whereas, for men, the statistics are one in 675 (AIHW, 2017). 
Although the five-year survival rate of breast cancer has increased from 74% to 90.8% within 
the past few decades, it is still the fourth leading cause of cancer-related deaths in females in 
Australia (AIHW, 2017). The incidence and mortality of breast cancer reflect on our lack of 
knowledge and inadequate control of the disease. It is therefore very important that we further 
our understanding of the mechanisms involved in breast cancer initiation, growth, and 
progression.  
Triple-negative breast cancer (TNBC) is a subclass of breast cancer with poor prognostic 
outcomes. About 15% of breast cancer patients are TNBC patients. TNBC lacks the oestrogen 
receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 
(HER2) (Reddy, 2011). Breast cancer patients differ in their prognostic outcomes because they 
respond differently to the drugs. Hormone therapies can only treat breast cancers with hormone 
receptors, and HER2 inhibitors are used for treating breast cancers with HER2 overexpression 
(Jamdade et al., 2015). Unlike breast cancers with well-known receptors, TNBCs are usually 
treated with systemic chemotherapy and radiotherapy (Collignon et al., 2016) because there are 
very few targeted therapeutic strategies available to them (Kalimutho et al., 2015).  
One of the potential therapeutic targets for breast cancer treatment is the endogenous transposon, 
long interspersed nucleotide element 1 (LINE-1). In the mid-1990s, the incidence of  acquired 
immune deficiency syndrome (AIDS)-related cancers was greatly reduced in human 
immunodeficiency virus (HIV)-infected patients owing to the introduction of antiretroviral 
therapy (Simard and Engels, 2010). Some scientists believed the decreasing incidence of AIDS-
related cancers was not only due to the successful inhibition of HIV reverse transcriptase (RT) 
but also to the inhibitory effect of antiretroviral drugs on the autonomous LINE-1 RT activity 
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in tumour cells (Jones et al., 2008). LINE-1 is almost silent in differentiated tissues via several 
cell self-defence mechanisms because of its mutagenicity to normal differentiated cells; 
however, it is highly expressed in tumour cells (Sciamanna et al., 2016). LINE-1 expression 
has been identified in various cancers, including most breast carcinoma (97% LINE-1 positive 
cases in a screening study), as identified by screening studies of clinical samples (Rodić and 
Burns, 2013, Rodić et al., 2014). Furthermore, inhibition of LINE-1 has been shown to 
eliminate cancer cells in prostate cancer, melanoma and some non-TNBCs. Therefore the role 
of LINE-1 in TNBCs have been investigated in this study in order to improve targeted 
therapeutic strategies for TNBCs. 
The focus of this chapter was to test antiretroviral drugs for their inhibitory effects on TNBCs. 
Whether LINE-1 plays a critical role in any observed inhibitory effects was investigated as was 
the mechanism involved. These experiments give a brief insight into the effectiveness of 
repurposing antiretroviral drugs as anticancer drugs in TNBCs. 
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3.2 Results 
3.2.1 Antiretroviral drugs effective against breast cancer cells 
The anticancer effects of certain antiretroviral drugs have previously been confirmed in 
epithelial cancer cell lines such as prostate, colon, lung, pancreatic cancers, and leukemia 
(Rodić and Burns, 2013). Some studies suggest that nucleoside reverse transcriptase inhibitors 
(NRTIs), or nucleoside analogs, may have more potential for eliminating cancer cells than non-
nucleoside reverse transcriptase inhibitors (NNRTIs). Other studies, however, show NNRTIs 
to have significant anticancer effects (Jones et al., 2008). These results suggest that drug 
responses may vary depending on the cell type.  
Table 3-1 List of the tested antiretroviral drugs and their structures 
  
(NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase inhibitor) 
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In order to verify the anticancer effects of antiretroviral drugs on TNBCs, some antiretroviral 
drugs were selected and tested on a variety of human TNBC cell lines, using a cell viability 
assay. Some commonly used antiretroviral drugs including Efavirenz (EFV, NNRTI), 
Delavirdine (DEL, NNRTI), Zidovudine (AZT, NRTI), Abacavir sulfate (ABC, NRTI), 
Lamivudine (3TC, NRTI), and a newly synthesised drug SPV122 (SPV, NNRTI) (Table 3-1) 
were chosen for testing on MCF10AT, MCF10CA1α, and MDA-MB-231 TNBC cell lines. 
MCF10A cell line was a non-cancerous control, whereas the T47D cell line was selected as a 
luminal-type breast cancer control because T47D is highly sensitive to many antiretroviral 
drugs. The cytotoxic effects of the drugs were investigated on the chosen cell lines, using the 
XTT cell viability assay.  
To investigate breast cancer cell viability under various treating conditions, different 
concentrations of the drugs EFV, SPV, DEL, AZT, ABC, and 3TC (0 µM, 10 µM, 20 µM, 30 
µM, 40 µM, and 50 µM) were individually incubated with MCF10A, MCF10AT, 
MCF10CA1α, MDA-MB-231, and T47D cells. The cells were treated with the drugs for four 
days because the greatest variations in cell number were observed at the 96-hour time point of 
drug treatment (in appendix Figure S3-1). The cell viability results (Figure 3-1) indicated that 
EFV and SPV were the most effective anticancer drugs on all the breast cancer cell lines tested; 
DEL and AZT were less toxic than EFV and SPV; whereas 3TC and ABC under 50 µM were 
non-toxic (data are not shown) against all breast cancer cell lines tested. In contrast and as 
predicted, MCF10A, a non-cancerous cell line, showed no response to any of these drugs at 
concentrations less than 50 µM.  
The half-maximal effective concentration (EC50) values of the drugs were calculated by Prism 
software (Table 3-2). After converting drug concentrations to logarithmic doses, the ‘log 
(inhibitor) versus normalized response – variable slope’ function in Prism was utilized to 
calculate EC50 values of the drugs by using the equation: ‘Y=100/(1+10^((LogEC50-
X)*HillSlope)))’. The EC50 values of EFV in MCF10AT, MCF10CA1α, MDA-MB-231, and 
T47D were 23.32 µM, 21.84 µM, 27.89 µM, 9.19 µM, respectively; the EC50 values of SPV 
in MCF10AT, MCF10CA1α, MDA-MB-231, and T47D were 23.41 µM, 12.47 µM, 28.13 µM, 
and 6.57 µM, respectively. As expected, SPV was a slightly more effective anticancer drug than 
EFV in most of the cell lines except MCF10AT. This observation agreed with previous findings 
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in skin malignant melanoma carried out by the manufacturer of SPV, who designed it to 
precisely target LINE-1 RT, unlike EFV repurposed from an HIV inhibitor which may possibly 
lose its target on LINE-1 (Sbardella et al., 2011).  
 
Figure 3–1 Cell viabilities at different antiretroviral drug concentrations 
MCF10A gave no response to any of the tested drugs. EFV (red), SPV (blue), AZT (green), and DEL 
(purple) were toxic to T47D cells. TNBC cell lines – MCF10AT, MCF10 CA1α, and MDA-MB-231 cell lines 
had fewer responses to AZT and DEL compared with T47D cell line; whereas, EFV and SPV were more 
toxic to TNBC cell lines compared with other tested drugs. Among the six drugs tested, EFV and SPV 
were highly toxic for all tested breast cancer cell lines. Cell viability was determined at day 4 using a 
cell viability assay. Error bars: ±SD, n = 3. 
 
Table 3-2 The EC50 values of EFV and SPV in each cell line 
Drug type MCF10AT MCF10CA1α MDA-MB-231 T47D 
Efavirenz (EFV) NNRTI 23.32 μM 21.84 μM 27.89 μM 9.19 μM 
SPV122 (SPV) NNRTI 23.41 μM 12.47 μM 28.13 μM 6.57 μM 
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In summary, the EC50 values indicated that EFV and SPV are effective anticancer drugs for 
treating TNBC cell lines compared with other tested antiretroviral drugs. T47D luminal-type 
breast cancer cell line was sensitive to EFV, SPV as well as to AZT and DEL, and had lower 
EC50 values for all these drugs than did TNBCs. This illustrated that TNBCs could be more 
resistant to these antiretroviral drugs than luminal-type T47D cancer cells, yet were still affected 
by the drugs at relatively higher concentrations. The following experiments were based on the 
EC50 values for EFV and SPV for each cell line.  
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3.2.2 EFV inhibits LINE-1 expression  
After determining EFV and SPV to be the most effective compounds against the selected TNBC 
cell lines, we questioned the role of LINE-1 in this process. Western blot data compared LINE-
1 protein ORF1 and ORF2 expression in DMSO-untreated-control and EFV-treated MCF10AT, 
MCF10CA1α, MDA-MB-231, and T47D cancer cells as well as in non-cancerous MCF10A 
control cells (Figure 3-2). These data indicated that very limited LINE-1 protein expression was 
detected in the MCF10A cell line (Figure 3-2A); whereas all breast cancer cell lines expressed 
LINE-1 proteins (Figure 3-2A, 3-2B). Also, the data showed that less LINE-1 proteins were 
detected after EFV treatment compared with untreated-controls (Figure 3-2A, 3-2B). LINE-1 
protein expression in the EFV-treated cancer cells was reduced to about 60% of that in untreated 
cancer cells (Figure 3-2D). In addition, after treating these breast cancer cells with EFV, ORF2, 
which is the protein containing reverse transcriptase region (the potential target of antiretroviral 
drugs), and ORF1 were suppressed in all of the cancer cell lines tested, suggesting an overall 
LINE-1 knockdown in EFV-treated breast cancer cells. Moreover, T47D western blot data 
indicated that the longer (six days) the cancer cells were exposed to EFV, the less LINE-1 
proteins were expressed (compared with four days of EFV treatment) (Figure 3-2C).  
Consistent with the western blot data, the qRT-PCR data suggested that the expression of both 
LINE-1 orf1 RNA and orf2 RNA (including endonuclease (EN) and reverse transcriptase (RT) 
regions) was reduced after EFV treatment in MCF10A, MCF10CA1α, MDA-MB-231, and 
T47D cell lines (Figure 3-3). These experiments implied that EFV might affect the expression 
and function of LINE-1 protein for generating novel LINE-1 RNA in the cancer cell by a 
positive feedback loop. This indicated a possible link between EFV treatment-induced 
cytotoxin and LINE-1 inhibition in breast cancer cells, further supporting our view that EFV 
could be a valid LINE-1 inhibitor in these breast cancer cell lines.  
LINE-1 insertion in human genome relies on L1RNP which is assembled with LINE-1 RNA, 
LINE-1 ORF1 protein, and LINE-1 ORF2 protein (Goodier et al., 2013). Once LINE-1 RT is 
blocked by antiretroviral drugs, LINE-1 reverse transcription can be terminated leading to less 
new LINE-1 being present in the cancer genome. Additionally, dissociated LINE-1 RNAs can 
be degraded (Kemp and Longworth, 2015), and therefore reduced levels of LINE-1 protein and 
RNA is detected in these antiretroviral drug-treated cells. 
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Figure 3–2 LINE-1 protein expression in different cell lines 
Western blot data showing LINE-1 expression in breast cancer cell lines. (A) Almost no LINE-1 
expression in non-cancer MCF10A cell line. LINE-1 proteins (ORF1 and ORF2 RT) were detected in 
MCF10AT and MCF10CA1α, but the expression levels were reduced by EFV treatment. (B) LINE-1 
proteins were also detected in MDA-MB-231 and T47D cell lines and were inhibited by EFV treatment. 
(C) Increasing the EFV treatment period further inhibited LINE-1 expression. (D) The relative ORF1 and 
ORF2 RT fold-changes reflected LINE-1 inhibition by EFV in cancer cell lines. Error bars: ±SD, n = 3. 
A 
B 
D 
C 
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Figure 3–3 LINE-1 RNA expression in different cell lines 
The qRT-PCR data showed that LINE-1 orf-1 and orf-2 (including endonuclease and reverse 
transcriptase regions) were expressed in breast cancer cell lines including MCF10AT, MCF10CA1α, 
MDA-MB-231 and T47D. EFV-treated breast cancer cells detected lower levels of LINE-1 RNA orf-1 and 
orf-2 compared with DMSO-controls. Error bars: ±SD, n = 4. 
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3.2.3 Antiretroviral drugs inhibit LINE-1 reverse transcriptase activities         
3.2.3.1 LINE-1 overexpression 
To further confirm the functional link between EFV and SPV anticancer effects and LINE-1 
inhibition, a LINE-1 RT functional activity assay was performed in a non-cancerous and low-
LINE-1-expressed cell line MCF10A. pBS-L1PA1-CH-mneo (Figure 3-4A) (Wagstaff et al., 
2011) is an optimized LINE-1 overexpressing plasmid which can be transfected into a 
mammalian cell to express a target protein, in this case, optimized LINE-1. Its amino acid 
sequence is 74% consistent with the original LINE-1 sequence ensuring its escape from the 
cells’ self-defence mechanisms while maintaining most of the LINE-1 characteristics. It has 
been shown to be capable of performing reverse transcription in cells (Wagstaff et al., 2011). 
The complete map of pBS-LAPA1-CH-mneo plasmid DNA was illustrated in section 2.1.7. 
In this experiment, only the successfully pBS-L1PA1-CH-mneo transfected MCF10A cells 
survived in culture medium containing 200 μg/ ml Geneticin™ (Figure 3-4B1), which is usually 
harmful to normal (untransfected) cells (Figure 3-4B7, 3-4B8, 3-4B9). LINE-1 reverse 
transcriptase activities produce Geneticin™ resistance for the host cells. This Geneticin™ 
resistance was suppressed by antiretroviral drug treatment thus less antiretroviral drug-treated 
transfected cells survived (Figure 3-4B2, 3-4B3) compared with untreated-transfected cells 
(Figure 3-4B1). To quantify the numbers of viable cells in each condition, the cells were stained 
with crystal violet solution and de-stained with methanol. The de-stained crystal violet-
methanol solution was collected and the optical densities of each flask measured at 570nm. A 
significant decrease was shown in EFV or SPV treated-transfected cells compared with their 
control (Figure 3-4C). The LINE-1 RT functional assay confirmed the effectiveness of EFV 
and SPV at inhibiting LINE-1 reverse transcriptase.   
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Figure 3–4 LINE-1 reverse transcription simulation assay in MCF10A cells  
The pBS-L1PA1-CH-mneo plasmid (A) transfected cells have Geneticin resistance enabling their survival 
under Geneticin selection (200 μg/ ml of Geneticin) (B1); whereas, the untransfected control cells were 
all killed by 200 μg/ ml of Geneticin (B7, B8, B9). The cells’ resistance was reduced by treating them 
with EFV or SPV (B2, B3). (B4, B5, B6 was no Geneticin selection control). Error bars: ±SD, n = 3. 
(Transfected cells with Geneticin selection, EFV-treated: p = 0.0082, SPV-treated: p = 0.0052. ** p-
value < 0.01, two-tailed paired Student’s t-test) 
A 
B 
C 
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3.2.3.2 LINE-1 RNA inhibition 
The experiments described in the previous section revealed a relationship between LINE-1 
inhibition and the anticancer effects of EFV and SPV; however, the results did not confirm a 
direct link between them. Therefore, an RNA inhibition experiment was designed to compare 
the similarity of the phenotypes resulting from direct RNA inhibition and inhibition of LINE-1 
by antiretroviral drugs.  
In order to generate LINE-1 RNA inhibition cell lines, the pUTR plasmid (Figure 3-5B) 
encoding short hairpin RNA targeted towards the LINE-1 element promoter, its negative 
control, and the pSM2 plasmid (Figure 3-5A), which is an empty vector, were transfected into 
MCF10AT and MCF10CA1α cells using the Nucleofector® I machine. Since the pUTR and the 
pSM2 plasmids contain Puromycin resistance genes, those transfected cells had been culturing 
in the complete culture medium with 200 µg/ml Puromycin to allow selection of successfully 
transfected cells. More details about this shRNA inhibition system were described in Chapter 
2. 
To examine the consequence of shRNA inhibition, western blot was utilized to confirm the 
shRNA efficiency. Two critical cancer cell morphological indicators, fibronectin and E-
cadherin, were stained in transfected cells to allow inspection of the morphological variations 
between LINE-1 inhibited TNBCs and their uninhibited controls.  
Surprisingly, after ten days of Puromycin selection, the pUTR-transfected cells expressed 
marginally higher E-cadherin (an epithelial marker) and fibronectin (a mesenchymal marker) 
than the pSM2-control, in accordance with the immunofluorescence data (Figure 3-5D). 
However, no obvious morphological differences were observed between the pUTR-transfected 
cells and the pSM2-control cells in both MCF10AT and MCF10CA1α cell lines. Additionally, 
the western blotting result suggested that LINE-1 RNA inhibition was extremely low in 
MCF10CA1α cells: a very limited decrease of LINE-1 RT but not LINE-1 ORF1 was detected 
in the pUTR-transfected cells (Figure 3-5C). Thus, the comparison between direct RNA 
inhibition and inhibition of LINE-1 by antiretroviral drugs was unsuccessful. Possible 
explanations of these results are discussed in Chapter 6. 
Chapter 3 
62 
 
          
       
pUTRpSM2
E-Cadherin/Fibronectin
MCF10AT
MCF10CA1α
 
Figure 3–5 Morphological phenotypes in LINE-1 RNA silencing cells 
(A) The pSM2 plasmid contains a puromycin resistant region and an shRNA insertion region. (B) The 
shRNA sequence can target the LINE-1 promoter and silence LINE-1. (C) The LINE-1 protein expression 
levels in the pUTR-transfected cells and the pSM2-transfected cells. α-tubulin is internal control. (D) 
The pUTR and the pSM2 plasmids were transfected into MCF10AT and MCF10CA1α cells. No obvious 
difference between the pUTR plasmid transfected cells and the pSM2 plasmid transfected cells was 
observed. Red dye stained E-cadherin; green dye stained fibronectin; blue dye stained cell nucleus. 
(Scale bar: 25 µm)  
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3.2.4 The influences of antiretroviral drugs in cancer cell growth. 
After confirming the effect of antiretroviral drugs on the reduction of TNBCs, we investigated 
the mechanisms involved. Cancer is a severe disease that is strongly associated with the 
dysregulation of somatic cell proliferation (Evan and Vousden, 2001). Cell proliferation is 
defined as the process of increasing cell numbers and takes into account cell division, cell death, 
and other mechanisms changing cell numbers (Iván, n.d.). An uncontrollable increase in cell 
numbers may potentially generate a tumour. Therefore, reducing cancer cell proliferation might 
be an effective strategy for eliminating cancers. In this study, we have shown that antiretroviral 
drugs are capable of affecting cancer cell proliferation in XTT cell viability assay, and so we 
investigated whether cell division, cell cycle, and cell death were involved.   
The XTT cell viability assay was first performed to observe the changes in the cell proliferation 
rate between untreated-control cells, EFV-treated cells, and SPV-treated cells at multiple time 
points for each cell line. This experiment (in appendix Figure S3-2) demonstrated that EFV 
treatment and SPV treatment could appropriately reduce the cell proliferation rate to half that 
of the untreated-control in all breast cancer cell lines. However, the XTT cell viability assay 
can only measure the relative numbers of live cells and the results can be influenced by cell 
death, hence the actual cell proliferation rate is uncertain.  
3.2.4.1 Cell division  
Therefore, we used the CFSE (Carboxyfluorescein succinimidyl ester) cell division tracking kit 
(Thermo Fisher Scientific) to confirm the XTT cell proliferation results. The CFSE kit utilizes 
a fluorescent molecule, carboxyfluorescein, to observe cell division. Carboxyfluorescein 
succinimidyl ester can be assimilated to cells and generates covalent coupling with amine 
sources within them, thus continues to fluoresce in cells for a long period of time. Once cell 
division has occurred, the brightness of the fluorescence reduces by half owing to the 
fluorescent carboxyfluorescein being equally divided between the two daughter cells. Hence, 
the brighter cell can be determined as an older cell which has gone through fewer cell divisions 
and has a lower cell proliferation rate.  
In this experiment, the brightness of the cells was negatively correlated with the cell 
proliferation rate of the cell lines (Figure 3-6). The darkest MCF10CA1α had the highest cell 
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proliferation rate, whereas the brightest T47D had the lowest cell proliferation rate. The 
proliferation rate of MCF10AT was slightly lower than MCF10CA1α but higher than MDA-
MB-231. Untreated-control cells divided faster than EFV-treated cells in all cell lines since 
brighter fluorescence was detected in EFV-treated cells compared with their controls. This 
indicated that EFV affects cell proliferation in these breast cancer cell lines. To further 
understand the possible reasons for the anti-proliferative effect of EFV, cell cycle and cell 
apoptosis experiments were performed. 
 
Figure 3–6 Cell division rates in EFV-treated cells and untreated-control cells 
This experiment is to determine how fast cell division occurs in EFV-treated cells and untreated-control. 
The dark-yellow peak represents the unstained control, whereas the dark peak represents the 
untreated-control which had uptake CFSE before the culture period; the red peak represents the EFV-
treated cells which also up took CFSE at the same time as the untreated-control cells. The CFSE is 
degraded through the passages, i.e., more the cell division show less fluorescence, which is closer to 
the dark-yellow peak in this FACS data. 
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3.2.4.2 Cell cycle  
After observing the effect of EFV at reducing cell division with the CFSE assay, we investigated 
how the drugs influence the cell cycle. The samples were fixed by 80% ethanol on the fourth 
day of EFV treatment and then stained with Propidium iodide (PI), followed by fluorescence-
activated cell sorting (FACS) analysis which can identify the brightness of the cells. Since PI 
can bind to DNA, the brighter cells contain more DNA. Cells in G1/G1 phase have 23 pairs of 
chromosomes; cells in S phase, which are in the synthesis stage have slightly more DNA than 
in G0/G1 phase; and cells in G2 phase, which are ready for cell division, have 46 pairs of 
chromosomes. Thus, PI staining can identify the different stages of the cell cycle.   
Cell cycle data revealed some differences in Gap0 and Gap 1 (G0/G1), Synthesis (S) and Gap 
2 (G2) phases between untreated- and EFV-treated cells in all cell lines (Figure 3-7). The results 
show the average of three independent experiments, the statistical results of Student’s t-test 
were listed in the appendix Table S3-1. Comparisons between untreated- and SPV-treated cells 
was also noted, and the trend of cell cycle shifting in SPV-treated cells was similar to that in 
EFV-treated cells. Only a single successful experiment is shown due to the shortage of the SPV 
compound (in appendix Figure S3-3).  
Not surprisingly, MCF10A cells showed very similar cell cycle patterns in antiretroviral drug-
treated and untreated-control cells. Except for the MCF10A cell line, all the breast cancer cell 
lines had a lower proportion of S phase cells after drug treatment (MCF10AT: reduced from 
11.42±2.56% to 6.02±3.63%; MCF10CA1α: reduced from 20.39±2.79% to 10.81±1.19%; 
MDA-MB-231: reduced from 21.52±3.99% to 18.81±5.74%; T47D: reduced from 
19.46±3.46% to 15.70±0.17%), however, the changes varied in G0/G1 and G2 phase depending 
on the cell line. The EFV-treated MDA-MB-231 cells (increased from 23.53±5.02% to 
29.28±6.01%) and T47D cells (increased from 21.70±2.17% to 25.80±4.32%) had higher 
proportions of G2 phase cells compared with their untreated-control cells; in contrast, the EFV-
treated MCF10AT cells (reduced from 16.94±6.66% to 11.76±10.93%) and MCF10CA1α cells 
(reduced from 28.13±3.58% to 25.71±1.20%) had a lower proportion of G2 phase cells 
compared with their untreated-control cells. Altogether, these results indicated that DNA 
replication is reduced, and cell cycle retardation may occur during drug treatments. 
Chapter 3 
66 
 
 
Figure 3–7 Cell cycle patterns of untreated-control and EFV-treated cells in MCF10A, MCF10AT, 
MCF10CA1α, MDA-MB-231, and T47D cell lines 
The percentage of cells in different phases when exposed to different conditions was calculated and is 
presented in this figure. The green bar represents the percentage of cells in G0/G1 phase; the yellow 
bar represents the percentage of cells in S phase; the red bar represents the percentage of cells in G2 
phase. C is the untreated-control cells; E is the EFV-treated cells. n = 3 for each cell line.  
 
 
 
The proportion of subG1 phase cells (late stage of apoptosis) in the different treatment 
conditions was also investigated (in appendix Figure S3-4). They were raised in almost all EFV-
treated cell lines except MCF10A. This suggests that apoptosis might be responsible for 
reducing cell numbers in antiretroviral drug-treated breast cancer cells.  However, some papers 
recommend separating subG1 detection experiments from cell cycle experiments because the 
accumulation of apoptotic cells may affect the cell cycle results (Wlodkowic et al., 2011). Thus, 
the conclusions drawn from this experiment need to be reconsidered and we might need to 
perform further experiments to confirm the results. 
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3.2.4.3 Cell death 
The Annexin V/ Propidium iodide (PI) apoptosis detection assay was then used to clarify the 
role of cell programmed death (apoptosis) and non-programmed death (necrosis) in 
antiretroviral drug-treated breast cancer cells. Annexin V is impermeable and can bind to 
phosphatidylserine (PS). PS can only bind to Annexin V when it translocates to the membrane 
surface i.e., the cell has undergone apoptosis or necrosis. The cell membrane is impermeable to 
PI, not PI impermeable to the cell membrane, and PI can only stain nucleotides if the cell 
membrane collapses. Therefore, cells with Annexin V positive and PI negative features are 
likely to be early apoptotic cells; whereas, cells with Annexin V positive and PI-positive 
features are probably late apoptotic and necrotic (Figure 2-7). 
In this experiment, the data showed that after EFV treatment, the proportion of apoptotic and 
necrotic cells increased, compared with the untreated control cells (Figure 3-8). After excluding 
the majority of dead cells, the apoptotic and necrotic cells increased from 4.17% to 10.08% in 
MCF10AT; from 4.53% to 9.04% in MCF10CA1α; from 4.14% to 5.34% in MDA-MB-231, 
and from 3.58% to 9.86% in T47D. The data suggested that EFV treatment can induce cell 
apoptosis and necrosis in breast cancer cells.  
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Figure 3–8 Cell apoptosis in untreated-control and EFV-treated breast cancer cells 
This experiment detected the apoptotic cells and necrotic cells under different treating conditions by 
flow cytometry. Annexin V+/PI+ cells are late apoptotic and necrotic cells; Annexin V+/PI- cells are early 
apoptotic cells; Annexin V-/PI- cells are live cells; Annexin V+/PI+ cells are dead cells.   
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3.2.5 The effects of antiretroviral drugs on cell morphology 
Cell morphology is an important indicator for distinguishing cancer cells from normal cells. 
Normal breast cell lines usually display differentiated epithelial phenotypes. In contrast, many 
breast cancer cell lines present undifferentiated and migration phenotypes associated with 
cancer invasion and metastasis (Bravo-Cordero et al., 2012). In addition, mesenchymal-like 
phenotypes can be observed which are strongly correlated with cancer malignancy (Zhang et 
al., 2017). The morphological phenotypes have been investigated with Phalloidin, a powerful 
F-actin probe, on untreated- and antiretroviral drug treated-cells in order to confirm whether 
the drugs can reduce the malignancy of TNBCs. The methods used for Phalloidin staining were 
described in Chapter 2. 
As predicted, some morphological changes were observed in the drug treated-cells. In Figure 
3-9, antiretroviral drug-treated breast cancer cells displayed cell projections due to elongated 
microtubules, representing cell differentiation (more images in Appendix Figure S3-5). The 
results showed that LINE-1 inhibition could potentially induce cellular differentiation, 
returning breast cancer cells to their original epithelial states. They also suggested that LINE-1 
expression could be important for cancer cell mesenchymal to epithelial transition (MET). 
There were a few inconsistencies between cell lines. In MDA-MB-231 and T47D cell lines, cell 
differentiation was evident. There were a significant number of changes in the differentiation 
of cells observed between untreated- and EFV-treated cells of these cell lines (Figure 3-10). 
However, in MCF10AT and MCF10CA1α cell lines, some drug-treated cells were quiescent, 
some displayed cell scattering and an elongated shape, while others displayed lamellipodia, 
filopodia, and observable migratory behaviour (fan shape with clear direction) (Figure 3-11). 
These phenotypes could be associated with epithelial to mesenchymal transition (EMT) and be 
linked to unfavourable prognostic outcomes (Fedele et al., 2017). Thus, we were unable to 
confirm any enhancement of cell differentiation by antiretroviral drugs. This raised the 
following questions: Do antiretroviral drugs induce EMT? Would antiretroviral drug treatment 
lead to worse outcomes for patients? 
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Figure 3–9 Cell morphologies in EFV- and SPV-treated and untreated cells 
This figure compares the morphologies of antiretroviral drug-treated and untreated cells in MCF10AT, 
MCF10CA1α, MDA-MB-231, and T47D cell lines. F-actin (green, for detecting F-actin) and DAPI (blue, 
for detecting nucleus) were stained by Phalloidin. (Scale bar: 50 μm) 
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Figure 3–10 Differentiated cells in EFV-treated MDA-MB-231 and T47D cell lines 
(A) immunofluorescence images for observing differentiated cells in MDA-MB-231 and T47D cell lines 
(Scale bar: 10 μm) (B) Numbers of differentiated cells in MDA-MB-231 and T47D cell lines. Error bars: 
±SD, n = 3. (MDA-MB-231 p = 0.0008, T47D p = 0.0025. **p-value <0.01. Two-tailed paired Student’s t-
test.)  
 
Figure 3–11 Different morphologies of EFV-treated MCF10AT and MCF10CA1α cells 
After antiretroviral drug treatment, different cell morphologies can be observed in MCF10AT and 
MCF10CA1α cells. Migrating cells show clear filopodia and clear direction. Quiescent cells are usually 
be considered as potential CSCs and may cause cancer metastasis and cancer relapse. (Scale bar: 25 
μm) 
MDA-MB 
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3.2.6 EFV treatment affects the expression of epithelial and mesenchymal 
markers in MCF10AT and MCF10CA1α cells 
To help understand the reasons why MCF10AT and MCF10CA1α cells present multiple 
morphological changes after antiretroviral drug treatment, we used immunofluorescence and 
western blot to examine some well-studied cell morphological markers. E-cadherin is the most 
commonly used epithelial phenotype marker. It is considered to play a role in tumour 
suppression and has a critical role in the maintenance of the epithelial phenotype (Pećina-Slaus, 
2003). Fibronectin and Snail Family Transcriptional Repressor 2 (SLUG or SNIL2) are 
confirmed mesenchymal phenotype markers, with relevance to tumour invasion and metastasis 
(Wang and Hielscher, 2017). Cell division control protein 42 homolog (CDC42) is a cell cycle 
regulator (Melendez et al., 2011).  Lack of CD24 has been recognised as a marker for cancer 
stem cells (CSC), and DEAD-box protein 5 (DDX5) dysregulation is associated with cancer 
development (Wang et al., 2012). 
According to the results shown in Figure 3-12, the immunofluorescence experiments suggested 
that more EFV-treated MCF10AT cells expressed more fibronectin and SLUG than untreated 
control cells. These proteins are the mesenchymal markers for mammalian cells. Less CD24 
protein expression and E-cadherin dislocation in EFV-treated MCF10AT cells indicated the 
loss of cell-cell adhesion since these two proteins are typical adhesion molecules. In addition, 
western blot data confirmed the increased expression of the fibronectin and SLUG proteins in 
both EFV-treated MCF10AT and MCF10CA1α cells (Figure 3-13). Moreover, western blot 
data further illustrated decreasing CDC42, a crucial protein for cell skeleton formation, in EFV-
treated MCF10AT and MCF10CA1α cells, suggesting that the cell skeletons might be 
dysregulated when levels of CDC42 are low. All these changes could be signs of EMT, 
metastasis, and invasiveness. They may be linked to cancer malignancy and poor therapeutic 
outcomes. However, at the same time, EFV-treated cells expressed more E-cadherin, a classic 
epithelial marker, in the same batch of samples. Similarly, less DDX5, a protein related to 
cancer malignancy, was detected in EFV-treated cells compared with untreated controls (Figure 
3-13). It appears that EFV-treated MCF10AT and MCF10CA1α cells expressed some epithelial 
markers and some mesenchymal markers, at the same time, emphasising the complexity of the 
drug’s effects on TNBCs.  
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Figure 3–12 Immunofluorescence experiments for detecting the protein expression patterns of 
various morphological markers in untreated-control and EFV-treated MCF10AT cells 
The untreated-control and EFV-treated MCF10AT cells were stained with different antibodies, 
representing various cell markers including E-cadherin (red), SLUG (light blue), fibronectin (green), 
CD24 (yellow), and nucleus (blue). (Scale bar: 25 μm) 
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Figure 3–13 Expression patterns of cell morphology proteins in EFV-treated cells and 
untreated-control cells 
The untreated-control and EFV-treated MCF10AT, MCF10CA1α, MDA-MB-231, and T47D cells 
were detected by western blotting with different antibodies representing various cell markers 
including fibronectin, E-cadherin, DDX5, CDC43, SLUG, and α-tubulin as internal control.  
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3.2.7 Antiretroviral drug treatment in other TNBC cell lines 
TNBC heterogeneity may be responsible for the inconsistent drug responses observed with 
antiretroviral drugs. Breast cancer is heterogeneous, with morphological variation and 
molecular alteration able to be detected in different regions of a tumour (Fisher et al., 2013). 
Histologic and molecular heterogeneity have been widely observed in TNBCs and are 
considered one of the main obstacles to anti-TNBC drug development (Abramson and Mayer, 
2014, Mills et al., 2018). In previous experiments, MCF10AT and MCF10CA1α showed a few 
distinct patterns with the MDA-MB-231 cell line suggesting diverse drug responses were 
displayed in various TNBC cell lines. To determine the consistency of antiretroviral drug 
responses on TNBC cell lines, two other commonly used TNBC cell lines, BT-549 and BT-20, 
were chosen to investigate antiretroviral drug responses in TNBCs.  
Some experiments which were similar to the drug response experiments conducted on 
MCF10AT, MCF10CA1α, and MDA-MB-231 had been studied in BT-549 and BT-20 cell 
lines. These included cell viability, cell proliferation, cell cycle, and cell morphological 
experiments. Most of the experimental methods were consistent with previous experiments; 
except for the cell proliferation experiment which used immunofluorescence to detect the 
expression of the Ki-67 protein to indicate cell proliferation, in the cell nucleus. These 
experiments might be able to illustrate a greater view of antiretroviral drug responses on TNBCs 
and to further confirm the potential of antiretroviral drugs to treat TNBCs effectively.  
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3.2.7.1 Anticancer capacities of EFV and SPV in BT-20 and BT-549 cell lines 
A cell viability assay was conducted to determine the correct drug concentrations for treating 
BT-20 and BT-549 TNBC cells (Figure 3-14), and the EC50 values of EFV and SPV in BT-20 
and BT-549 cell lines were calculated by Prism software (Table 3-3), as described previously. 
The EC50 values of both EFV and SPV for BT-20 were lower than the EC50 values of BT-
549, they were 18.56 µM for EFV and 19.25 µM for SPV. While, in BT-549 cells, the EC50 
value for EFV was 30.55 µM and for SPV was 51.94 µM. This experiment suggested that BT-
20 could be less tolerant of antiretroviral drugs than other TNBCs including MCF10AT, 
MCF10CA1α, MDA-MB-231, and BT-549. Among all the tested TNBC cell lines, BT-549 cell 
line needed the highest antiretroviral drug concentration for reaching the EC50 points.  
 
Figure 3–14 Cell viabilities when exposed to different antiretroviral drug concentrations 
Cell viability curves of EFV treatment (red) and SPV treatment (blue) in BT-549 and BT-20 cells. Cell 
viability was determined at day 4 using a cell viability assay. Error bars: ±SD, n = 3. 
 
 
Table 3-3 The EC50 values of EFV and SPV in BT-549 and BT-20 cell lines 
 BT-549 BT-20 
EFV  30.55 μM 18.56 μM 
SPV 51.94 μM 19.25 μM 
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3.2.7.2 LINE-1 drug inhibition in BT-20 and BT-549  
After determining the EC50 values for treating BT-549 and BT-20, the efficiency of LINE-1 
inhibition by EFV in BT-20 and BT-549 was examined. Western blot data (Figure 3-15) were 
consistent with the previous finding that the expressions of LINE-1 ORF1 and LINE-1 RT can 
be reduced by EFV treatment in both BT-20 and BT-549 cell lines.  
 
Figure 3–15 LINE-1 protein expression in BT-549 and BT-20 cell lines 
The western blot data showed that LINE-1 is expressed in BT-549 and BT-20 cell lines. The relative ORF1 
and ORF2 RT expressions were reduced after EFV treatment. α-tubulin was an internal control. Both 
ORF1 and ORF2 RT expressions decreased after EFV treatment in BT-549 and BT-20. *p-value <0.05; 
**p-value <0.01. Error bars: ±SD, n = 3. 
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3.2.7.3 The effects of EFV on cell proliferation and cell cycle in BT-20 and BT-549 
After EFV was confirmed to target BT-20 and BT-549 cells and to inhibit LINE-1 expression 
in BT-20 and BT-549, its precise effects were investigated in BT-20 and BT-549 cells. 
Cell cycle data for BT-20 and BT-549 cells (Figure 3-16 and in appendix Figure S3-6) were 
consistent with the other tested cancer cell lines. EFV treatment reduced the percentage of cells 
in S phase (BT-549: 19.46±3.46% to 15.70±0.17%; BT-20: 12.61±2.35% to 9.86±1.51%) and 
increased the percentage of cells in G2 phase compared with their untreated control (BT-549: 
21.70±2.17% to 25.80±4.32%; BT-20: 25.52±3.33% to 36.66±5.05%).  
 
 
Figure 3–16 Cell cycles of untreated-control and EFV-treated cells in BT-20 and BT-549 cell lines 
The percentage of G2 phase cells increased after EFV treatment, and the percentage of S phase cells 
decreased after EFV treatment (n = 3). 
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Drug responses of BT-549 and BT-20 were observed via immunofluorescence experiments.  
Ki-67 (a cell proliferation marker) staining in antiretroviral drug-treated and untreated BT-20 
and BT-549 cell lines (Figure 3-17) indicated that antiretroviral drug treatment is able to reduce 
cell proliferation in these two cell lines. Previous observations showed fewer Ki-67-stained-red 
dots in antiretroviral drug-treated BT-20 and BT-549 cells, compared with their untreated-
controls. Also, phalloidin cell morphology staining (Figure 3-17) showed very clear 
morphological differences between antiretroviral drug-treated and untreated cells indicating 
that antiretroviral drug-treated BT-549 and BT-20 cells were differentiated because of distinct 
cell projection structures (more images in Appendix Figure S3-7). These responses were similar 
to MDA-MB-231 cells and not MCF10AT and MCF10CA1α cells, suggesting that the drug 
effects of BT-549 and BT-20 might be close to the effects of MDA-MB-231; while MCF10AT 
and MCF10CA1α could have slightly different drug responses to other TNBCs. This suggested 
that drug responses could be varied because of the diverse genetic background in TNBCs.  
 
Figure 3–17 Cell morphologies in EFV- and SPV-treated and untreated cells 
This figure compares the morphologies of antiretroviral drug-treated and untreated BT-549 and BT-20 
cell lines. Phalloidin (green, for detecting F-actin), Ki-67 (red, for detecting cell proliferation), and DAPI 
(blue, for detecting nucleus) were used for immunofluorescence staining (Scale bar: 50 μm). 
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3.3 Discussion 
According to two different papers published in 2005, Efavirenz treatment can effectively reduce 
cell numbers to less than half of untreated controls and enhance G0-G1 phase cells but decline 
S phase cells in human thyroid carcinoma (ARO and FRO), prostate carcinoma (PC3), and 
melanoma (A-375) cell lines (Landriscina et al., 2005; Sciamanna et al., 2005). This anti-
proliferation effect has also been reported in the non-TNBC T47D cell line and pancreatic 
cancer BxPC-3 and Panc-1 cell lines (Ranala et al., 2014; Hecht et al., 2015). Hecht’s team 
specifically pointed out the cytotoxic effect (by inducing apoptosis and necrosis) of Efavirenz 
implying its potential use as an anti-cancer drug. Our TNBC data is highly consistent with all 
these findings apart from a minor difference where cells in the G0-G1 phase show an increase 
in MCF10AT and MCF10CA1α cell lines but a decrease in MDA-MB-231, BT-549, and BT-
20 cell lines. This suggests Efavirenz could act as a potential anti-TNBC drug with systemic 
effects in diverse cancers. 
In this chapter, we have shown the effectiveness of EFV and SPV at eliminating TNBC cells 
but not non-cancerous MCF10A cells. We have also demonstrated the effectiveness of EFV 
and SPV at reducing reverse transcription activities of LINE-1. EFV and SPV were then used 
for the remaining experiments presented in this thesis. The results implied a potential link 
between LINE-1 inhibition and breast cancer elimination when using antiretroviral drug 
treatment, which was consistent with previous research in other cancers and non-TNBCs. 
Further studies were conducted to confirm that antiretroviral drugs can retard cell division, 
reduce DNA synthesis within the cell cycle, and induce programmed and non-programmed cell 
death in TNBCs. Moreover, clear morphological changes are observed in the drug-treated 
cancer cells. These results strongly suggested that antiretroviral drugs were functioning by 
inducing TNBC cell alterations. One of the critical challenges we encountered when conducting 
these experiments was LINE-1 overexpression and inhibition. To overexpress LINE-1 in non-
cancer cells is difficult because there are various self-defence mechanisms, including 
methylation and degradation present in normal cells to prevent LINE-1 expression and protect 
cell status. Thus, the plasmid with the modified LINE-1 sequence, instead of the original LINE-
1 sequence, was utilized for the experiments. Moreover, many commonly used non-cancerous 
breast cells with very limited LINE-1 expression, such as MCF10A and primary mammary 
epithelial cells (HMEC), might be insufficiently competent making it difficult to insert plasmid 
                                                              The effects of antiretroviral drugs on triple negative breast cancer cell lines 
81 
 
DNA into these cells. Therefore, we used the same batch of transfected cells for the LINE-1 
overexpression experiment rather than conducting three independent transfections. On the other 
hand, LINE-1 inhibition by shRNA was more challenging than LINE-1 overexpression in 
TNBCs.  Thus, the LINE-1 silencing plasmid was previously used in the T47D (luminal-type 
breast cancer) cell line to investigate the responses of LINE-1 direct inhibition (Chen et al., 
2012). The results suggested that direct inhibition of LINE-1 by shRNA gave similar responses 
to inhibition of LINE-1 by EFV. This result confirmed that EFV treatment might inhibit LINE-
1 in the same way that RNA did. However, silencing of LINE-1 shRNA had very limited effects 
in MCF10AT and MCF10CA1α cell lines. One reason for this could be that the cell 
proliferation rates of MCF10AT and MCF10CA1α cells were much greater than T47D cells. 
Consequently, the shRNA cannot appropriately inhibit LINE-1 expression. A slow-growing 
TNBC may be able to improve the observation of shRNA inhibition effects. Yet, most of the 
well-studied TNBC cell lines proliferate faster than other breast cancer cell lines. 
Inconsistent drug-induced morphological changes, possibly caused by TNBC heterogeneity, 
were equally challenging. Much evidence including immunofluorescence and western blot 
experiments supported previous observations that antiretroviral drugs were able to change the 
status of TNBCs. However, we have presented controversial data in disagreement with the 
original hypothesis i.e. antiretroviral drugs can return cancer cells back into normal-like cells, 
in MCF10AT and MCF10CA1α cell lines. Although there is no doubt that antiretroviral drugs 
induce cell differentiation in TNBC cell lines; the phenotypes which are associated with cancer 
invasion, metastasis, and recurrence were also observed at the same time. The detection of 
molecular markers after the treatment further suggested the drug treatments may lead to 
alternative prognostic outcomes in TNBCs.  
There are two major limitations worth discussing: Firstly, many TNBC cells express limited E-
cadherin protein and some breast cancer cells lack fibronectin expression endogenously. 
Therefore, it could be difficult to compare changes in the levels of these proteins. Secondly, 
inconsistencies in the drug responses among MCF10AT and MCF10 CA1α and MDA-MB-231 
cell lines led us to conduct similar experiments in BT-549 and BT-20 cell lines. We did this in 
order to confirm which protein and molecular changes could be universal responses to 
antiretroviral drugs by TNBCs. The results suggested that BT-549 and BT-20 cell lines respond 
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similarly to the MDA-MB-231 cell line and less so to the MCF10AT and MCF10CA1α cell 
lines. Limited time and resources restricted the number of cell lines that we were able to test, 
hence our conclusions are based on the pattern of drug responses in these five TNBC cell lines. 
The diversity and heterogeneity of TNBCs also need to be considered. Recently, it has been 
proposed that TNBCs should be separated into the following subtypes, basal-like 1 subtype, 
basal-like 2 subtype, immunomodulatory subtype, mesenchymal-like subtype, mesenchymal 
stem-like subtype, luminal AR subtype, and others (Lehmann et al., 2011). This new 
classification method highlighted that breast cancer cells with ER-/PR-/HER- features are all 
classified as TNBCs, but might have different drug responses as a result of the variation in their 
genetic backgrounds. For example, some of them are highly enriched in cell cycle-related 
pathways like basal-like 1 and 2 subtypes; and others strongly express pathways relevant to cell 
motility and cell differentiation, such as mesenchymal-like and mesenchymal stem-like subtypes 
(Lehmann et al., 2011). Each of these different subtypes of TNBCs could have diverse drug 
responses and might need to be treated differently. 
To further understand how these TNBC cells were affected by antiretroviral drugs, we 
investigated their gene regulation. We used next-generation RNA sequencing (RNA-Seq) to 
compare the differences in RNA level between antiretroviral drug-treated cells and untreated-
control cells. It was hoped that RNA-Seq analysis might help to explain why some 
mesenchymal markers were unexpectedly detected in antiretroviral drugs-treated cells. We 
were also interested to see whether the gene regulation data would agree with the western blot 
data, shown previously. The details are outlined in the next chapter which mainly focuses on 
how antiretroviral drugs regulate the anticancer process, and how we can improve the strategies 
for treatment by identifying the key genes/pathways involved in the anti-cancer process.  
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Chapter 4 Anticancer mechanisms of antiretroviral drugs in triple-
negative breast cancers 
4.1 Introduction   
The main theme explored in this study was whether antiretroviral drugs can act as anticancer 
agents in triple-negative breast cancers (TNBCs). In the previous chapter, antiretroviral drugs 
Efavirenz (EFV) and SPV122 (SPV) were found to decrease cancer cell proliferation and to 
promote cancer cell death, thus effectively reducing breast cancer cells. In parallel, LINE-1 
expression was suppressed by treatment with antiretroviral drugs in all tested breast cancer cell 
lines. Since LINE-1 expression could be one of the causes of cancer development (Sciamanna 
et al., 2018), antiretroviral drugs may effectively antagonize TNBC growth through LINE-1 
inhibition. However, antiretroviral drug-treated MCF10AT and MCF10CA1α TNBC cell lines 
were found to display some unexpected mesenchymal markers indicating unfavourable 
prognostic outcomes such as cancer metastasis and cancer recurrence. These findings are at 
odds with our original hypothesis and further emphasise the complexities of TNBCs.  
The second goal in this study was to determine the mechanisms which govern the anticancer 
properties of antiretroviral drugs in TNBCs. Despite the fact that some antiretroviral drugs with 
potential for treating certain cancers are now in clinical trials (Sciamanna et al., 2018), the 
molecular and pathway regulations remain vague. RNA sequencing (RNA-Seq) is a powerful 
technique for studying epigenetic regulation. It helps to identify the phenotypic variations 
among different treatment conditions (Evsikov and Marin de Evsikova, 2016). In this chapter, 
some epigenetic experiments were conducted, mainly based on RNA-seq analysis, which 
improves the understanding of the gene and pathway regulations for antiretroviral drug in 
cancer cells and to explore possible anticancer mechanisms of this class of drug. 
Here, the basic process of RNA-Seq analysis, including experimental design, data analysis 
methods are described. This is followed by a discussion of the gene and pathway regulations 
involved in antiretroviral drug treatments. This also includes analysis of data which at first 
glance contradicts the original predictions that were first made. Finally, the potential 
mechanisms behind antiretroviral drug-induced cancer responses are discussed, as are the 
potential roles of cancer stem cells (CSCs) in the process. 
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4.2 Results  
4.2.1 The process of RNA sequencing analysis 
RNA sequencing (RNA-Seq) is capable of generating massive data for studying the 
transcriptome; therefore, it is important to interpret all information correctly and accurately. 
Below, the analytical methods which were used to identify important genes and pathways from 
the RNA-Seq data were briefly described. 
4.2.1.1 Analysis of variance (ANOVA)  
Analysis of variance (ANOVA) is one of the most widely used statistical methods for analysing 
RNA-Seq data. As reported in the RNA-Seq results section, some genes showed dramatic 
changes after antiretroviral drug treatment. ANOVA analysis compares group means, enhances 
analysis and highlights the significance of these changes. q-values, instead of the traditional p-
values, are calculated to indicate whether each gene shows a statistically significant variation 
after antiretroviral drug treatment. The use of the p-value as a criterion in a multiple testing 
analysis, like RNA-Seq, may result in an increase in the false-positive rate with the increased 
numbers of samples (lose the power) in multiple tests (Storey, 2003). Unlike p-values, q-values 
(optimised p-values) take into consideration the false discovery rate (FDR) and have a higher 
chance of detecting significant differences (Li et al., 2007). After the FDR correction, the 
appropriate cut-off for genes with significant differences in this RNA-Seq analysis was set as 
the q-value less than 0.25 (Yu et al., 2012) (Table 4-1). These genes are likely to have a role in 
antiretroviral drug-induced cancer responses.  
 
Table 4-1 The numbers of genes in different q-value cut-offs in ANOVA analysed RNA-Seq 
result 
 <0.001 <0.01 <0.025 <0.05 <0.1 <0.2 <0.25 <0.275 <0.3 <0.4 <1 
EFV 0 0 0 0 0 371 848 981 1284 2918 11282 
SPV 0 0 0 0 0 778 1465 1860 2294 3886 11282 
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Genes associated with drug responses may vary depending upon different experimental 
conditions and the mechanism of the drugs. The top ten candidate genes, displaying the greatest 
changes according to the RNA-Seq analysis upon EFV and SPV treatment, are exhibited in 
Table 4-2. Some candidate genes are in both drug lists; whereas, others are listed in either the 
EFV-treatment list or the SPV-treatment list. Candidate genes such as stearoyl-CoA desaturase 
(SCD), alkaline phosphatase, placental (ALPP), and ETS-related transcription factor 3 (ELF3) 
showed extensive changes after treatment with antiretroviral drugs. Another candidate genes 
including pyruvate dehydrogenase kinase, isozyme 4 (PDK4), Guanylate-binding protein 7 
(GBP7), sterol regulatory element-binding transcription factor 1 (SREBF1), complement 
component 3 (C3), acyl-CoA synthetase long-chain family member 5 (ACSL5), and high 
mobility group AT-hook 2 (HMGA2) were found among the EFV-treatment top ten. Other 
candidate genes including interferon-induced protein with tetratricopeptide repeats 3 (IFIT3), 
angiopoietin-like 4 (ANGPTL4), retinoic acid receptor responder 1 (RARRES1), IGF-like 
family member 1 (IGFL1), kallikrein-related peptidase 10 (KLK10), CD14, and interferon-
induced protein with tetratricopeptide repeats 2 (IFIT2) were among the SPV-treatment top ten. 
Interestingly, the expression of overlapped candidate genes including SCD, ALPP, and ELF3 
decreased after antiretroviral drug treatment which may potentially be linked to better 
prognostic outcomes. Further analyses were conducted based on this preliminary ANOVA 
analysis and were discussed later on. 
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Table 4-2 The top 10 candidate genes involved in antiretroviral drug-induced cancer responses 
Gene name 
Drug 
response  Role in cancers References 
EFV or SPV-treated TNBCs 
SCD  
stearoyl-CoA desaturase ↓ 
Cancer proliferation, tumour expansion 
(prostate, breast cancer) 
(Kim et al., 2011, 
Belkaid et al., 2015, 
Peck et al., 2016) 
ALPP 
alkaline phosphatase, placental ↓ 
Tumour marker (seminoma, ovarian, and 
metastatic prostate cancer) 
(Fishman, 1987, 
Albrecht et al., 2004, 
Rao et al., 2016) 
ELF3 
ETS-related transcription factor 3  ↓ 
Metastasis (colorectal and lung cancer), 
poor prognosis (colorectal) 
(Nakarai et al., 2012, 
Wang et al., 2014b, 
Wang et al., 2018) 
EFV-treated TNBCs 
PDK4 
pyruvate dehydrogenase kinase, 
isozyme 4  
↓ Tumorigenesis, drug resistance (colon, breast, lung and pancreatic cancer) 
(Liu et al., 2014b, 
Leclerc et al., 2017, 
Woolbright et al., 
2018) 
GBP7 
Guanylate-binding protein 7  ↓ Unknown  
 
SREBF1 
sterol regulatory element-binding 
transcription factor 1  
↓ Cancer cell growth (prostate and colon cancer), tumorigenesis (pancreatic cancer) 
(Griffiths et al., 2013, 
Sun et al., 2015, 
Audet-Walsh et al., 
2018, Wen et al., 
2018) 
C3 
complement component 3  ↓ 
Epithelial cancer marker and EMT marker 
(ovarian & endometrial cancer) 
(Cho et al., 2016) 
ACSL5 
acyl-CoA synthetase long-chain 
family member 5  
↓ Cancer cell survival (glioma cell) (Mashima et al., 2008) 
HMGA2 
high mobility group AT-hook 2  
↑ Cancer proliferation and metastasis (epithelial cancer) 
(Morishita et al., 
2013, Wu et al., 
2016b, Gao et al., 
2017) 
SPV-treated TNBCs 
IFIT3 
interferon-induced protein with 
tetratricopeptide repeats 3  
↓ Poor prognostic outcome (pancreatic ductal adenocarcinoma) (Zhao et al., 2017) 
ANGPTL4 
angiopoietin-like 4  ↑ Tumorigenesis 
(Tan et al., 2012) 
RARRES1 
retinoic acid receptor responder 1  ↓ Tumour suppressor, autophagy inducer and angiogenesis inhibitor (TNBC) (Sahab et al., 2011) 
IGFL1 
IGF-like family member 1  ↓ CSC marker 
(Birnie et al., 2008) 
KLK10 
kallikrein-related peptidase 10 ↓ 
Cell proliferation repressor, apoptosis 
inducer (oesophageal and prostate cancer) 
(Hu et al., 2015b, Li et 
al., 2015) 
CD14 
CD14 molecule  ↓ Tumour growth, EMT (gastric cancer) 
(Cheah et al., 2015) 
IFIT2 
interferon-induced protein with 
tetratricopeptide repeats 2  
↓ Prevents metastasis (oral squamous cell carcinoma)  (Lai et al., 2012) 
(The gene changes related to positive outcomes are labelled with a yellow background; the gene changes related to negative outcomes are 
labelled with the grey-blue background. EMT: epithelial-to-mesenchymal transition. CSC: cancer stem cell.) 
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4.2.1.2 STRING-DB analysis 
Antiretroviral drugs affect certain genes through various pathways in TNBCs. To further 
investigate whether the responses of TNBC cells to such drugs were associated with any 
existing signalling pathway, the STRING-DB pathway search tool (version: 10.5, https://string-
db.org/) (Szklarczyk et al., 2017) was used. Genes in the same signalling pathways may be up 
regulated or down regulated according to their roles. However, because of its algorithm, 
STRING-DB imports too many genes at once may sometimes conceal some potential pathways. 
Therefore careful information input is critical for the STRING-DB analysis. Six gene sets: EFV 
up regulated, EFV down regulated, EFV up and down, SPV up regulated, SPV down regulated, 
and SPV up and down, was established based on different selection criteria. Firstly, all the 
candidate genes had to show significant drug-induced differences (q-value less than 0.25). 
Additionally, more weight was placed on the genes displaying greater response differences after 
treatment. Only the genes with higher variations were included (up regulated: fold-change 
greater than 1.2, or down regulated: fold-change less than -1.2). These gene sets were uploaded 
to the STRING-DB online database to analyse the potential protein-protein association 
networks. From this, it was possible to determine signalling pathways involved in antiretroviral 
drug treatments, based on the Kyoto Encyclopaedia of Genes and Genomes (KEGG) database 
(https://www.genome.jp/kegg/) and the Gene Ontology Consortium database 
(http://www.geneontology.org/). More details are discussed later in this chapter. 
4.2.1.3 Network analysis 
The RNA-Seq data included a massive amount of information, and one runs the risk of losing 
important details by only using ANOVA analysis. Network analysis is an alternative method of 
analysis that overcomes this problem by grouping genes with similar drug responses. The 
concept of network analysis is that the genes exhibiting similar expression patterns, under 
different conditions (cell lines and treatments), may be related and belong to corresponding 
signalling pathways. Thus, network analysis was utilised to investigate whether any significant 
pathway could be emphasised to reinforce the analysis of RNA-Seq.  
In network analysis, many separate modules representing different gene expression patterns 
were observed. Although there were forty-four modules identified using this approach, only 
eleven passed the selection criteria (q-value less than 0.05) (Figure 4-1) and were regarded as 
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valid. The genes in these modules were analysed by the STRING-DB search tool to identify the 
significant pathways involved.  
In the original experimental design of the RNA-Seq for this project, gene regulations in the 
DMSO-control cells with antiretroviral drug-treated cells in MCF10A, MCF10AT, 
MCF10CA1α, MDA-MB-231, and MCF7 cell lines were compared. In the initial analysis, only 
the gene regulations in TNBC cell lines were analysed because the MCF7 cell line was 
considered to be a non-TNBC luminal-type breast cancer control. Due to the expression of its 
oestrogen receptors and progesterone receptors, the MCF7 cell line may launch alternative 
signalling pathways and gene regulations than the TNBCs. However, candidate genes regulated 
by drug treatments in the TNBC-only gene set and the TNBC+MCF7 gene set were partially 
identical. Moreover, the candidate gene with the greatest fold-change, SCD, was identical in 
the TNBC-only and the TNBC+MCF7 gene set. Also, the significant signalling pathways 
highlighted by the STRING-DB search tool overlapped in both EFV and SPV ANOVA lists. 
These findings suggested that the anticancer effects of antiretroviral drugs in TNBCs may share 
some mechanisms with MCF7. In addition, the more samples imported to the network analysis, 
the easier it is to find genes with similar patterns owing to greater tolerance in a larger dataset. 
Therefore, the network analysis was done for both TNBC-only and TNBC+MCF7 gene sets. 
The candidate pathways involved in antiretroviral drug treatments are discussed in the 
following sections. 
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Figure 4-1 Bar Plot of ANOVA q-values for module eigengenes in the network analysis 
The modules identified by network analysis are listed on the x-axis. The horizontal line is the 0.05 cut-
off for the Storey q-values. The nine modules which pass the cut-off are considered as significant 
modules. 
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4.2.2 Down regulated pathways after antiretroviral drug treatment 
As mentioned above, after ANOVA analysis, STRING-DB analysis was used to further 
discover relevant genes and pathways which may be affected by antiretroviral drugs in TNBCs. 
Combination of down regulated and up regulated gene sets, which included more than 400 
genes, may reduce the number of significant results due to the algorithms of STRING-DB. 
Thus, the first step was to focus on possible genes and pathways involved in the down regulation 
of genes by antiretroviral drugs. The results of the EFV down regulated gene set and the SPV 
down regulated gene set were discussed separately, since the genes listed in these two gene sets 
could be different due to the pharmacological mechanisms of the drugs. 
Three significant KEGG pathways were highlighted in the EFV down regulated gene set. This 
gene set contained 237 genes (in appendix Table S4-1) that fitted the selection criteria (q-value 
less than 0.25, fold-change less than -1.2). These genes were imported and analysed by the 
STRING-DB to discover potential genes and pathways involved in the EFV-induced cancer 
responses. 231/237 genes had been identified their protein products, and 232 potential links had 
been calculated among these proteins. The number of predicted links were greater than the 
number of expected links (141 links) and the protein-protein interaction (PPI) enrichment p-
value was less than 10-16 suggesting that these proteins might have some biological connections. 
The significant KEGG pathways (Figure 4-2 and Table 4-3) arising from this gene set were 
‘fatty acid metabolism’ (seven genes, q-value = 0.0003), ‘biosynthesis of unsaturated fatty acids’ 
(four genes, q-value = 0.0078) and ‘FoxO signalling pathway’ (eight genes, q-value = 0.0078). 
Only four candidate genes were involved in ‘biosynthesis of unsaturated fatty acids’, and three 
of them were shown in ‘fatty acid metabolism’ pathways. Thus ‘biosynthesis of unsaturated 
fatty acids’ could be considered a relevant branch of ‘fatty acid metabolism’. Consequently, 
only ‘fatty acid metabolism’ and ‘FoxO signalling pathway’ were focused on in this thesis and 
are discussed later in the chapter.   
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Figure 4-2 The STRING-DB gene network for EFV-treatment induced down regulated genes in 
TNBCs 
This figure represents possible protein-protein interaction which was calculated by the STRING-DB 
software. A node represents a protein; a line represents a potential link. The thickness of the line 
indicates the strength of data support. The finest line represents medium confidence (0.400); the 
middle thickness line represents high confidence (0.700); the thickest line represents the highest 
confidence (0.900). The green nodes are proteins related to ‘fatty acid metabolism’; the yellow nodes 
are proteins related to ‘biosynthesis of unsaturated fatty acids’; the pink nodes are proteins related to 
‘FoxO signalling pathway’. 
 
Table 4-3 Highlighted KEGG pathways in EFV down regulated gene set by STRING-DB  
Pathway ID Pathway description Count in network  q-value 
01212 Fatty acid metabolism 7 0.0003 
01040 Biosynthesis of unsaturated fatty acids 4 0.0078 
04068 FoxO signalling pathway 8 0.0078 
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Four significant KEGG pathways were highlighted in the SPV down regulated gene set. This 
gene set contained 379 genes (in appendix Table S4-2) which corresponded to the selection 
criteria (q-value less than 0.25 and fold-change less than -1.2). Not surprisingly, as more genes 
were imported into the STRING-DB search tool, more pathways arose. Four significant 
pathways were highlighted in the SPV down regulated gene set; whereas, only three significant 
pathways were listed in the EFV down regulated gene set. 374/379 genes had been identified 
their protein products, and 860 potential links had been calculated among these proteins. The 
number of predicted links were greater than the number of expected links (552 links) and the 
PPI enrichment p-value was less than 10-16 suggesting that these proteins might have some 
biological connections. The most significant KEGG pathway from the SPV down regulated 
gene set (Figure 4-3 and Table 4-4) was ‘fatty acid metabolism’ (eleven genes, q-value = 
2.33x10-7) which was similar to the result of the EFV down regulated gene set. These results 
highlight the importance of ‘fatty acid metabolism’ in antiretroviral drug-induced cancer cell 
responses. Many genes in the other highlighted pathways were also shown in ‘fatty acid 
metabolism’. For instance, ‘fatty acid degradation’ (seven genes, q-value = 0.00169) had five 
genes, ‘biosynthesis of unsaturated fatty acids’ (five genes, q-value = 0.00304) had four genes, 
and ‘PPAR signalling pathway’ (seven genes, q-value = 0.0172) had five genes which 
overlapped with ‘fatty acid metabolism’ genes, respectively. This suggested these three 
pathways could be highly relevant to ‘fatty acid metabolism’; therefore, ‘fatty acid metabolism’ 
was prioritised as the main focus of the SPV down regulated gene set. 
As predicted, the most significant pathway in the EFV down regulated gene set and the SPV 
down regulated gene set was the same. This implied that EFV and SPV may share the same 
target and thus induce a similar pathway down regulation. At the same time, these results 
emphasised the importance of ‘fatty acid metabolism’ in antiretroviral drug treatment in TNBCs. 
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Figure 4-3 The STRING-DB gene network for SPV-treatment induced down regulated genes in 
TNBCs 
This figure represents possible protein-protein interaction which was calculated by the STRING-DB 
software. A node represents a protein; a line represents a potential link. The thickness of the line 
indicates the strength of data support. The finest line represents medium confidence (0.400); the 
middle thickness line represents high confidence (0.700); the thickest line represents the highest 
confidence (0.900). The green nodes are proteins related to ‘fatty acid metabolism’; the dark green 
nodes are proteins related to ‘fatty acid degradation’; the yellow nodes are proteins related to 
‘biosynthesis of unsaturated fatty acids’; the light blue nodes are proteins related to ‘PPAR signalling 
pathway’. 
  
Table 4-4 Highlighted KEGG pathway in SPV down regulated gene set by STRING-DB 
Pathway ID Pathway description Count network q-value 
01212 Fatty acid metabolism 11 2.33x10-7 
00071 Fatty acid degradation 7 0.00169 
01040 Biosynthesis of unsaturated fatty acids 5 0.00304 
03320 PPAR signalling pathway 7 0.0172 
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4.2.2.1 Fatty acid metabolism  
The anticancer effects of antiretroviral drugs appeared to be strongly associated with down 
regulation of fatty acid metabolism in cancers. The down-regulation of fatty acid metabolism-
related genes had been emphasised not only in the KEGG database (Table 4-3 and Table 4-4) 
but also in the GO database according to the calculation of the STRING-DB. Also, SCD which 
had the greatest fold-change after antiretroviral drug treatment in TNBCs, according to the 
ANOVA analysis, was a crucial gene in fatty acid metabolism. Moreover, the heat maps (Figure 
4-4), which represent RNA expression levels across different treatments, illustrated that most 
of the key fatty acid metabolism-related genes, including SCD, acyl-CoA synthetase long-chain 
family member 1 (ACSL1), acyl-CoA synthetase long-chain family member 3 (ACSL3), acyl-
CoA synthetase long-chain family member 5 (ACSL5), fatty acid synthase (FASN), fatty acid 
desaturase 1 (FADS1), fatty acid desaturase 2 (FADS2), 3-hydroxyacyl-CoA dehydratase 2 
(HACD2 or PTPLB), acetyl-CoA carboxylase alpha (ACACA), sterol regulatory element-
binding transcription factor 1 (SREBF1), ATP-citrate synthase  (ACLY), acetyl-CoA 
acetyltransferase 2 (ACAT2), and Hydroxyacyl-CoA dehydrogenase (HADH) were decreased 
(red) after antiretroviral drug treatments, compared with their controls, in all breast cancer cell 
lines. These results were in agreement with many previous studies suggesting that fatty acid 
metabolism plays a critical role in cancer (Yi et al., 2018, Wang et al., 2017c, Kuo and Ann, 
2018).  
The fatty acid metabolism-related genes (according to the KEGG database) highlighted in both 
of the EFV up regulated gene set and the SPV up regulated gene set are listed in Table 4-5 with 
their potential roles in cancer. These genes included SCD, ACSL5, FASN, ACSL3, FADS1, 
PTPLB and ACACA. The order of these genes was descending of the fold-changes. Most of 
them (SCD, ACSL5, FASN, ACSL3, and ACACA) have been linked to tumorigenesis and tumour 
growth in many types of cancer (Kim et al., 2011, Tirinato et al., 2017). 
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Table 4-5 Antiretroviral drugs induced down regulated fatty acid metabolism-related genes 
Gene names Roles in cancers References 
EFV or SPV-treated TNBCs 
SCD 
stearoyl-CoA desaturase 
Cancer proliferation, tumour expansion 
(prostate, breast cancer) 
(Kim et al., 2011, Belkaid et al., 
2015, Peck et al., 2016) 
ACSL5 
acyl-CoA synthetase long-chain 
family member 5  
Cancer cell survival (glioma cell) (Mashima et al., 2008) 
FASN 
fatty acid synthase 
Cell proliferation, cell survival, cell 
adhesion, migration, and invasion (most 
human carcinomas) 
(Wang et al., 2017c, Cui et al., 
2017, Kuo and Ann, 2018) 
ACSL3 
acyl-CoA synthetase long-chain 
family member 3  
Tumorigenesis, cancer initiation (lung 
cancer) 
(Perera et al., 2009, Padanad et 
al., 2016, Migita et al., 2017) 
FADS1 
fatty acid desaturase 1  Unknown 
 
HACD2 (PTPLB) 
3-hydroxyacyl-CoA dehydratase 2 Unknown 
 
ACACA (ACSS1) 
acetyl-CoA carboxylase alpha 
Tumour growth, malignancy (hepatocellular 
carcinoma) 
(Tirinato et al., 2017) 
(The gene changes related to positive outcomes are labelled with a yellow background; the gene changes which have no 
evidence to be associated with cancer are labelled with white background) 
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Fatty acid metabolism may play multiple roles in cancer; most of the crucial genes relevant to 
fatty acid metabolism have been linked to cancer cell proliferation. Several of these genes have 
been recognised as critical regulators of cancer stem cells (CSCs) and thus could be responsible 
for drug resistance, cancer invasion, metastasis, and cancer recurrence (Yi et al., 2018). SCD 
and FASN, which are associated with cancer survival and CSCs, are discussed below. 
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Figure 4-4 Heat-maps for presenting the expression levels of the key genes of fatty acid 
metabolism in different treatments and cancer cell lines 
The key genes of fatty acid metabolism pathway are labelled on the right-hand side. And the colour 
code blocks present the relative expression levels of each gene in different conditions. The Z-score is 
to measure the relative number of the average number. The green colour represents higher RNA level; 
whereas, the red colour represents lower RNA level. 
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 Stearoyl-CoA desaturase (SCD)  
Among the candidate genes in fatty acid metabolism, SCD showed the most dramatic fold-
change after antiretroviral drug treatment according to the ANOVA results. In TNBC cell lines, 
SCD was more than three times lower than the untreated control cells. Thus, it is worthwhile 
considering the possible role of SCD in antiretroviral drug-induced anti-cancer process.  
There are several reasons why SCD could be a key factor linking antiretroviral drug treatment 
with anticancer processes. It has been shown to be one of the genes associated with various 
cancers, including breast cancer (Belkaid et al., 2015, Cui et al., 2017). It is also associated with 
breast cancer cell proliferation and tumour expansion in prostate and breast cancers (Kuo and 
Ann, 2018). Therefore, inhibiting SCD might potentially combat cancer. In this RNA-Seq 
experiment, both EFV- and SPV-treated cells were shown to significantly reduce SCD 
expression compared with the untreated control cells. This indicates that antiretroviral drugs 
can effectively suppress SCD expression, and it could explain how antiretroviral drugs 
eliminate TNBCs. Moreover, SCD is involved in CSC regulation (Tirinato et al., 2017). The 
overexpression of SCD has been linked to CSCs in many different cancers; whereas, decreasing 
SCD expression has been shown to affect CSC formation and to reduce their drug resistance. 
Drug resistance by CSCs is considered to be one of their major characteristics in lung and liver 
cancers (Yi et al., 2018). Therefore, the SCD suppression effect which was found in this RNA-
Seq experiment is most likely relevant to CSC elimination. 
 Fatty Acid Synthase (FASN) 
FASN is another fatty acid metabolism-related gene, which has been well-investigated in the 
past decade and is a confirmed therapeutic target for breast cancer (Menendez and Lupu, 2017a). 
No FASN inhibitor, however, has successfully passed clinical trials because of the drug 
efficiencies and the complexity of the human body (Flavin et al., 2010). FASN has also been 
implicated in HIV replication. Since HIV and LINE-1 share reverse transcription ability, it 
implies that FASN can be linked with LINE-1 regulation and thus play a role in antiretroviral 
drug-induced anti-TNBC effects. In this study, FASN expression was reduced by half after drug 
treatment in TNBCs suggesting that antiretroviral drugs might be able to regulate FASN 
expression directly or indirectly. However, more experiments need to be done to further explore 
this idea. 
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4.2.2.2 FoxO signalling pathway 
The FoxO signalling pathway is considered important in antiretroviral drug treatment. Unlike 
fatty acid metabolism, the FoxO signalling pathway was only highlighted in the EFV down 
regulated gene set (eight genes, q-value = 0.0078) but not in the SPV down regulated gene set 
because of the selection criteria. The fold-change of catalase (CAT) in the SPV down regulated 
gene set was not as significant as in the EFV down regulated gene set. Cyclin-dependent kinase 
inhibitor 2D (CDKN2D) was increased rather than decreased after SPV treatment. However, 
serum and glucocorticoid regulated kinase 1 (SGK1), B-cell lymphoma 6 (BCL6), polo-like 
kinase 2 (PLK2), phosphoinositide-3-kinase, regulatory subunit 3 (PIK3R3), forkhead box O1 
(FOXO1), and transforming growth factor beta 2 (TGFB2) passed the selection criteria (q-value 
less than 0.25, fold-change less than -1.2) in both the EFV and the SPV down regulated gene 
sets. The reduction of expression levels in SGK1, BCL6, and PI3KR3, which are associated with 
negative prognostic outcomes after antiretroviral drug treatment, implied a role for FoxO 
signalling pathway in the antiretroviral drug-induced anticancer process (Table 4-6). However, 
the decrease of PLK2, TGFB2 and FOXO1 after treatment led to conflicting results, since PLK2 
and TGFB2 can act as either tumour suppressor or oncogene, depending on the stage and type 
of cancer (Dave et al., 2011, Ou et al., 2016). FOXO1 has been considered both as a tumour 
suppressor gene and as an inducer of programmed cancer cell death (Lu and Huang, 2011, 
Farhan et al., 2017). The role of the FoxO signalling pathway in cancer can be very complicated. 
Many FoxO signalling pathway-related genes have been considered tumour suppressors; 
however, some new evidence suggests FoxO signalling pathway-related genes may be potential 
targets for treating cancer (Farhan et al., 2017, Hornsveld et al., 2018). The exact functions of 
the FoxO signalling pathway in cancer remain unclear. 
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Table 4-6 Antiretroviral drugs induced down regulated FoxO signalling pathway-related genes 
Gene names Role in cancers References 
EFV-treated or SPV-treated TNBCs 
SGK1 
serum/glucocorticoid regulated 
kinase 1 
Drug resistance (many cancers), tumour development 
(colorectal cancer)  
(Talarico et al., 2016, Liang 
et al., 2017) 
BCL6 
B-cell lymphoma 6 Oncogene (leukaemia, lung and breast cancers)  
(Cardenas et al., 2017, Wu 
et al., 2014) 
PLK2 
polo-like kinase 2 
Tumour growth (colorectal cancer), oncogene (HCC), 
tumour suppressor (HCC) 
(Ou et al., 2016) 
PIK3R3 
phosphoinositide-3-kinase, 
regulatory subunit 3 (gamma) 
EMT inducer and metastasis promoter (colorectal, 
pancreatic cancer) 
(Wang et al., 2014a, Peng 
et al., 2018) 
FOXO1 
forkhead box O1 Tumour suppressor  
(Farhan et al., 2017, 
Hornsveld et al., 2018) 
TGFB2 
transforming growth factor, 
beta 2 
Tumour suppressor in early stages; cancer promoter in 
advanced stages  
(Dave et al., 2011) 
(The gene changes related to positive outcomes are labelled with a yellow background; the gene changes related to negative 
outcomes are labelled with a grey-blue background; the gene changes related to either positive or negative outcomes are 
labelled with a red-orange background. HCC: hepatic cellular cancer.) 
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4.2.3 Up regulated pathways after antiretroviral drug treatment 
After analysing down regulated genes and pathways involved in antiretroviral drug treatment, 
up regulated pathways potentially involved in antiretroviral drug treatment were also analysed. 
There were 262 genes (in appendix Table S4-3) that fitted the selection criteria (q-value less 
than 0.25, fold-change greater than 1.2) in the EFV up regulated gene set and 502 genes (in 
appendix Table S4-4) in the SPV up regulated gene set. Overall, up regulated pathways in both 
gene sets were more alike than the two down regulated gene sets. In EFV up regulated gene set, 
246/262 genes had their protein products identified by the STRING-DB, and 231 potential links 
had been calculated among these proteins. The number of predicted links were greater than the 
number of expected links (168 links) and the protein-protein interaction (PPI) enrichment p-
value was less than 2x10-6 suggesting that these proteins might at least partially have some 
biological connections. In SPV up regulated gene set, 460/502 genes had their protein products 
identified by the STRING-DB, and 630 potential links had been calculated among these 
proteins. The number of predicted links were greater than the number of expected links (457 
links) and the protein-protein interaction (PPI) enrichment p-value was less than 4.95x10-11 
suggesting that these proteins might have some biological connections. Genes associated with 
‘microRNAs in cancers’ (EFV: eleven genes, q-value = 0.0004; SPV: eleven genes, q-value = 
0.0447) (Figure 4-5, Table 4-7) and ‘amino sugar and nucleotide sugar metabolism’ (EFV: five 
genes, q-value = 0.0318; SPV: seven genes, q-value = 0.02) KEGG pathways were highlighted 
in both of the EFV up regulated and the SPV up regulated gene sets as shown in Figure 4-6 and 
Table 4-8.    
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Figure 4-5 The STRING-DB gene network for EFV-treatment induced up regulated genes in 
TNBCs 
This figure represents possible protein-protein interaction which was calculated by the STRING-DB 
software. A node represents a protein; a line represents a potential link. The thickness of the line 
indicates the strength of data support. The finest line represents medium confidence (0.400); the 
middle thickness line represents high confidence (0.700); the thickest line represents the highest 
confidence (0.900). The red nodes are proteins related to ‘microRNAs in cancer’; the blue nodes are 
proteins related to ‘Amino sugar and nucleotide sugar metabolism’. 
 
Table 4-7 Highlighted KEGG pathways in EFV up regulated gene set by STRING-DB 
Pathway ID KEGG Pathway  Count in network q-value 
05206 MicroRNAs in cancer 11 0.0004 
00520 Amino sugar and nucleotide sugar metabolism 5 0.0318 
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Figure 4-6 The STRING-DB gene network for SPV-treatment induced up regulated genes in 
TNBCs 
This figure represents possible protein-protein interaction which was calculated by the STRING-DB 
software. A node represents a protein; a line represents a potential link. The thickness of the line 
indicates the strength of data support. The finest line represents medium confidence (0.400); the 
middle thickness line represents high confidence (0.700); the thickest line represents the highest 
confidence (0.900). The red nodes are proteins related to ‘microRNAs in cancer’; the blue nodes are 
proteins related to ‘Amino sugar and nucleotide sugar metabolism’. 
 
Table 4-8 Highlighted KEGG pathways in SPV up regulated gene set by STRING-DB 
Pathway ID KEGG Pathway  Count in network q-value 
00520 Amino sugar and nucleotide sugar metabolism 7 0.02 
05206 MicroRNAs in cancer 11 0.0447 
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4.2.3.1 Genes associated with cancer-related microRNAs 
‘MicroRNAs in cancer’ represents a group of genes relevant to cancer-related microRNA 
regulations. The genes including high mobility group AT-hook 2 (HMGA2), vimentin (VIM), 
fascin homolog 1(FSCN1), cluster of differentiation 44 (CD44), glutaminase (GLS), mdm4 p53 
binding protein homolog (MDM4), ataxia telangiectasia mutated (ATM), SHC-transforming 
protein 1 (SHC1), and DNA-methyltransferase 3 alpha (DNMT3A) were pointed out in both the 
EFV  and the SPV up regulated gene set (Table 4-9). HMGA2, VIM, FSCN1, CD44, GLS, and 
SHC1 have been connected to cancer growth and metastasis; while, CD44 has also been 
recognised as one of the CSC markers in prostate, ovarian and breast cancers (Basakran, 2015). 
Interestingly, DNMT3A has been considered as an oncogene in hepatic cellular cancer (HCC) 
but also as a tumour suppressor gene in acute myeloid leukaemia (AML) (Chen and Chan, 2014, 
Brunetti et al., 2017). In contrast to the results observed for down regulating fatty acid 
metabolism-related genes, the up regulation of genes associated with cancer-related 
microRNAs is typically linked to poor prognostic outcomes. 
Table 4-9 Antiretroviral drugs induced up regulated microRNAs in cancer-related genes 
Gene names Role in cancer References 
EFV or SPV-treated TNBCs 
HMGA2 
high mobility group AT-hook 2  
Cancer proliferation and metastasis, 
poor prognostic outcome  
(Morishita et al., 2013, Wu et 
al., 2016b, Gao et al., 2017) 
VIM 
vimentin EMT marker (epithelial cancers) 
(Satelli and Li, 2011) 
FSCN1 
fascin homolog 1, actin-bundling protein 
Cancer development and metastasis 
(epithelial cancers) 
(Hanker et al., 2013, Wang et 
al., 2017a) 
CD44 
a cluster of differentiation 44 
Cancer stem cell marker, poor 
prognostic outcome (lung, breast and 
ovarian cancers) 
(Basakran, 2015, Lin and Ding, 
2017, Hu et al., 2018) 
GLS 
glutaminase Cancer growth  
(Katt and Cerione, 2014, Lampa 
et al., 2017) 
MDM4 
Mdm4 p53 binding protein homolog Negative tumour suppressor regulator  
(Li and Lozano, 2013, Haupt et 
al., 2017, Bardot and Toledo, 
2017) 
ATM 
ataxia telangiectasia mutated 
Cancer predisposition (lymphoid, 
gastric, breast cancers) 
(Ahmed and Rahman, 2006, 
Choi et al., 2016) 
SHC1 
SHC-transforming protein 1  
Cancer proliferation (breast and 
prostate cancers) 
(Ravichandran, 2001) 
DNMT3A 
DNA-methyltransferase 3 alpha  
Oncogene (HCC), tumour suppressor 
gene (AML) 
(Chen and Chan, 2014, Brunetti 
et al., 2017) 
(The gene changes related to negative outcomes are labelled with a grey-blue background; the gene changes related to 
either positive or negative outcomes are labelled with a red-orange background. EMT: epithelial-to-mesenchymal 
transition. HCC: hepatic cellular cancer. ALM: adult acute myeloid leukaemia.) 
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4.2.3.2 The regulation of miR-21 and miR-182 after antiretroviral drug treatments 
Since genes associated with ‘microRNAs in cancers’ were highlighted under antiretroviral drug 
treatment conditions, based on the STRING-DB search tool, it is worth investigating the 
relationship between microRNAs, antiretroviral drug treatment, and cancer malignancy. 
Various microRNAs are involved in breast cancer regulation. According to the results from  
microRNA microarray experiments conducted in our laboratory (unpublished data from Dr 
Radhika Patnala, Dr Stephen Ohms, and Dr Danny Rangasamy), several microRNAs exhibited 
significant changes after EFV treatment (Figure 4-7). These experiments were based on a 
luminal-type breast cancer cell line T47D. The experimental design involved the treatment of 
T47D cells with EFV and then a comparison of variations in microRNA expression between 
EFV-treated and untreated T47D cells. They used microarray analysis to investigate the 
correlation between microRNAs and drug responses. Since ‘microRNAs in cancer’ had been 
shown in the up regulated gene set, it is worth examining whether the cancer-related 
microRNAs themselves can be up regulated in the drug-treated cells.  
Two of the critical microRNAs showing vast changes after EFV treatment were microRNA 21 
(miR-21) and microRNA 182 (miR-182). In the microRNA microarray assay, the EFV-treated 
T47D cells showed an increase in expression of 2.56 times for miR-21 and an increase of 2.58 
times for miR-182, compared with the control cells (Figure 4-7). This suggested that miR-21 
and miR-182 were strongly affected by EFV treatment. Thus, miR-21 and miR-182 were chosen 
for further investigation using microRNA quantitative reverse transcription polymerase chain 
reaction (qRT-PCR) in TNBCs. 
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Figure 4-7 Scatterplots for gene expression between control and EFV treatment based on 
microarray data 
The blue dots represent significant microRNAs detected in a microarray experiment. X-axis and y-axis 
represent the raw reads of the microRNAs. miR-21 and miR-182 (indicated by red circles) have greater 
fold-changes than other microRNAs. 
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Significant differences in miR-21 and miR-182 after EFV treatment were consistently detected 
in TNBCs. Both miR-21 and miR-182 increased after EFV treatment in MCF10AT, 
MCF10CA1α, and MDA-MB-231 cell lines (Figure 4-8). The following fold-change increases, 
in miR-21, of 0.61, 1.05, and 0.28 occurred in MCF10AT, MCF10CA1α, and MDA-MB-231 
cells, respectively.  There were fold-change increases, in miR-182 of 0.97, 1.92, and 0.45 in 
MCF10AT, MCF10CA1α, and MDA-MB-231 cells, respectively. The increased expression of 
miR-21 and miR-182 in this experiment agreed with the findings of the microarray experiment 
in T47D cell lines. 
miR-21 has been correlated with poor prognostic outcomes in breast cancers and is a biomarker 
of mesenchymal cancer cells (Yan et al., 2008, Pfeffer et al., 2015). It is also one of the CSC 
markers and may inhibit some tumour suppressor genes, including programmed cell death 4 
protein (PDCD4), phosphatase and tensin homolog (PTEN) and others (Asangani et al., 2007, 
Zhang et al., 2010). Inhibiting miR-21 increases cell apoptosis and reduces cell proliferation 
(Pfeffer et al., 2015). Interestingly, our experiments showed that miR-21 increased after 
antiretroviral drug treatment, either in the T47D microarray experiment or in the TNBC 
microRNA qRT-PCR experiment. This implied that the drugs may enhance the malignant 
potential of cells. 
miR-182, however, displays dual roles in cancer regulation. Similar to miR-21, miR-182 has 
been linked to cancer metastasis and unfavourable prognostic outcomes for cancer patients 
(Chiang et al., 2013, Lei et al., 2014). Yet, an alternative role for miR-182 has recently been 
discovered: it can reduce certain drug resistance in breast cancers (Kouri et al., 2015, Li et al., 
2018, Yue and Qin, 2019). Some microRNAs can present with multiple functions; acting as a 
tumour suppressor or as an oncogene in different circumstances (Ding et al., 2018). The exact 
functions of microRNAs in antiretroviral drug treatment are difficult to determine. Thus further 
experiments are essential before stating further conclusions. 
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Figure 4-8 qRT-PCR data for comparison of miR-21 and miR-182 in different cell lines 
miR-21 and miR-182 are increased after drug treatment in all tested TNBC cell lines. The standard for 
the relative fold-change is the microRNA expression of untreated MCF10A cell line. Error bars: ±SD, n 
= 4. 
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4.2.3.3 Amino sugar and nucleotide sugar metabolism 
Amino sugar and nucleotide sugar metabolism were also highlighted in up regulated gene sets 
(Table 4-10). Several of the candidate genes listed in the amino sugar and nucleotide sugar 
metabolism pathway, including UDP-N-acetylglucosamine pyrophosphorylase 1 (UAP1), 
hexokinase 2 (HK2), and glutamine-fructose-6-phosphate transaminase 1 (GFPT1), were 
associated with poor prognostic outcomes. GFPT1 can also be considered as a suppressor of 
epithelial-to-mesenchymal (EMT) transition and metastasis in gastric cancers (Duan et al., 
2016). HK2 which is a key gene for cancer initiation and growth is the most well-known among 
these candidate genes. It has been linked to glycolytic regulation, which could be associated 
with cancer growth (Wang et al., 2016, DeWaal et al., 2018). There is evidence suggesting that 
HK2 inhibition or depletion could be an effective strategy in treating many different cancers 
(Wu et al., 2017). Few reports show the relationship with UAP1 and cancer; however, a current 
study (Itkonen et al., 2014) suggests that UAP1 may be overexpressed in prostate cancers and 
protect cancer cells from cell stress. It might be improving cancer growth under cancer 
treatment. To date, little is known about any direct link between amino sugar and nucleotide 
sugar metabolism and cancers. 
Table 4-10 Antiretroviral drugs induced up regulated amino sugar and nucleotide sugar 
metabolism-related genes 
Gene names Role in cancers References 
EFV or SPV-treated TNBCs 
UAP1 
UDP-N-acetylglucosamine 
pyrophosphorylase 1  
Cancer growth, drug resistance  (Itkonen et al., 2014) 
GFPT2 
glutamine-fructose-6-phosphate 
transaminase 2  
Unknown   
HK2 
hexokinase 2  Tumour initiation and growth 
(Patra et al., 2013, Wang et al., 
2016, DeWaal et al., 2018, Wu 
et al., 2017) 
GFPT1 
glutamine-fructose-6-phosphate 
transaminase 1  
Poor prognosis marker (Pancreatic cancer, 
HCC), EMT and metastasis suppressor (Gastric 
cancer)  
(Yang et al., 2016, Duan et al., 
2016, Li et al., 2017) 
GALE 
UDP-galactose-4-epimerase Unknown  
 
(The gene changes related to negative outcomes are labelled with a grey-blue background; the gene changes related to either 
positive or negative outcomes are labelled with a red-orange background; the gene changes which have no evidence to be 
associated with cancer are labelled with white background. EMT: epithelial-to-mesenchymal transition. HCC: hepatic cellular 
cancer) 
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4.2.4 The role of p53 in antiretroviral drug treatment 
The combination of the down regulated and the up regulated gene sets may also identify critical 
genes pathways which were not identified in the individual down regulated or up regulated gene 
set. While some genes are up regulated, others are down regulated in a given pathway; hence if 
we focus on a specific regulating side, we may miss out on the big picture. Although by 
enlarging the gene pool we may decrease the sensitivity of the STRING-DB software and 
reduce the significance of pathways, it is important to analyse the combined gene sets for EFV 
and SPV treatments in order to discover the masked genes and pathways.  
Our analysis combined the significant genes (q-value less than 0.25) with fold-changes greater 
than 1.2 and less than -1.2 (EFV: 499 genes; SPV: 881 genes), and found that most of the 
pathways being highlighted overlapped with the down regulated or the up regulated gene sets 
(Figure 4-9, Table 4-11, and in appendix Figure S4-1, Table S4-5). ‘Fatty acid metabolism’ was 
highlighted in both EFV- and SPV-treated cells; while, ‘FoxO signalling pathway’ and 
‘microRNAs in cancers’ was only indicated in EFV-treated cells. The genes involved in these 
pathways were very similar to the genes described in individual gene sets. However, Tumor 
protein p53 (TP53) appeared in the significant ‘microRNAs in cancer’ pathway when down 
regulated and up regulated gene sets were combined; but not in any of the individual gene sets. 
This meant that unlike other genes associated with the ‘microRNAs in cancer’ pathway, TP53 
was down regulated after antiretroviral drug treatment.   
TP53 is the most intensely studied tumour suppressor gene and has multiple functions in cancer. 
TP53 can act as a negative regulator of proliferation in cancer cells via apoptosis, and it can 
also be an EMT and a cell cycle regulator (Varna et al., 2011). It plays roles in ageing, 
autophagy, mitotic catastrophe, and angiogenesis (Varna et al., 2011). TP53 has long been 
recognised as an oncogene (Soussi and Wiman, 2015); however, scientists now acknowledge 
that the oncogenic functions of p53 protein are caused by mutant p53 protein rather than wild-
type p53 protein. The mutant protein has lost its tumour suppressor abilities and induces cancer 
progression (Muller and Vousden, 2014). TP53 mutation has been found to exist in more than 
half of human cancers (Parrales and Iwakuma, 2015). Frequently, TP53 has a missense mutation 
enabling the stable expression of mutant p53 protein within tumour cells. In numerous 
situations, these mutant p53 proteins are unable to target p53-responsive genes thus terminating 
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oncogene suppression in cancers (Liu, 2011). Other functions of mutant p53 protein have also 
been confirmed in cancers which explains why p53 mutation is a crucial area of cancer research 
(Freed-Pastor and Prives, 2012). Thirty per cent of breast cancers overall and sixty per cent of 
TNBCs carry the mutated TP53 gene (Bertheau et al., 2013, Turner et al., 2013). The mutant 
p53 protein is related to cancer development and has been associated with therapeutic resistance 
to chemotherapy, hormonotherapy and radiotherapy (Varna et al., 2011). It has been strongly 
linked with unfavourable prognostic outcomes in TNBCs and may be responsible for cancer 
initiation (Varna et al., 2011). Therefore, the targeting of mutant p53 is considered to be a 
potential therapeutic strategy.  
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Figure 4-9 The STRING-DB gene network for EFV-treatment induced up regulated and down 
regulated genes in TNBCs 
This figure represents possible protein-protein interaction which was calculated by the STRING-DB 
software. A node represents a protein; a line represents a potential link. The thickness of the line 
indicates the strength of data support. The finest line represents medium confidence (0.400); the 
middle thickness line represents high confidence (0.700); the thickest line represents the highest 
confidence (0.900). The red nodes are proteins related to ‘microRNAs in cancer’; the pink nodes are 
proteins related to ‘FoxO signalling pathway’; the green nodes are proteins related to ‘fatty acid 
metabolism’. 
Table 4-11 Highlighted KEGG pathways in EFV down regulated and up regulated gene sets 
using STRING-DB  
Pathway ID Pathway description Count network q-value 
05206 Micro RNAs in cancer 15 0.000376 
04068 FoxO signalling pathway 12 0.00349 
01212 Fatty acid metabolism   7 0.011 
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Antiretroviral drug treatment specifically reduced the expression of TP53 in three tested TNBC 
cell lines. In this RNA-Seq study, it had been predicted that antiretroviral drug treatment may 
universally repress the expression of TP53 according to the significant reduction of TP53 in 
ANOVA analysis. However, contrary to the expectation, TP53 was only suppressed in 
MCF10AT, MCF10CA1α, and MDA-MB-231 cell lines after the drug treatment. Antiretroviral 
drug-treated TNBC cells expressed approximately two-third of TP53 RNA compared with their 
untreated-controls; whereas, only subtle differences in TP53 RNA levels were detected in 
MCF10A and MCF7 cell lines (Figure 4-10). This result indicates that antiretroviral drugs 
might have very limited effects on TP53 RNA in MCF10A and MCF7 cell lines which contain 
wild-type TP53 gene (Lim et al., 2009). Unlike MCF10A and MCF7 cell lines, the MDA-MB-
231 cell line expresses the mutant TP53 gene (Lim et al., 2009), whereas no report has been 
published on whether MCF10AT and MCF10CA1α express the wild-type or mutant TP53 gene. 
These observations imply that either antiretroviral drugs can suppress TP53 RNA expression 
specifically in TNBCs, or that MCF10AT and MCF10CA1α cells contain mutant TP53, as do 
MDA-MB-231 cells, that can be inhibited by antiretroviral drugs.  
Based on our RNA-Seq results and reading of the published literature, we have proposed the 
following hypothesis to explain the diverse morphological changes observed after treatment of 
the TNBC cell lines with antiretroviral drugs. Antiretroviral drugs may specifically suppress 
the expression of both mutant and wild-type TP53 genes in TNBCs. The MDA-MB-231 cells 
contain mutant TP53 and express mutant p53 protein (Lacroix et al., 2006); whereas, the 
MCF10AT and the MCF10CA1α cells, similar to MCF10A cells, contain wild-type TP53 and 
express wild-type p53 protein (Lim et al., 2015). Mutant p53 protein is well-recognised as a 
potential therapeutic target for cancer (Parrales and Iwakuma, 2015), and suppressing it in 
MDA-MB-231 cells might effectively reduce cancer proliferation. In contrast, knocking-down 
wild-type p53 may induce EMT (Jiang et al., 2011, Wang et al., 2013). When MCF10AT and 
MCF10CA1α cells were treated with the drugs, they displayed mesenchymal markers such as 
SLUG and fibronectin (mentioned in chapter 3) which may be linked to poor prognostic 
outcomes. This suggests that extensive suppression in TNBCs of p53 may be responsible for 
the altered morphological changes observed in antiretroviral drug-treated TNBC cells. 
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Figure 4-10 The RNA-Seq result of TP53 RNA expression in different cell lines 
The y-axis represents the reads of Fragments per Kilobase Million (FPKM). The black-bars represent 
untreated-controls; the red-bars represent EFV treatments; the blue-bars represent SPV treatments. 
The antiretroviral drug-treated cells express around 70% of TP53 RNA compared with untreated-
control cells in MCF10AT, MCF10CA1α, and MDA-MD-231 cell lines. MCF10A and MCF7 express wild-
type TP53 RNA; whereas MDA-MB-231 expresses mutant TP53 RNA. There is no evidence to suggest 
which type of TP53 RNA is expressed by MCF10AT and MCF10CA1α. 
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Interestingly, EFV, LINE-1, and p53 can be connected by several studies. p53 has been shown 
to influence the early replication of HIV by inhibiting HIV RT (Shi et al., 2018). This RT shares 
a similar function to that of LINE-1 RT. In addition, the p53 binding site has been identified in 
the LINE-1 promoter region (Harris et al., 2009). Therefore, p53 might be relevant to LINE-1 
regulation. Recent studies suggested that p53 co-evolved with endogenous transposons, 
including LINE-1, in the germline millions of years ago. p53 regulated their function in the 
genome, possibly by a positive-feedback loop (Levine et al., 2016). Therefore, it might be 
possible that the expression of LINE-1 affects the expression level of p53 by a feedback signal. 
Moreover, EFV has been linked with p53-induced autophagy-related cell death in human 
keratinocyte cells, (Dong et al., 2013), which links EFV treatment and p53 regulation.  Taken 
together, these findings suggest that EFV treatment can affect both LINE-1 and p53, while 
LINE-1 and p53 may interact with each other. The exact relationship and the mechanisms 
involved are still vague, and more evidence and experiments are needed to test our hypothesis. 
Although this topic is beyond the scope of this project, it could be a further direction for 
researchers who want to understand the role of p53 in antiretroviral drug-induced cancer 
activities. 
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4.2.5 Other important genes in antiretroviral drug induced cancer responses 
Although the importance of fatty acid metabolism and genes associated with cancer-related 
microRNAs have been illustrated, many other genes may have a role to play in how cancer cells 
respond to antiretroviral drugs. When analysing the gene sets via STRING-DB, we found that 
some genes were highlighted in various groups according to the GO database. In contrast to the 
KEGG database, the GO database focuses more on the locations and functions of proteins rather 
than their pathways. Based on the GO database, many genes with closely-related functions 
which might further explain the phenotypes described in the previous chapter were pointed out 
and are reviewed at the end of this chapter. Furthermore, as mentioned, network analysis also 
provided some important information, the results of which were considered. Finally, genes 
displaying highly statistical significances in ANOVA analysis but which were not involved in 
any particular pathways and networks were listed and discussed.   
4.2.5.1 Cell morphology-related genes  
As shown in the previous chapter, genes related to morphological changes in the cells were 
emphasised in two up regulated gene sets. Many genes related to cell morphology were 
highlighted in antiretroviral drug-treated up regulated gene sets suggesting that antiretroviral 
drugs might be able to induce morphological changes in cancer cells. This result was observed 
with immunofluorescence and western blotting and discussed in the previous chapter. 
Consistent with previous observations, increases were observed not only in cell projection-
related genes, but also in cell migration-related genes, after antiretroviral drug treatment. Cell 
projection is a sign of cell differentiation and these results suggested that the cells tested tended 
to differentiate after antiretroviral drug treatment. This is consistent with previous findings that 
some antiretroviral drugs might be able to transit cancer cells from mesenchymal states to 
epithelial states, thus reducing the malignancy of the cancers. Cell migration has been linked to 
cancer metastasis and the expression of the cell migration genes may lead to unfavourable 
prognostic outcomes. Many modules in our network analysis also displayed similar trends with 
focal adhesion, cell junction, and stress fibre highlighted in three out of eleven TNBC-only 
modules (in appendix Figure S4-2). The RNA-Seq data was consistent with the phenotypes 
observed in the previous chapter, in which some TNBCs, especially MCF10AT and 
MCF10CA1α, showed signs of favourable and unfavourable prognostic outcomes after 
antiretroviral drugs treatment.  
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4.2.5.2 The role of mitochondria in antiretroviral drug-induced cancer responses 
The network analysis of the TNBC+MCF7 gene set extended the analysis in an alternative 
direction. There were eight modules that passed the selection criteria in the TNBC+MCF7 gene 
set (in appendix Figure S4-3), and only three of them indicated significant protein-protein 
association networks (in appendix Table S4-6). In agreement with the network analysis for the 
TNBC-only gene set, the modules based on the TNBC+MCF7 gene set identified many genes 
related to cell morphological changes, including adherens junction, cell projection, and focal 
adhesion genes (Figure S4-4). There were many genes which corresponded mitochondria in 
some modules (in appendix Table S4-7). 
This result suggested the potential involvement of mitochondria in antiretroviral drug-induced 
cancer responses. EFV seems to affect mitochondrial complex I (Lee and Boelsterli, 2014, 
Apostolova et al., 2014) which might further affect the balance between oxidised and reduced 
nicotinamide adenine dinucleotide (NAD+/NADH) (Lee and Boelsterli, 2014). This 
NAD+/NADH balance is crucial for CSC maintenance and thus influences the malignancy of 
cancers (Bonuccelli et al., 2017). Additionally, EFV has been shown to damage the 
mitochondrial complex I (Purnell and Fox, 2014). Thus, a possible link between EFV and 
mitochondrial complex I regulation has been illustrated. Moreover, LINE-1 suppression affects 
a piRNA which might target human mitochondrial Hsp 70 (Mortalin) and thereby regulating 
the functions of mitochondria (Ohms and Rangasamy, 2014). Mitochondria might also play a 
role in antiretroviral drug-induced cancer responses; however, this is beyond the scope of this 
project and more studies are needed to support this hypothesis. 
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4.2.5.3 CSC-related genes 
The importance of CSC was drawn to our attention when several CSC-related genes were 
highlighted in RNA-Seq analysis. Interestingly, among those genes which changed 
significantly with treatment, CSC-related genes such as CD44, MED8, DMXL2, and PROCR, 
as well as miR-21, increased, while others such as CHMP4B, ACSL3, ALDH9A1, SCD, and 
FASN decreased. The inconsistent results emphasised the complexity of CSCs within TNBCs. 
Therefore, a further study of CSC was conducted, and it is described in the next chapter. 
Table 4-12 CSC-related genes involved in antiretroviral drug-induced cancer responses 
Gene names Drug response Role in cancers Reference 
CD44 
a cluster of differentiation 
44 
↑ CSC indicator (lung, breast and ovarian cancers) 
(Basakran, 2015, Lin and 
Ding, 2017, Hu et al., 2018) 
MED8 
mediator complex subunit 8 
↑ 
Downstream of Notch signalling pathway 
(CSC regulator),  metastasis (renal cell, lung 
cancers) 
(Dewi et al., 2011) 
DMXL2 
Dmx-like protein 2 ↑ EMT and CSC indicator  
(Alison et al., 2010, Faronato 
et al., 2015) 
PROCR 
protein C receptor ↑ EMT and CSC indicator  
(Hwang-Verslues et al., 2009) 
CHMP4B 
charged multivesicular 
body protein 4B 
↓ drug resistance (hepatocellular cancer) (Hu et al., 2015a) 
ACSL3 
acyl-CoA synthetase long-
chain family member 3 
↓ promoting cancer initiation (lung cancer) (Padanad et al., 2016) 
ALDH9A1 
aldehyde dehydrogenase 9 
family member A1 
↓ CSC indicator (renal cancer) (Henrion et al., 2015, Chang et al., 2018) 
SCD 
stearoyl-CoA desaturase ↓ CSC indicator (epithelial cancer) 
(Tirinato et al., 2017) 
FASN 
fatty acid synthase ↓ CSC indicator (epithelial cancer) 
(Tirinato et al., 2017) 
(The gene changes related to positive outcomes are labelled with a yellow background; the gene changes related to negative 
outcomes are labelled with a grey-blue background. EMT: epithelial-to-mesenchymal transition. CSC: cancer stem cell.) 
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4.3 Discussion 
In the previous chapter, some contentious results were analysed and discussed. Our major 
experiments suggested that antiretroviral drug-treated cancer cells become more normal; 
whereas, other data including a part of immunofluorescence and western blotting results 
suggested that antiretroviral drug-treated cancer cells could be linked to unfavourable 
prognostic outcomes such as cancer metastasis, drug resistance and cancer recurrence. In an 
effort to understand the conflicting results, RNA-Seq experiments were undertaken to 
investigate the changes induced in the RNA by antiretroviral drugs.  
In this chapter, RNA-Seq analysis detected quite a few possible regulatory pathways in breast 
cancer cell lines which may be influenced by antiretroviral drug treatment. We compared the 
variation in the entire genome’s RNA expression for different TNBC cell lines when treated 
with antiretroviral drugs and when untreated. According to the STRING-DB analysis, ‘fatty 
acid metabolism’, ‘FoxO signalling pathway’, ‘microRNAs in cancer’, and ‘amino sugar and 
nucleotide sugar metabolism’ were involved in antiretroviral drug-induced cancer responses. 
Also, the network analysis indicated that the cell morphology regulating genes were strongly 
altered during the drug treatment. Moreover, we hypothesised that there is a link between 
antiretroviral drug-induced mitochondrial damage and anticancer effects.  
One significant pathway being highlighted in both EFV and SPV treatments was ‘fatty acid 
metabolism’. Fatty acid metabolism has been proven to play a key function in cancer (Tirinato 
et al., 2017): it is linked to cancer metastasis, therapeutic resistance, and cancer stemness (Kuo 
and Ann, 2018). A demonstration version of the STRING-DB, STRING-DB version 11.0 
(https://string-db.org/), was released very recently. This new version takes into account the 
changes of every imported gene in order to enhance its prediction function. It also adds two 
other databases as references, the Reactome pathway database (https://reactome.org/) and the 
UniProt Knowledgebase (https://www.uniprot.org/), thereby further improving its analysis. 
According to this latest STRING-DB, ‘fatty acid metabolism’ was the only pathway being 
highlighted in EFV treatment gene set. It had arisen not only in the KEGG pathway but also in 
the Reactome and the UniProt pathways. Similarly, ‘fatty acid metabolism had been identified 
in the SPV treatment gene set. Although the results from the Reactome and the UniProt 
databases suggested that SPV might not only influence fatty acid metabolism and also affect 
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interferon, ‘fatty acid metabolism’ was the only pathway being highlighted in the KEGG 
pathway in the STRING-DB version 11.0. These results strongly implied that fatty acid 
metabolism is the key pathway involved in antiretroviral drug-induced anti-TNBC effects. Our 
analysis presented a vast majority of fatty acid metabolism-related gene inhibition as a result of 
antiretroviral drug treatment, which is in agreement with the published literature (Belkaid et al., 
2015, Menendez and Lupu, 2017a). This indicated that the anti-breast cancer effects of 
antiretroviral drugs could be associated with fatty acid metabolism dysfunction. This result not 
only highlights a further direction for TNBC studies but also points to a possible way to improve 
anti-FASN drugs.  
The experiment of examining FASN expression in drug-treated TNBCs had been considered. 
Because of the time constraints and a shortage of materials, we decided to focus on cancer stem 
cell (CSC) regulation. However, it is worth to examine the regulations of the fatty acid 
metabolism pathway in EFV-treated TNBCs in the future. 
Pathways linking to unfavourable prognostic outcomes were also identified by RNA-Seq 
analysis. Increasing expression of several cancer- and CSC-related genes was detected in 
antiretroviral drug treated-cancer cells. These results suggested that RNA-Seq data opened up 
more complex questions, and therefore a huge gap in our knowledge needs to be filled. Before 
we can conduct further investigations, we must consider some limitations of the methods used. 
The major limitation of ANOVA analysis is that the variation of every sample set might be 
ignored despite different cell lines having different responses to drugs because of their 
genetically diverse backgrounds. By using ANOVA analysis, a complete picture is observed 
but it lacks data from a single cell line. It indicates that significant genes (with the highest fold-
change) could mask information from individual cell lines. If a gene in an individual cell line 
shows no response to a particular drug but exhibits strong responses in other cell lines, this gene 
would be recognised as significant.  
There are also some limitations in the network analysis which should be considered. The major 
problem is that some important information for individual genes may be lost when considering 
‘significant change’. The other limitation of network analysis is that gene responses may not be 
consistent even in the same pathway. For instance, in a particular pathway, some genes are up 
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regulated while others are down regulated, and this resulted in them being put into different 
modules. If fewer genes were placed into the same module, the potential link within modules 
may be difficult to interpret. This may be why the morphologically related genes are the only 
ones observed in the TNBC-only network analysis. Because the changes in cell morphology 
are dominant, other regulatory pathways might be masked. This may indicate that many 
relevant genes are altered to induce cellular phenotypes.  If more data were collected, more 
tolerance could be built into the network analysis and minor differences accommodated.  
RNA-Seq analysis is a preliminary step for assessing the possible pathways involved. More 
experiments need to be performed in order to confirm the results. Thus, in order to validate 
these results an attempt to generate a LINE-1 overexpression cell line was made to examine 
whether LINE-1 inhibition was the cause of fatty acid metabolism down regulation. The 
MCF10A non-cancer cell line only expresses limited amounts of SCD, FASN and LINE-1. If 
an overexpressing LINE-1 MCF10A cell line is generated, it could test whether SCD and FASN 
are regulated by LINE-1. However, because endogenous LINE-1suppression mechanisms exist 
in the MCF10A cell line, it is very difficult to successfully generate this cell line. Additional 
methods need to be considered to overcome the challenge. 
Regardless of all these limitations, the importance of heterogeneity within TNBCs is deliberated 
in this study. According to the RNA-Seq results, antiretroviral drugs may potentially induce an 
anticancer process by inhibiting fatty acid metabolism in breast cancers. However, some other 
pathways involved can be linked to poor prognostic outcomes. A number of CSC-related genes 
have been highlighted in RNA-Seq analysis, and some of these increase after antiretroviral drug 
treatment. This raises the following questions: did antiretroviral drugs kill most of the non-
CSCs, so that CSCs became the majority in the surviving population? or did antiretroviral drugs 
actually induce the development of CSCs?    
To answer these questions, comparisons between the responses of the CSC population and the 
entire population was considered; the details of which are outlined in the next chapter.
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Chapter 5 The effects of EFV and SPV on breast cancer stem cells  
5.1 Introduction 
Cancer stem cells (CSCs) are a small group of cancer cells that contain stem cell-like 
characteristics. These include an ability for self-renewal and differentiation into different types 
of cancer cells. More importantly, they are capable of initiating tumours (Chen et al., 2013). 
Researchers are paying increasing attention to CSCs in cancers because they are thought to play 
a significant role in cancer recurrence and metastasis (Clevers, 2011). CSCs may also be 
responsible for tumours developing resistance to traditional cancer therapeutic methods, such 
as chemotherapy and radiotherapy (Wu and Alman, 2008, McDermott and Wicha, 2010, 
Bielecka et al., 2017). Thus, specifically targeting CSCs could be a potential strategy for 
treating and preventing cancers.  
The results presented in the previous chapters clearly emphasised the importance of CSCs in 
antiretroviral drug-induced cancer responses. The evidence from drug response experiments 
suggested a critical role for cancer heterogeneity and implied that a small population of cancer 
cells may respond differently to the drugs. Furthermore, the RNA-Seq experiments showed that 
CSC-related genes could be altered upon treatment with antiretroviral drugs. 
In Chapter 3, differentiation phenotypes, which usually identify normal cells, were observed in 
antiretroviral drug-treated MCF10AT, MCF10CA1α, MDA-MB-231, and T47D cells. In 
addition, antiretroviral drug-treated MCF10AT and MCF10CA1α cells showed mesenchymal-
cell phenotypes which are usually correlated with malignant cancers. This finding was 
supported by immunofluorescence and western blot data showing that EFV-treated TNBCs 
exhibited some mesenchymal cell characteristics, such as increasing fibronectin and SLUG 
proteins, decreasing CD24 protein, and the relocation of E-cadherin protein. These data were 
in contrast to the original prediction that antiretroviral drugs might be able to reverse cancer 
cells to normal cell-like status (Sbardella et al., 2011). Although some of the TNBC cells did 
return to being non- cancerous, others expressed obvious cancer phenotypes. These results, 
therefore, emphasised the complexities arising from cancer heterogeneity in TNBC cells and 
suggested that some cells might become more cancerous after antiretroviral drug treatment. 
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In Chapter 4, RNA-Seq data further confirmed that TNBCs express epithelial non-CSC 
markers, mesenchymal markers and CSC markers simultaneously after the drug treatment. The 
expression of epithelial markers successfully represents antagonising cancer growth. 
Mesenchymal and CSC markers are associated with poor prognostic outcomes and can be 
linked to cancer recurrence and cancer metastasis. These data agreed with the 
immunofluorescence and western blot data which indicated the possibility of increased levels 
of breast CSCs (BCSCs) in the whole cancer population after the treatment. This then gave rise 
to the question of whether antiretroviral drugs eliminated most of the non-CSCs leaving only 
highly drug-resistant CSCs to survive, or whether the drugs may induce CSCs by some 
unknown mechanisms. To address these questions, it is important to compare the drug 
responses of the whole cancer cell population, the CSC-only population, and the non-CSC 
population. 
In this chapter, the effects of antiretroviral drug treatment on the CSC population were 
investigated for several TNBC cell lines, including MCF10AT, MCF10CA1α, MDA-MB-231, 
BT-549, and BT-20. Because CSC classification methods can vary, initially the CSC population 
was sorted from the whole cancer population using the two most well-known CSC identification 
methods, Aldehyde Dehydrogenase (ALDH) activity and CD44/CD24 characteristics. The 
percentage of CSCs in the whole population was determined for both antiretroviral drug-treated 
cells and untreated cells. The method of CSC isolation is addressed and the disadvantages of 
CSC isolation and the difficulties for CSC maintenance is explained. Finally, CSC tumorsphere 
functional assays are discussed and the responses of CSCs to the drugs investigated. The chapter 
concludes with a discussion of the effects of antiretroviral drugs in BCSCs. 
  
                                                                                           The effects of EFV and SPV on breast cancer stem cells 
123 
 
5.2 Results  
5.2.1 Antiretroviral drug responses of CSCs in triple-negative breast cancer 
cell lines 
Over the past few decades, several CSC identification methods have been discovered; however, 
the lack of universal CSC markers has hindered CSC research. The main reason for this is that 
CSC markers vary depending on the type of cancer and also on the subtype of certain cancers 
(Wu and Alman, 2008). Moreover, CSCs identified by different methods may exhibit various 
phenotypes, enrich alternative genes, and have minimal overlap with each other (Liu et al., 
2014a). It is therefore critical to evaluate and compare diverse clusters of CSCs when 
undertaking CSC research.  
The most commonly used markers for determining BCSC are CD44 and CD24 cell surface 
antigens. The breast cancer cells with high CD44 and low CD24 expression have stem cell-like 
characteristics and are recognised as CSCs (Sheridan et al., 2006). Other types of BCSCs with 
different features are known as ‘mesenchymal-like CSCs’ (Liu et al., 2014a). Additionally, 
breast cancer cells with high aldehyde dehydrogenase (ALDH) activities have been named 
‘epithelial-like CSCs’ (Liu et al., 2014a). Furthermore, cells divergent from the main population 
in fluorescence-activated cell sorting (FACS) analysis have been defined as ‘side population’. 
This subset of cells exhibits a higher chemical efflux capacity, compared to the main population 
of cancers, which may contribute to their drug resistance (Wu and Alman, 2008). Recently, the 
CSC tumorsphere functional assay has become a popular tool in the field of CSC research. 
There is evidence to suggest that such three-dimensional culture conditions are relatively 
similar to in vivo microenvironments and that they might simulate CSC growth under pseudo-
physiological conditions.  
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5.2.1.1 Epithelial-like CSCs 
Changes in the epithelial-like CSC population, after antiretroviral drug treatment, were 
examined in this study. Significant suppression of ALDH9A1 RNA, a member of ALDH, in 
antiretroviral drug-treated TNBCs was observed in RNA-Seq analysis. The ALDEFLUOR kit 
(Stemcell Technology) was utilised to detect cells with higher aldehyde dehydrogenase 
activities, which is the epithelial-like CSCs (Figure 5-1). The proportion of epithelial-like CSCs 
was reduced after EFV treatment in all tested breast cancer cell lines, yet very little decrease 
was observed in the non-cancerous MCF10A cell line (Figure 5-2). The percentage of 
epithelial-like CSCs decreased from 7.56±0.71% to 4.53±0.79% in MCF10AT cells; from 
66.30±8.97% to 20.76±7.51% in MCF10CA1α cells; from 11.06±1.96% to 3.87±1.05% in 
MDA-MB-231 cells; and from 16.76±1.17% to 2.32±0.86% in T47D cells (Table 5-1). The 
epithelial-like CSCs were reduced by more than 1.5-fold, after EFV treatment, in all tested 
cancer cell lines. Notably, the epithelial-like CSCs in EFV-treated MCF10CA1α and MDA-
MB-231 cells were decreased 3-fold compared to their untreated controls. As predicted, T47D, 
a non-TNBC control, showed a 7-fold decrease in its epithelial-like CSC population after EFV 
treatment. This implied that the epithelial-like CSCs in luminal breast cancer, particularly T47D 
cell, might be more sensitive to the epithelial-like CSCs in TNBCs. All these cancer cell lines 
display significant differences when exposed to untreated- and EFV-treated conditions. The p 
values of the Student’s t-test (paired, two-tails) were 0.033, 0.018, 0.038, and 0.006 for 
MCF10AT, MCF10CA1α, MDA-MB-231, and T47D, respectively (Table 5-1). In the non-
cancerous control, MCF10A, the percentage of the ALDHhigh CSCs was decreased from 
4.08±1.17% to 3.13±1.50%. This difference was not statistically significant (p-value = 0.233) 
for EFV-treated and untreated cells (Figure 5-2 and Table 5-1). These data demonstrate that the 
proportion of the epithelial-like CSCs can be reduced by EFV treatment.  
Consistent with the results of EFV treatment, the SPV-treated breast cancer cells included a 
relatively small ALDHhigh CSC population compared with the untreated controls (in appendix 
Figure S5-1). After SPV treatment, the percentage of the ALDHhigh CSCs was reduced:  by 
3.6% in MCF10AT; by 17.9% in MCF10CA1α; by 2.0% in MDA-MB-231; and by 10.6% in 
T47D cancer cell lines. In contrast, there was only 0.1% difference between SPV-treated and 
untreated-MCF10A cells. However, because of the shortage of the SPV compound, no replicate 
was performed and therefore no statistical analysis was available.  
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Figure 5–1 The ALDHhigh CSCs detected using flow cytometry in EFV-treated and untreated- 
MCF10A, MCF10AT, MCF10CA1α, MDA-MB-231, and T47D cells  
The dots inside the frame lines represent the cells with high ALDH activities. The frame lines were set 
based on their ALDH suppression controls. 
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Figure 5–2 The percentages of the epithelial-like CSCs presented in EFV-treated and untreated 
cancer cells 
This figure is a quantitative bar chart for the ALDEFLUOR™ results in TNBC cell lines. The black bars 
represent untreated control cells; the grey bars represent EFV-treated cells. Significant differences 
were detected in all EFV-treated cancer cell lines. Two-tailed, paired Student’s t-test was conducted 
for statistical analysis. *p<0.05; **p<0.01. Error bars: ±SD, n = 3. 
 
Table 5-1 The percentages of ALDHhigh cells presented in EFV-treated and untreated population 
  % of ALDHhigh AVERAGE SD p-value 
MCF10A Control 4.56 4.93 2.74 4.08 1.17 0.23261 
EFV 2.55 4.83 2.00 3.13 1.50   
MCF10AT Control 7.61 6.82 8.24 7.56 0.71 0.03259* 
EFV 3.64 4.79 5.15 4.53 0.79   
MCF10CA1α Control 62.89 76.47 59.53 66.30 8.97 0.01823* 
EFV 28.43 20.44 13.42 20.76 7.51   
MDA-MB-
231 
Control 13.27 10.4 9.51 11.06 1.96 0.03773* 
EFV 3.26 5.09 3.27 3.87 1.05   
T47D Control 16.12 16.05 18.11 16.76 1.17 0.00619** 
EFV 3.14 2.40 1.42 2.32 0.86   
(Two-tail, paired Student’s t-test, *p<0.05; **p<0.01) 
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These results showed that EFV and SPV could be effective drugs for reducing the epithelial-
like CSCs in both TNBC and non-TNBC cell lines. However, increasing expression of CSC-
related genes such as CD44, HK2, DMXL2, and PROCR could not be explained by the 
epithelial-like CSC results. If the epithelial-like CSC represents all CSCs within the whole 
cancer population, the CSC-related genes should largely be down-regulated, unless they are 
being activated by alterative molecular pathways unrelated to CSC regulation. Therefore, other 
types of CSCs were investigated to better understand the whole picture of CSC responses to the 
drugs.  
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5.2.1.2 Mesenchymal-like CSCs 
The mesenchymal-like CSCs were investigated in order to observe the changes resulting from 
the drug treatment. The results of CD44/CD24 staining suggested an increase in the 
mesenchymal-like CSC population upon treatment with antiretroviral drugs. In this study, the 
percentage of the CD44+/CD24- cells was increased after EFV treatment in all tested TNBC 
cell lines (Figure 5-3, 5-4). This trend was opposite to the result of the epithelial-like CSCs. In 
MCF10AT cells, the CD44+/CD24- population increased from 3.69±1.14% to 9.81±1.64%; in 
MCF10CA1α, the CD44+/CD24- population increased from 29.49±0.57% to 45.83±4.69%; and 
in MDA-MB-231, the CD44+/CD24- population increased from 87.64±0.78% to 92.35±1.79% 
(Table 5-2). A 1.1-fold to 2.7-fold increase in the mesenchymal-like CSC population in TNBC 
cell lines was observed. Very few mesenchymal-like CSCs were detected in MCF10A (non-
cancerous control) and T47D (non-TNBC control). Statistical analysis of these results showed 
significant differences in the population of mesenchymal-like CSCs under EFV-treated and 
untreated-conditions for MCF10AT, MCF10CA1α, and MDA-MB-231 cells. The p-values of 
the Student’s t-test (two-tailed, paired) were 0.004, 0.002, and 0.004 for MCF10AT, 
MCF10CA1α, and MDA-MB-231, respectively (Table 5-2). A similar trend was observed 
when TNBC cells were treated with SPV (in appendix Figure S5-2); however statistical analysis 
could not be performed owing to the shortage of SPV. These data indicated the CD44+/CD24- 
mesenchymal-CSC populations were altered by EFV or SPV drug treatments, and that different 
cell lines respond differently to the drugs.  
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Figure 5–3 The CD44+/CD24- cells detected in untreated- and EFV-treated MCF10A, MCF10AT, 
MCF10CA1α, MDA-MB-231, and T47D cells 
The dots in the up-left corner represent the CD44+/CD24- mesenchymal-like CSCs. The frame lines were 
set based on their unstained controls. 
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Figure 5–4 The percentages of CD44+/CD24- cells presented in untreated and EFV-treated cells 
This figure is a quantitative bar chart for the CD44/CD24 staining results in TNBC cell lines. The black 
bars represent untreated control cells; the grey bars represent EFV-treated cells. The significant 
differences were detected in all EFV-treated TNBC cell lines. Two-tailed, paired Student’s t-test is 
conducted for statistical analysis. *p<0.05; **p<0.01. Error bars: ±SD, n = 3. 
 
Table 5-2 The percentages of CD44+/CD24- cells presented in EFV-treated and untreated cells 
 % of CD44+/CD24- AVERAGE SD p-value 
MCF10A control 0.01 0.08 0.06 0.05 0.03 0.21371 
EFV 0.02 0.44 0.75 0.40 0.30   
MCF10AT control 2.11 4.21 4.75 3.69 1.14 0.00360** 
EFV 7.50 10.78 11.15 9.81 1.64   
MCF10CA1α control 31.58 24.47 32.43 29.49 3.57 0.00190** 
EFV 47.21 39.52 50.76 45.83 4.69   
MDA-MB-
231 
control 88.68 87.46 86.79 87.64 0.78 0.02281* 
EFV 94.59 92.26 90.20 92.35 1.79  
T47D control 0.00 0.99 0.31 0.43 0.41 0.30985 
EFV 0.00 0.28 0.15 0.14 0.11   
(Two-tailed, paired Student’s t-test, *p<0.05; **p<0.01) 
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5.2.1.3 Side population 
As previously mentioned, CSCs are made up of a diverse set of population cells, one of which 
is the ‘side population’ (SP). The SP describes a minor population of cells which has stem cell-
like characteristics including self-renewal and an ability to survive after chemotherapy (Wu and 
Alman, 2008). These types of cells express large amounts of multidrug-resistance-type ATP-
binding cassette protein (ABC) transporters. They are, therefore, able to efflux more Hoechst 
33342 nucleotide staining dye than other cells (Wu and Alman, 2008, Bielecka et al., 2017). It 
is possible that SP cells are more resistant to chemotherapy than the epithelial-like and the 
mesenchymal-like CSCs because of their drug efflux capabilities (Nakanishi et al., 2010).  
There are several reasons why it was very difficult to identify SP cells in our tested cell lines: 
The SP is an extremely small population in TNBC and T47D cell lines (less than 1% in total 
population) compared with most of the non-TNBC cell lines (Nakanishi et al., 2010). In 
addition, the insufficient staining and gating techniques, as well as dynamic dye efflux process, 
may greatly affect the results (Wu and Alman, 2008, Golebiewska et al., 2011). Furthermore, 
the cytotoxicity of the Hoechst 33342 SP staining dye, i.e., its mutagenicity and the damage to 
DNA that it causes, may also be responsible for the difficulties experienced in studying these 
cells (Wu and Alman, 2008). Moreover, EFV- or SPV- treated cells were unhealthy, compared 
to the untreated cancer cells. As a consequence and not surprisingly, very few SP cells were 
observed in all cell lines tested using the typical SP identification method (in appendix Figure 
S5-3).  These difficulties make the stem-like ‘side population’ unfeasible to study in triple-
negative CSCs.  
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5.2.2 Exploring mesenchymal-like CSC results 
Given that the epithelial-like CSC and the mesenchymal-like CSC data gave rise to conflicting 
results, a critical examination of the methodology of CSC determination was required. One 
consideration was that the cell surface proteins including CD44 and CD24 were compromised 
by cell apoptosis and necrosis. Moreover, it is possible that drug treatment influenced the 
CD44/CD24 staining and the accuracy of the results. It is also possible that antiretroviral drugs 
may increase the CSC population through mechanisms unrelated to LINE-1 inhibition. The 
following experiments were conducted to address these questions. 
5.2.2.1 Alteration of functional CSCs after drug treatment 
The tumorsphere formation assay was employed to determine whether the increasing 
percentage of mesenchymal-like CSCs in drug-treated cancer cells was directly linked to the 
destruction of the cell surface membrane. Only the cells with self-renewal ability can survive 
and proliferate in low-nutrition MammoCult Medium. These cells were postulated to be 
functional CSCs and were strongly correlated with the mesenchymal-like CSCs in certain breast 
cancer cell lines (Wang et al., 2017b). The experiment involved treating cells with DMSO 
(untreated-control), EFV, and SPV for four days, after which the healthy cells were harvested 
(in appendix Figure S5-4).  This was followed by seeding the same number of cells (1x104) in 
MammoCult medium and culturing the cells for seven days to form tumorspheres. The 
tumorspheres were then photographed, counted and their size measured for each individual 
treatment.  
The results (Figure 5-5 and Table 5-3) suggested that EFV- and SPV-treated MCF10AT and 
MCF10CA1α cells formed more tumorspheres and their size was larger than their controls. The 
SPV-treated MCF10CA1α cells, in particular, produced more than twice the number of 
tumorspheres than untreated cells. Although the tumorsphere-forming cells might not strictly 
correlate with mesenchymal-like CSCs, this data can still partially confirm that the treatment 
can increase the CSC numbers in the entire cancer population. Therefore, the integrity of the 
cell membrane might be less relevant to the observation that the mesenchymal-like CSC 
increase after the drug treatment. 
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MCF10AT
MCF10CA1α
Control EFV SPV
Figure 5–5 Tumorsphere formation after antiretroviral drug treatment 
MCF10AT and MCF10CA1α cells were originally cultured in traditional two dimensional-culture and 
treated with antiretroviral drug. After the treating period, the remaining cells were harvested and 
seeded into MammoCult™ three-dimensional culture. Under this culture condition, the remaining cells 
grew after a few days. At the seven-day time point, the entire culture plate was photographed by 
Olympus IX81 inverted brightfield/fluorescence microscope. Scale bar: 200 µm 
 
 
Table 5-3 The numbers of tumorspheres formed from different pre-treatment conditions 
Number of spheres 
/104 cells seeded 
60-100 µm 100-200 µm 200-400 µm >400 µm total 
 
MCF10AT 
Control 49 37 6 0 92 
EFV 49 42 8 0 99 
SPV 75 38 12 1 126 
 
MCF10CA1α 
Control 92 133 32 0 257 
EFV 177 189 57 0 423 
SPV 229 213 81 2 525 
 
  
Chapter 5 
134 
 
5.2.2.2 Mesenchymal-like CSCs and LINE-1 siRNA inhibition  
LINE-1 short hairpin RNA (shRNA) inhibition was employed to exclude any potential side 
effects caused by the anti-retroviral drugs. A pUTR plasmid, encoding an shRNA sequence 
targeting the LINE-1 promoter, was transfected into MCF10AT and MCF10CA1α cells (as 
described in Chapter 2) in order to inhibit LINE-1 expression in the cells. The non-functional 
empty vector, pSM2 plasmid, was transfected as a control for the pUTR plasmid. By comparing 
the drug inhibition with the direct shRNA inhibition of LINE-1, it was hoped to better 
understand the activity of the antiretroviral drugs in CSC enrichment. 
Even though the siRNA inhibition results were not straightforward to interpret due to the 
extremely fast cell proliferation rate of the cancer cells, there was an increase in the 
mesenchymal-like CSC population upon transfection with the pUTR plasmid (Figure 5-6). The 
percentage of the mesenchymal-like CSCs was 0.5% in MCF10AT-pSM2 cells and 9.3% in 
MCF10AT-pUTR cells; whereas, it was 14.5% in MCF10CA1α-pSM2 and 27.8% in 
MCF10CA1α-pUTR cells. Both MCF10AT and MCF10CA1α with partial LINE-1 silencing 
by pUTR presented with much smaller numbers of mesenchymal-like CSCs compared to their 
controls. Therefore, LINE-1 inhibition through shRNA seemed to increase the mesenchymal-
like CSC population in MCF10AT and MCF10CA1α cell lines which were consistent with the 
results arising from drug treatment. Hence, the increase in the mesenchymal-like CSCs in TNBC 
cell lines, induced by EFV- or SPV-treatment, was attributed to LINE-1 inhibition. 
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Figure 5–6 The mesenchymal-like CSCs in MCF10AT-pSM2, MCF10AT-pUTR, MCF10CA1α-pSM2, 
MCF10CA1α-pUTR cells 
The dots in the up-left corner of each FACS figure represent the CD44+/CD24- mesenchymal-like CSCs. 
The frame lines were set based on their unstained controls. 
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5.2.3 Cancer Stem Cell isolation  
To further understand the basis for the contradictory results between the epithelial-like and the 
mesenchymal-like CSC populations after the drug treatment (see section 5.2.1.1 and section 
5.2.1.2), a pure CSC population was sorted. Thus, CSC isolation may be an appropriate strategy 
to provide some clarity on the CSC population.  
5.2.3.1 Isolating CD44+/CD24- mesenchymal-like CSCs 
The CD44+/CD24- and the CD44-/CD24- cancer cells were isolated and collected by a cell 
sorter. The intracellular staining methods, such as ALDEFLUOR assay, may be more harmful 
to the cells than the cell surface marker staining methods, CD44 and CD24 staining. 
Furthermore, these unhealthy sorted cells can be difficult to re-culture. The observation of an 
increasing population of the CD44+/CD24- mesenchymal-like CSCs after antiretroviral drug 
treatment was supported by the immunofluorescence and the RNA-Seq results. Therefore, the 
CD44+/CD24- mesenchymal-like CSCs were isolated by a cell sorter, and their responses to 
drugs examined. The CD44-/CD24- population was used as a non-CSC control since, in theory, 
they should be easier to culture.  
Although the sorted cells could survive and proliferate slowly, the additional stress of drug 
treatment compromised their viability (in appendix Figure S5-5). Thus, to solve this problem, 
different staining and sorting conditions were tested, until finally cell viability and operability 
were increased (expanding the cell numbers to 108, reducing the staining to twenty minutes, 
and increasing the sorting speed). After sorting, the purity of the CD44+/CD24- CSC population 
was approximately 98%, while the purity of the CD44-/CD24- population was usually around 
40%. This was because the fluorescence signals from the fluorescence positive cells could be 
masked by other cells resulting in them being incorrectly classified as fluorescence negative 
cells (Figure 5-7A and 5-7B). 
The other problem arising from the separation of CSC types was that some cancer cells 
frequently switch between CSC and non-CSC status (CSC plasticity). This CSC maintenance 
challenge has been reported in several papers (Meacham and Morrison, 2013, Liu et al., 2015) 
and has strongly influenced CSC drug response experiments. After sorting, the CD44+/CD24- 
CSCs differentiated into non-cancer stem cells very rapidly (Figure 5-7D); also, the non-CSC 
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control (CD44-/CD24- cells) was able to convert to the patterns of the total cancer population 
within only a few days (Figure 5-7E). After culturing sorted cells for five days, the CSC-
enriched group (all of the CD44+/CD24- cells during sorting) had only about 50% CD44+/CD24- 
CSCs remaining (Figure 5-7D). The proportion of the CD44+/CD24- population in the CSC-
enriched group was relatively higher than in the CD44-/CD24- non-CSC control group (27%) 
and in non-sorted total cells (29.3%) (Figure 5-7C and 5-7E). Yet the accuracy of the CSC 
experiments may be highly affected by the presence of the non-CSC cells (approximately 50%) 
in the sorted CSC-enriched group. Thus, it was necessary to improve the CSC maintenance 
method before performing further experiments.  
The cancer cell line employed in this experiment was MCF10CA1α. A greater proportion of 
the sorted-CSCs in MCF10AT rapidly differentiated into non-CSCs, one to two days after 
culturing; whereas the CD44+/CD24- cells dominated in the MDA-MB-231 cell line of which 
more than 85% of cells were the mesenchymal-like CSCs. Thus, cell sorting was unnecessary 
in this cell line preventing further damage to the cells during the staining and sorting process.    
           
Figure 5–7 The percentage of the CD44+/CD24- cells in the unsorted total population and sorted-
CSC-enriched population versus the percentage of the CD44-/CD24- cells 
The dots in the up-left corner of each FACS figure represent the CD44+/CD24- mesenchymal-like CSCs. 
The dots in the down-left corner of each FACS figure represent the CD44-/CD24- cells which are used 
as non-CSC control. The frame lines were set based on their unstained controls. 
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5.2.3.2  Mesenchymal-like CSCs culturing in serum-free medium 
Many published studies have suggested that maintaining cancer cells in CSC status is extremely 
challenging due to a strong tendency of CSCs from epithelial cancers to differentiate into non-
CSCs in cultured conditions (Meacham and Morrison, 2013, Liu et al., 2015). However, there 
are several methods that can potentially support CSC maintenance. They combine cell sorting, 
chemo- or radiotherapy, mesenchymal induction, and serum-free culturing (Liu et al., 2015). 
The advantages and disadvantages of these methods are described below.  
Firstly, cell sorting can result in a relatively pure CSC population but is unable to provide long-
term CSC maintenance. Secondly, some epithelial-mesenchymal transition (EMT) inducers, 
such as Twist and Snail, may help cells to remain in CSC status; however, adding extra inducers 
might strongly affect CSC experiments by directly or indirectly altering some CSC markers, 
thereby potentially compromising the data. Similarly, chemotherapy and radiotherapy may also 
result in the same problems as the EMT inducers. Lastly, serum-free cultivation alone is unable 
to greatly enrich CSCs. However, the most feasible method for obtaining stable CSCs could be 
to combine cell sorting with serum-free cultivation.  
Sorted CD44+/CD24- CSCs were cultured in serum-free medium in order to investigate the 
possibility of CSC enrichment. Surprisingly, after five days of culturing, there was no 
observable CSC population difference between serum-free and serum-containing medium 
(Figure 5-8B and 5-8C). Culturing sorted-CSCs in the serum-containing medium for eight hours 
and then changing the medium to serum-free medium for the remainder of the culturing period 
resulted in the highest percentage (nearly 60%) of CD44+/CD24- CSCs (Figure 5-8C). Culturing 
sorted-CSCs in the serum-containing medium for 48 hours and then changing the medium to 
serum-free medium maintained a higher percentage (about 53%) of the CD44+/CD24- CSCs 
(Figure 5-8) compared with culturing sorted-CSCs in serum-free medium for the whole 
culturing period (about 46%). Although none of these culture conditions could maintain stable 
CSCs for five days, cultivation for 8 hours in serum-containing medium followed by four days 
in the serum-free medium resulted in the best CD44+/CD24- CSC enrichment. Therefore, these 
culture conditions were used for observing the effects of drugs on CD44+/CD24- CSCs.   
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Figure 5–8 Sorted-CD44+/CD24- CSCs cultured under different serum-free conditions  
The dots in the up-left corner of each FACS figure represent the CD44+/CD24- mesenchymal-like CSCs. 
The frame lines were set based on their unstained controls. (A) Sorted CSCs cultured in the complete 
medium with 5% horse serum supply for 96 hours. (B) Sorted CSCs cultured in the complete medium 
without serum supply for 96 hours. (C) Sorted CSCs cultured in the complete medium without serum 
supply for 8 hours and then exchanged the medium to the complete medium with 5% horse serum 
supply for 88 hours. (D) Sorted CSCs cultured in the complete medium without serum supply for 48 
hours and then exchanged the medium to the complete medium with 5% horse serum supply for 48 
hours. 
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5.2.3.3 Drug treatment of CD44+/CD24--sorted CSCs  
When sorted-MCF10CA1α-CD44+/CD24- cancer cells were cultured in modified serum-free 
medium, less than half of the CD44+/CD24- CSCs differentiated into non-CSCs. About 62.4% 
of the CD44+/CD24- CSCs were observed in the untreated control; while, 45.5% of the 
CD44+/CD24- CSCs were observed in EFV-treated cells (Figure 5-9). Contrary to the results in 
the total population, the CSC-enriched population showed a reduction in the CD44+/CD24- CSC 
population after EFV treatment. This suggests that EFV could be effective for eliminating the 
CD44+/CD24- mesenchymal-like CSCs. 
Additionally, the qRT-PCR data (Figure 5-10) suggested that the expression of LINE-1 RNA 
in MCF10CA1α was reduced both in the CSC-enriched population and in the total population 
after EFV treatment. However, the low purity of the CD44+/CD24- CSCs might affect the 
results. In theory, with a population of pure CSCs, we should be able to determine whether the 
drug treatment induces them to transform into non-CSCs. Yet, with a mixture of CSCs and non-
CSCs, it was difficult to determine the effect of the drugs on CSCs. The percentage of CSCs in 
the population not only resulted from CSC transformation but also from non-CSCs 
transforming into CSCs. Therefore, in reality, the drug effect of CSCs transforming to non-
CSCs could be more frequent than the observation showed in the FACS experiments. This 
suggested that the accuracy of the experiments could be enhanced if the purity of the studied 
CSCs could be increased. Since maintaining stable CD44+/CD24- CSCs was an issue, the 
tumorsphere CSC functional assay was investigated as a compromise solution. 
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Figure 5–9 Sorted-CD44+/CD24- CSC after drug treatment  
The dots in the up-left corner of each FACS figure represent the CD44+/CD24- mesenchymal-like CSCs. 
The frame lines were set based on their unstained controls. These sorted mesenchymal-like CSCs were 
cultured in the serum-free complete medium for 8 hours and then changed the medium to the 
complete medium with 5% horse serum containing DMSO (control) or EFV for 88 hours. The 
percentage of the CD44+/CD24- population was lower in EFV treated cells (right-hand side) than in the 
control cells (left-hand side).    
 
 
 
Figure 5–10 qRT-PCR data comparing LINE-1 RNA levels within EFV-treated and untreated 
MCF10CA1α cells and the CSCs isolated from MCF10CA1α cell lines  
The pink bars represent the expression of LINE-1 ORF1 RNA; the green bars represent the expression 
of the endonuclease region of LINE-1 ORF2 RNA; the blue bars represent the expression of the reverse 
transcriptase region of ORF2 RNA. Error bars: ±SD, n = 4. 
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5.2.4 Functional assay: three-dimensional MammoCult culture for 
tumorsphere formation.  
After failing to maintain CSCs under culturing conditions, growing cells in the MammoCult™ 
Medium (Stemcell technology) was used as an alternative strategy for undertaking CSC 
experiments. Cultivation of cells in MammoCult™ Medium is a three-dimensional culture 
method specifically used for breast cancers and only cells with CSC ability can survive and 
proliferate under these conditions. It has been used for culturing many breast cancer cell lines, 
including MDA-MB-231, MCF7, SKBR3, AU565, BT474, and SUM149 which then progress 
to form tumorspheres. These tumorspheres can subsequently form tumours if injected into 
immunodeficient mice (Kim and Alexander, 2014), indicating that the cells which can grow in 
MammoCult™ Medium are functional CSCs. However, there are no reports showing that the 
MammoCult™ Medium has been used for the MCF10 cell series.  
A preliminary study was performed to observe whether MCF10A, MCF10AT, and 
MCF10CA1α cells could be cultured in MammoCult Medium. After transferring MCF10A, 
MCF10AT, and MCF10CA1α cells from two-dimensional to three-dimensional cultures with 
MammoCult Medium, cells started to form spheres which grew over subsequent days. On the 
third day, cells started to form complete tumorspheres; and on the fourth day, MCF10AT and 
MCF10CA1α tumorspheres formed dark centres which were difficult to split (Figure 5-11). 
MCF10A formed small and loose tumorspheres within two days; whereas, MCF10AT and 
MCF10CA1α formed small and tight tumorspheres within three days. Therefore, the third day 
of the MammoCult culture (the solid tumorsphere formed) was chosen as the starting point for 
the drug treatment.   
                                                                                           The effects of EFV and SPV on breast cancer stem cells 
143 
 
day 2 day 3 day 4
10A
AT
CA1α
 
Figure 5–11 Pre-test for culturing cells using the MammoCult three-dimensional culture 
conditions  
Images were taken every day from day 2 to day 4 after seeding in order to determine a suitable 
MammoCult culture condition for MCF10A, MCF10AT, and MCF10CA1α cell lines. Scale bar: 200 µm. 
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5.2.5 The influence of Efavirenz on tumorsphere formation  
Interestingly, the relative numbers of tumorspheres formed for each cell line mostly correlated 
with the relative malignancy of the cancer cell line. The most malignant cell line, MDA-MB-
231, formed the largest number of tumorspheres compared with other cell lines; while the low-
invasive MCF10AT produced the lowest number of tumorspheres. BT-549 was an exception: 
this highly invasive cell line produced relatively few tumorspheres compared with the low-
invasive BT-20 cell line; however, this cell line did form larger tumorspheres (larger than 400 
µm) than all the other cell lines.  
Treating MCF10A, MCF10AT, MCF 10 CA1α, BT-549, BT-20, and T47D cells with EFV or 
SPV for seven days, resulting in a reduction in the size of the tumorspheres. In addition, the 
structures of the tumorspheres were altered from tight to loosen (Figure 5-12). It was also noted 
that the number of tumorspheres decreased after EFV treatment (Table 5-4, Figure 5-13).  
 
                                                                                           The effects of EFV and SPV on breast cancer stem cells 
145 
 
Control EFV SPV
MCF10A
MCF10AT
MDA-MB-231
BT-549
BT-20
T47D
MCF10CA1α
 
Figure 5–12 MammoCult culture with drug treatments for seven days 
Harvested MCF10A, MCF10AT, MCF10CA1α, MDA-MB-231, BT-549, BT-20, and T47D cells from 2D 
cultures, then seeded an appropriate number of live cells in the complete MammoCult Medium. After 
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three days of sphere formation, the cells were incubated with EFV and SPV for seven days. Scale bar: 
200 µm. 
After EFV treatment, the total number of tumorspheres decreased from 92.3±16.2 to 11.0±6.2 
in MCF10AT; from 198.0±56.8 to 18.3±18.0 in MCF10CA1α; from 422.0±17.8 to 8.3±8.5 in 
MDA-MB-231; from 122.0±24.7 to 47.3±38.0 in BT-549; from 211.0±24.0 to 49.0±30.4 in 
BT-20; and from 158.0±36.9 to 10.8±4.5 in T47D (Table 5-4). There were significant 
differences in the total number of tumorspheres for untreated- and EFV-treated cells in all 
cancer cell lines tested (in appendix Table S5-1). Notably, after EFV treatment, the tumorsphere 
number was 50 times less than the control in MDA-MB-231; 14.5 times less in T47D; 10 times 
less in MCF10CA1α; and 8 times less in MCF10AT. Although the tumorsphere number was 
only reduced 1.5 times in BT-549 after EFV treatment, it showed the greatest change with 32 
tumorspheres larger than 400 µm being reduced to no tumorsphere larger than 400 µm (Table 
5-4). 
The data suggested that tumorspheres can be eliminated by EFV and SPV treatment, thus 
indicating that EFV and SPV might be able to treat both non-CSCs and CSCs. 
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Figure 5–13 Numbers of spheres being formed after EFV treatment in MCF10A, MCF10AT, 
MCF10CA1α, MDA-MB-231, BT-549, BT-20, and T47D cell lines  
This figure is a quantitative bar chart for the tumorsphere formation results. The dark-purple bars 
represent the spheres larger than 400 µm; the light-purple bars represent the spheres larger than 200 
µm but smaller than 400 µm; the dark-orang bars represent the size of the sphere in between 100 µm 
to 200 µm; the light-orange bars represent the size of the sphere in between 60 µm to 100 µm. Any 
clump smaller than 60 µm is not considered as tumorsphere. Two-tailed, paired Student’s t-test was 
conducted for statistical analysis, the total cell numbers are compared between untreated- and EFV-
treated conditions. *p<0.05; **p<0.01. Error bars: ±SD, n = 3. C: untreated-control cells, E: EFV-treated 
cells. 
Table 5-4 The numbers of tumorspheres formed after seven days of EFV treatment. 
Number of spheres 
/104 cell seeded 60-100 µm 100-200 µm 200-400 µm >400 µm total 
MCF10A control 9.5±4.5 12.3±4.7 5.0±2.7 1.0±0.0 27.8±11.7 
EFV 11.5±9.2 4.5±2.2 1.8±1.9 0.3±0.6 18.2±10.3 
MCF10AT control 34.0±14.1 39.7±11.0 12.3±2.3 6.3±3.1 92.3±16.2 
EFV 5.3±1.2 4.3±4.0 1.3±2.3 0.0±0.0 11.0±6.2 
MCF10CA1α control 73±25.5 86.3±31.3 32.3±5.0 6.7±3.2 198±56.8 
EFV 5.0±1.0 11.7±15.0 1.7±2.9 0.0±0.0 18.3±18.0 
MDA-MB-
231 
control 103.0±20.0 277.0±85.2 121.0±34.9 24.0±34.1 422.0±17.8 
EFV 17.3±17.2 7.7±8.6 0.7±1.2 0.0±0.0 8.3±8.5 
BT-549 control 28.0±16.5 36.0±15.1 25.7±4.7 32.0±2.0 122.0±24.7 
EFV 19.7±21.8 22.0±15.1 5.7±3.2 0.0±0.0 47.3±38.0 
BT-20 control 104.0±26.7 146.0±36.1 54.7±4.0 10.7±12.4 211.0±24.0 
EFV 32.0±13.1 45.0±24.1 4.0±6.9 0.0±0.0 49.0±30.4 
T47D control 48.8±7.2 90.0±29.0 45.7±7.4 22.3±10.8 158.0±36.9 
EFV 13.3±14.6 10.7±4.7 0.2±0.3 0.0±0.0 10.8±4.5 
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5.3 Discussion  
CSCs are believed to be one of the major causes of epithelial cancer metastasis, patient relapse, 
and therapy resistance. Therefore, specifically targeting CSCs may potentially enhance 
prognostic outcomes for patients. However, the lack of universal CSC markers increases the 
difficulties of CSC research. In this study, a few commonly used methods for identifying BCSC 
were utilised to further understand the effects of the antiretroviral drugs on BCSCs. 
BCSCs which potentially produce drug resistance in breast cancers can be eliminated by 
antiretroviral drugs. According to the evidence gained from this study, the percentage of 
epithelial-like CSCs decreased after the drug treatment, suggesting that antiretroviral drugs can 
effectively reduce BCSCs. Although mesenchymal-like CSCs experiments revealed opposite 
results, mesenchymal CSC-enrichment experiments can partially explain this discrepancy. The 
results obtained from the tumorsphere functional CSC assay further supported our finding of 
the effectiveness of antiretroviral drugs at eliminating CSCs. Therefore, the drugs may 
potentially be a powerful tool for treating TNBCs including CSCs and non-CSCs. However, 
there are some limitations of the CSC study which are yet to be overcome.     
The major limitation of hindering CSC research is how best to identify CSCs. To date, there is 
no single method which has been proven to identify all CSCs. Some studies only focus on one 
type of CSCs (Sheridan et al., 2006, Fillmore and Kuperwasser, 2007, Jaggupilli and Elkord, 
2012); while other studies have investigated different types of CSCs and observed similar drug 
responses (Mishra et al., 2017, Lin et al., 2013). Yet, according to the antiretroviral drug 
treatment experiments described in our study, different types of CSCs respond differently to 
different drug treatments. Antiretroviral drugs reduced the proportion of the ALDHhigh 
epithelial-like CSCs, suggesting that antiretroviral drugs can effectively eliminate the 
epithelial-like CSCs in breast cancers. In contrast, the percentage of the CD44+/CD24- 
mesenchymal-like CSCs increased after drug treatment in all TNBC cell lines tested. The LINE-
1 shRNA direct inhibition experiment supported this result implying that LINE-1 inhibition 
may potentially enlarge the mesenchymal-like CSC population within TNBCs. This 
antiretroviral drug-induced CSC enrichment pattern could be caused by the drug-resistant 
ability of CSCs; however, the exact regulation mechanisms remain unclear. These conflicting 
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results show the heterogeneity amongst CSCs and highlight the challenges facing CSC 
researchers.  
Another significant limitation to CSC research is CSC maintenance. It is difficult to preserve 
sorted CSCs with their CSC status intact. In traditional two-dimensional cell culture, some 
CSCs always tend to differentiate into non-CSCs in order to retain the original composition of 
cancers (Tang, 2012, Liu et al., 2015). This phenomenon has also been observed in this study, 
hence our difficulties with the BCSC enrichment experiments. Several potential solutions were 
considered, but only cell sorting in combination with serum-free medium seemed to enrich the 
mesenchymal-like CSC population. Even though this method managed to only maintain about 
60% of breast cancer cells in CSC status, a decreased proportion of the mesenchymal-like CSCs 
was observed after EFV treatment. This experiment indicated the ability of antiretroviral drugs 
to reduce BCSCs; however, more solid evidence is needed to confirm this result. Therefore, 
currently, a widely used BCSC enrichment assay, the tumorsphere BCSC functional assay was 
employed to create BCSC enrichment conditions which allowed us to examine the effectiveness 
of antiretroviral drugs at reducing BCSCs. The issue of CSC maintenance underlined CSC’s 
plasticity and this was a driving motivation for investigating which anticancer drugs can 
eliminate both CSCs and non-CSCs. 
CSC treatment has been drawing great attention in cancer research. CSCs have stronger drug 
tolerance than non-CSCs do, thus they are very difficult to deal with. Additionally, some cancer 
cells might be able to switch between CSC status and non-CSC status; however, the 
mechanisms involved are still not understood. A drug which can kill both CSCs and non-CSCs 
is expected to be superior to any other currently used in clinical practice. This study addressed 
the possibility of repurposing antiretroviral drugs as a novel anticancer therapy and highlighted 
their potential for inhibiting the growth of CSCs.  
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Chapter 6 Conclusions and discussions 
6.1 Summary  
The main goal of this project was to determine whether antiretroviral drugs can be repurposed 
for treating triple-negative breast cancers (TNBCs). This cancer cell subtype is difficult to treat 
with the limited therapeutic strategies currently available. The initial part of this study 
determined the effectiveness of commonly used antiretroviral drugs, as anticancer agents, in 
TNBCs. The second part of this study investigated the mechanisms involved in the antiretroviral 
drug-induced cell responses. The final part of this study examined the effectiveness of 
antiretroviral drugs in reducing BCSCs which are known to be responsible for many 
unfavourable prognostic outcomes, including cancer metastasis, drug resistance, and cancer 
recurrence. A discussion of the outcomes and implications follows.  
A significant result arising from this study has been the anticancer effects of two antiretroviral 
drugs Efavirenz (EFV) and SPV122 (SPV) on TNBCs via LINE-1 inhibition. Out of the six 
antiretroviral drugs tested, only EFV and SPV strongly decreased cell viability in the TNBC 
cell lines MCF10AT, MCF10CA1α, MDA-MB-231, BT-549, and BT-20; whereas, no obvious 
changes were observed in non-cancer control MCF10A cells. The studies have shown that 
antiretroviral drugs induce cancer cell toxicity and retard cell proliferation in TNBCs. This 
indicates that the antiretroviral drugs EFV and SPV act specifically and effectively to eliminate 
TNBCs. We also characterised the morphological and physiological effects of antiretroviral 
drugs on TNBC cell lines and found that they reduced cell proliferation, suppressed DNA 
synthesis within the cell cycle, increased programmed (apoptosis) and unprogrammed (necrosis) 
cell death, and altered cancer cell morphology. Moreover, inhibition of LINE-1 by antiretroviral 
drug in TNBC cell lines was confirmed by western blot and LINE-1 simulation experiments. 
Since LINE-1 overexpression has been strongly linked with breast cancer (Patnala et al., 2014), 
and the function of LINE-1 reverse transcriptase (RT) is reduced by antiretroviral drugs (Dai et 
al., 2011), we have established a link between antiretroviral drugs  reducing cancer cells and 
inhibition of LINE-1. This suggests that using antiretroviral drugs to block LINE-1 RT may be 
of potential therapeutic value in TNBCs. 
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The other important finding of this study was that antiretroviral drugs exert their anticancer 
effects by down regulating fatty acid metabolism. In this component of the project, we used 
whole-genome RNA sequencing (RNA-Seq) analysis to further our understanding of the 
possible anticancer mechanisms involved in MCF10AT, MCF10CA1α and MDA-MB-231 cell 
lines. According to the RNA-Seq data analysed by the STRING-DB protein-protein interaction 
search tool, several key genes involved in fatty acid metabolism play a key role in antiretroviral 
drug treatment. These genes included stearoyl-CoA desaturase (SCD), fatty acid synthase 
(FASN), and acyl-CoA synthetase long-chain family (ACSL) which were all significantly down 
regulated after the drug treatments. Since fatty acid metabolism has been strongly connected 
with cancer development, its down regulation makes it highly relevant to the antiretroviral drug-
induced anticancer activity. Thus, investigation of the relationship between LINE-1 inhibition 
and suppression of fatty acid metabolism could be an area for future study.  
The fatty acid metabolism pathway was not the only pathway implicated in antiretroviral drug 
treatment in the STRING-DB analysis. Other pathways such as ‘FoxO signalling pathway’, 
‘microRNAs in cancer’ pathway, and ‘Amino sugar and nucleotide sugar metabolism’ pathway 
were also highlighted. These pathways may help us to further understand the mechanisms 
involved in the molecular and morphological changes which were observed during the drug 
treatment. Interestingly, some of the pathway have been correlated with anticancer effects, but 
others have been associated with unfavourable prognostic outcomes of cancers. These diverse 
outcomes further emphasise the complexity of TNBCs as illustrated by the varied phenotypes 
encountered for a range of antiretroviral drug-treated TNBC cell lines.  
The increasing expression of ‘microRNAs in cancer’-related genes in the drug-treated TNBCs 
appeared to be associated with enhancing cancer cell malignancy. Genes involved in the 
‘microRNAs in cancer’ pathway, such as CD44, have been strongly linked with poor prognostic 
outcomes in breast cancers (Hu et al., 2018). In addition, not only the genes associated with 
cancer-related microRNAs, but also the cancer-related microRNAs, such as miR-21, were 
upregulated after drug treatment. We observed significant increases of miR-21 in antiretroviral 
drug-treated TNBC cell lines. An increase in the expression of CD44 and miR-21 in cancer cells 
is more than a sign of cancerous predisposition, it can also be associated with cancer stem cell 
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(CSC) enrichment. Therefore, this led us to consider how CSCs could be involved in 
antiretroviral drug treatment.   
The ANOVA analysis of RNA-Seq data also strongly suggested that CSCs may be induced 
during antiretroviral drug treatment. Quite a few CSC-related genes were highlighted in the 
RNA-Seq analysis with some decreasing and others increasing upon drug treatment. For 
instance, two fatty acid metabolism related-genes SCD and FASN, which had been associated 
with CSC (Kuo and Ann, 2018), were down regulated as a result of drug treatment. In contrast, 
CD44 and PROCR, two well-known CSC indicators (Hwang-Verslues et al., 2009), were up 
regulated. These inconsistent results can at least partially explain the dual directions of cancer 
morphological change in the drug-treated MCF10AT and MCF10CA1α cells. They also 
highlight the importance of researching antiretroviral drug responses in CSCs.    
Antiretroviral drugs target both general cancer cells and CSCs in TNBCs. In our experiments, 
different types of BCSCs responded differently to antiretroviral drugs. The high aldehyde 
dehydrogenase (ALDH) activity epithelial-like CSCs were significantly reduced after 
antiretroviral drug treatments; whereas, the CD44+/CD24- mesenchymal-like CSCs showed an 
increase. These results may explain the diametrically opposed results observed in previous 
experiments: some of the antiretroviral drug-treated TNBCs presented mesenchymal and CSC 
markers associated with unfavourable prognostic outcomes. These findings highlight the 
complexity and the heterogeneity of TNBCs and further indicate that different types of CSCs 
may have varying degrees of drug-resistance. The mesenchymal-like CSCs probably have 
greater resistance to antiretroviral drugs than other cancer cells. Finally, the tumorsphere CSC 
functional assay demonstrated that CSCs can be eliminated by antiretroviral drugs, thus 
continuous antiretroviral drug treatment at an appropriate concentration may be able to reduce 
both non-CSCs and CSCs simultaneously.  
In summary, several significant outcomes have been achieved during the course of this project. 
The most significant finding to emerge was that EFV and SPV could potentially be valid 
anticancer drugs for treating TNBCs. They are effective against CSCs and non-CSCs by their 
regulation of the fatty acid metabolism pathway. Although future studies are required to directly 
link LINE-1 inhibition and cancer fatty acid metabolism, this study suggests that LINE-1 is a 
potential therapeutic target in the treatment of TNBCs. However, considering the ability of 
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CSCs to resist existing drug treatment regimens (Singh and Settleman, 2010), a thorough 
evaluation is necessary to assess the efficacy of antiretroviral drugs as an anti-cancer therapy. 
More experiments are warranted so that we can fully understand how antiretroviral drugs act as 
inhibitors of cancer.  
 
Figure 6-1 putative functions of antiretroviral drugs in TNBC treatment 
Antiretroviral drugs may antagonise the progress of TNBCs by targeting both CSCs and non-CSCs. They 
can promote cell differentiation in undifferentiated cancer cells, can suppress cancer cell division, and 
can induce cancer cell death. Mesenchymal-like CSCs are more resistant to antiretroviral drugs 
compared with other types of TNBC cells, although the drugs can also reduce the mesenchymal-like 
CSCs. In this cancer reducing process, cancer cells may switch their status between CSCs and non-CSCs 
because of CSC plasticity. TNBC cells tend to have a preference for maintaining the mesenchymal-like 
CSC status under antiretroviral drug treatment condition. However, the functional CSC assay proves 
that CSCs can also be targeted by the drugs. Thus, antiretroviral drugs should be considered as a 
potential therapeutic strategy for treating TNBC patients.    
Chapter 6 
154 
 
6.2 Limitations  
Despite LINE-1’s long-time association with epithelial cancers, the nature of this association 
has remained ambiguous. LINE-1 is strongly inhibited in normal cells through many different 
endogenous mechanisms. Thus, the two major tools currently used in protein functional studies, 
a gain of function (overexpression) and a loss of function (inhibition), might be less applicable 
in LINE-1 research. The overexpression of LINE-1 in normal cells expressing low levels of 
LINE-1 would require the cell’s self-defence mechanisms to be overcome, which would be a 
challenge. Although a modified LINE-1 sequence can partially reduce the influence of such 
self-defence mechanisms, it may have a different structure or function to the original LINE-1. 
We must also remember that the exact protein structure of LINE-1 ORF2 protein, the predicted 
target of antiretroviral drugs, is still unproven. Whether antiretroviral drugs can directly target 
LINE-1 RT also remains unclear. Until now, no direct link has been confirmed between 
antiretroviral drug treatment, LINE-1 inhibition, and cancer cell elimination in TNBCs. 
However, our results suggest that LINE-1 expression is correlated with cancer growth in 
TNBCs. Thus, there is a great opportunity for LINE-1 to be advanced as a potential therapeutic 
target in TNBCs.    
Another limitation of this study concerns the efficacies of antiretroviral drugs. It is still unclear 
whether the diverse drug-induced morphological changes are caused by insufficient drug 
treatment, possibly due to the characteristics of the drugs and drug resistance of cancers. EFV 
is a commercially available antiretroviral drug with a long history of treating HIV patients. No 
reports have been published regarding its cell permeability and stability (Bastos et al., 2016). 
Such an issue may also apply to the newly synthesised SPV which may be unstable. We found 
that the efficacy of SPV decreased continuously with time and a precipitate was formed after 
two years storage in a -80°C freezer. The stability of SPV would have to be improved before 
any further experiments are conducted in the future. As for drug resistance, EFV has been 
recognised as an inhibitor of the breast cancer resistance protein (BCRP) which is responsible 
for a great proportion of multidrug resistance in breast cancers (Weiss et al., 2007, Peroni et al., 
2011). This implies that antiretroviral drugs may reduce cancer drug resistance and operate 
within the target cancer cells. It is likely that the diverse molecular and morphological changes 
in the drug-treated TNBCs might be caused by different cell responses to wild-type p53 
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suppression and mutant p53 suppression, as well as the involvement of CSCs, rather than by 
efficacy of the drug. However, more evidence is needed to test these assumptions. 
CSC research is an evolving field of cancer biology which is facing several challenges, 
including CSC heterogeneity and CSC plasticity. These characteristics of CSCs mean that it is 
difficult to assess the outcomes of drug treatment. A primary area of concern in the CSC field 
is the lack of universal CSC markers. Several molecular markers, such as CD44+/CD24-, and 
functional markers, such as high ALDH activity, have been recognised as CSC markers. 
However, only a small amount of different types of CSCs overlap. Thus, which types of CSCs 
can represent the major CSC population in cancers is currently under debate. In addition, 
different types of CSCs respond differently to different drugs, making it increasingly difficult 
to determine effective treatments. Some cancer cells even have the ability to shift between CSC 
and non-CSC status, the triggers and mechanisms of which are unclear. These characteristics 
greatly affect CSC maintenance and reduce the accuracy of CSC-enrichment experiments. 
Moreover, traditional in vitro two-dimensional culture conditions might not reproduce tumour 
microenvironments. This raises questions of whether the experimental conditions actually 
mimic CSCs’ native environment. Although the MammoCult three-dimensional culture may 
partially address this problem, little is known about how many true CSCs can be accumulated 
in this culture. CSC research is a relatively young and underdeveloped field of cancer research, 
many hypotheses and assumptions need to be tested. Further investigation of this discipline will 
enable more effective therapeutic methods to be developed for cancer patients. 
The first evidence of cancer stem cells (CSCs) arose in human acute myeloid Leukaemia about 
25 years ago (Lapidot et al., 1994); however, so far, there have been no specific markers for 
detecting CSCs. According to the current literature, CD44+/CD24- and ALDH+ are widely used 
and recognised as CSC markers in breast cancer (Liu et al., 2014). Nevertheless, the risk of 
exclusively relying on these CSC markers should also be considered. For instance, miR-21 is 
believed as a valid CSC marker which inhibits tumour suppressor genes such as PTEN and 
further induces cancer proliferation and migration (Han et al., 2011; Buscagla and Li, 2011). 
Interestingly, in our RNA-Seq data, pten increases after antiretroviral drug treatment, although 
miRNA level is relatively high in drug-treated TNBCs. This unexpected result has also been 
found in Frankel’s group (2008). They have confirmed that miR-21 inhibitors were very 
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unlikely to alter PTEN expression in breast cancer suggesting cell- and tissue-specific effects 
may influence the exact functions of these “markers” (Frankel et al., 2008). Therefore, it is 
dangerous to ignore the risk of using specific markers for determining cell status, supportive 
evidence is always essential for confirming the results. 
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6.3 Future research 
This study revealed the anticancer and anti-CSC effects, as well as the possible mechanisms, of 
antiretroviral drugs in TNBCs; however, additional experiments are needed to validate and 
expand these findings. 
Based on the RNA-Seq results, supplementary studies are feasible. RNA-Seq analysis suggests 
that several signalling pathways and genes were involved in antiretroviral drug treatment. Some 
of them have been linked to anticancer effects; others to the increase of unfavourable prognostic 
outcomes. A clear link between antiretroviral drug treatment and mitochondria has been shown 
in the RNA-Seq network analysis. Many genes associated with mitochondria, especially with 
mitochondrial complex I, have been highlighted in the network analysis of TNBC+MCF7 gene 
set. Mitochondria may play an important role in tumorigenesis, but can be damaged by 
antiretroviral drugs through oxidative stress (Hecht et al., 2018). A well-known repurposed 
anticancer drug, Metformin, has been shown to reduce tumour growth by inhibiting 
mitochondrial complex I and is associated with oxidative stress (Wheaton et al., 2014). 
Metformin has also been connected with mitochondrial enlargement which could be responsible 
for cancer cell death in MCF7 (luminal A) breast cancer (Zhuang and Miskimins, 2011). 
Metformin treatment shows quite a few common phenotypes with antiretroviral drug treatment. 
Consequently, antiretroviral drugs may induce their anticancer effects in TNBCs by disrupting 
mitochondrial regulation.  
As interesting as some of the results in this study are, it is worth making some improvements 
to some of the research methods and materials used in this study, in order to address some of 
the shortcomings of the LINE-1 experiments in TNBCs. Several issues relating to LINE-1 
research have not been answered as yet; i.e., the changes in LINE-1 overexpression and 
inhibition. Using novel techniques such as the CRISPR/Cas9 tool may increase the 
effectiveness and efficiency of plasmid insertion, and hence increase the success rates of the 
experiments. The discovery of appropriate TNBC model cells which are easily manipulated 
would improve the experiments likewise. Moreover, exploring the LINE-1 protein structure 
would build up a cornerstone and help bridge the gaps in LINE-1 knowledge. Once the exact 
role of LINE-1 in TNBCs is known, new therapeutic methods can be developed.  
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Considering the limitations of CSC research discussed previously, several studies could be 
implemented to expand the comprehension of CSCs in TNBCs. The tumorspheres used in this 
study were used sparingly because of the restrictions of materials. This was particularly 
problematic since only a few CSCs remained after antiretroviral drug treatment. Hence it was 
very difficult to make a comprehensive analysis of any molecular change in the drug-treated 
cells. Large scale tumorsphere formation is essential for collecting enough cells to allow further 
investigation of the molecular changes in TNBC’s functional BCSCs. These could enhance our 
understanding of how LINE-1 might affect BCSCs and how the proteins, RNAs, and regulation 
of microRNAs might be involved. Undoubtedly, more effort is needed to extend our knowledge 
of CSCs for fighting cancer.    
Potential networks between different EFV-induced anti-cancer pathways 
Although antiretroviral drugs, especially Efavirenz, have been considered as prospective anti-
cancer treatments in various cancers (see introduction section), the exact mechanism that 
underpins their mode of action is still unclear. In Chapter 4, a potential link to Efavirenz 
treatment (fatty acid metabolism inhibition and TNBC reduction) was highlighted; however, 
the detail surrounding their involvement is uncertain. A number of Efavirenz treatment studies 
performed in different tissues and cell lines indicated alternative pathways including the 
cannabinoid system (Hecht et al., 2013), oxidative stress(Hecht et al., 2018), Type-I interferon 
response (De Cecco et al., 2019), and fatty acid metabolism (in this thesis project). Investigating 
the possible relationships between these pathways may perhaps help us to understand a more 
comprehensive picture of Efavirenz-induced anti-cancer effects.  
Abnormal mitochondria may play a direct and/or indirect role in fatty acid metabolism 
reduction in antiretroviral drug-treated TNBCs. Mitochondria is the energy factory in 
eukaryotic cell; loss of its functions may result in lipids, proteins, and DNA damage (Schieber 
and Chandel, 2014) and this damage may lead to cell death and cell retardation proliferation 
(Sharma et al., 2011). Some aberrant changes in mitochondria including mitochondrial 
membrane depolarization (Hecht et al., 2018) and mitochondrial gene alteration (described in 
Chapter 4) have been observed in antiretroviral drug-treated cancer cells. More specifically, 
irregular mitochondria can lead to a dysfunctional tricarboxylic acid cycle (TCA cycle) and 
therefore influence the production of Acetyl-CoA which is crucial for fatty acid metabolism 
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(Menendez and Lupu, 2017b, Spinelli and Haigis, 2018). Mitochondrial dysfunction may also 
affect reactive oxygen species (ROS) expression and further alter PI3K/AKT regulations, 
subsequently reducing fatty acid synthase (FASN) expression in cancers (via Sterol regulatory 
element-binding protein 1) (Flavin et al., 2010). It seems very likely that abnormal mitochondria 
could be one of the reasons for Efavirenz-induced fatty acid metabolism inhibition. But how 
can Efavirenz promotes mitochondrial dysfunction remains a question. 
Pathways underpinning Efavirenz-related mitochondrial regulation are still lack of unclear, 
although evidence suggests that cannabinoid receptors may play a role. Cannabinoids have been 
reported as anti-cancer agents in different types of cancers by regulating cancer proliferation, 
invasion, and metastasis (Guindon and Hohmann, 2011, Chakravarti et al., 2014). While the 
anti-cancer effects of Efavirenz appear to be relevant to cannabinoid receptor expression in 
certain cell lines (Hecht et al., 2013) and the anti-cancer responses of cannabinoids relate in 
part to abnormal mitochondria-induced anti-cancer responses making it worthwhile exercise to 
inspect whether there is any connection in between. More specifically, highly expressed 
cannabinoid receptors such as cannabinoid receptor 1, cannabinoid receptor 2, and G-protein 
coupled receptor 55 are considered as a marker of Efavirenz-sensitive cancer cells (Hecht et al., 
2013); whereas, overexpressed cannabinoid receptors have been detected in certain types of 
breast cancers including TNBCs (Chakravarti et al., 2014). This suggests that the anti-TNBCs 
effects of Efavirenz could potentially be associated with cannabinoid receptor regulation. A 
review article has highlighted some functional links between cannabinoid receptors and many 
regulatory pathways in TNBCs (Chakravarti et al., 2014). Among these pathways, ROS 
pathway and PI3K/AKT pathway, which can be altered by mitochondrial dysfunction are 
distinguished as downstream events of targeting cannabinoid receptors (Chakravarti et al., 
2014). Thus, it is possible that Efavirenz affects cannabinoid receptors resulting in abnormal 
mitochondria, and further inhibit fatty acid metabolism by blocking Acetyl-CoA synthesis and 
altering the PI3K/AKT pathway ultimately reducing TNBCs. Interestingly, no direct binding 
has been detected between Efavirenz and any cannabinoid receptor (Gatch et al., 2013); only 
the synergistic effect has been reported in Efavirenz and cannabinoid agonists treated cancer 
cells (Hecht et al., 2013). Hence, more evidence is essential for confirming the role of 
cannabinoid receptors in Efavirenz-induced anti-cancer effects. 
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Other than the potential cannabinoid receptor-mitochondria-fatty acid metabolism pathway 
described above, type-I interferon (IFN-1) can also be a regulator of Efavirenz-induced anti-
cancer effects. A possible network among LINE-1, IFN, fatty acid metabolism, and cancer stem 
cells can be inferred from several indirect lines of evidence. Firstly, inhibiting LINE-1 by 
antiretroviral drugs can reduce IFN-1 expression in ageing cells (De Cecco et al., 2019) and 
IFN-1 controls fatty acid metabolism via STAT-regulated mitochondrial TCA cycle in immune 
cells (Wu et al., 2016a, Raniga and Liang, 2018). Moreover, the expression of INF-1, 
particularly INF-β, and STAT have been associated with cancer stem cell regulation in TNBCs 
(Doherty et al., 2017). Therefore, it seems logical to link this information together to propose a 
pathway involving LINE-1, IFN-1, STAT, mitochondrial TCA cycle, fatty acid metabolism, 
and TNBC reduction. However, relevant experiments performed in TNBCs are rare, thus 
further experiments need to be conducted in TNBCs to further prove this hypothesis. 
In summary, two possible Efavirenz-induced anti-cancer pathways are proposed in this section, 
one includes the cannabinoid pathway, the other includes the INF/STAT signalling pathway. 
Altering these two pathways might be able to drive mitochondrial dysfunction thereby 
decreasing fatty acid metabolism which could be a key factor in the reduction of TNBCs. Detail 
experiments are required to confirm exact pathways involved in Efavirenz-induced anti-cancer 
effects in order to add to our knowledge of antiretroviral drug treatment in cancer. 
Figure 6-2 predicted connections among various Efavirenz-induced pathways in breast cancers.   
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6.4 Conclusions 
The aim of this project was to show that antiretroviral drugs induce anticancer effects in TNBCs. 
Antiretroviral drugs can induce cell death, alter cell cycle, and prolong cell proliferation rate in 
TNBCs. Therefore, antiretroviral drugs are potential anticancer drugs for treating TNBCs. This 
anticancer process is associated with down regulating cancer fatty acid metabolism, which may 
be linked to LINE-1 RT inhibition. Furthermore, although we faced many challenges in the 
study of CSCs, we have used the tumorsphere CSC functional assay to reveal an anti-CSC effect 
of antiretroviral drugs. Follow-up experiments are necessary to further understand how 
antiretroviral drugs impact CSC regulation and anticancer activity.  
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Figure S 3-1 Normalized cell survival curves in different treating conditions  
  
Figure S 3-2 Cell proliferation curves compared antiretroviral drug-treated and control cells for 
different breast cancer cell lines in different time-points 
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Table S 3-1 The percentage of cells in different cell phases 
  G0/G1 phase S phase  G2 phase 
MCF10A Control 81.55±9.61% 6.79±3.64% 11.66±6.01% 
EFV 83.22±10.67% 5.77±3.95% 11.01±6.72% 
MCF10AT Control 71.64±7.70% 11.42±2.56% 16.94±6.66% 
EFV 82.22±14.52% 6.02±3.63% 11.76±10.93% 
MCF10CA1α Control 51.48±5.09% 20.39±2.79% 28.13±3.58% 
EFV 63.49±2.00%* 10.81±1.19%** 25.71±1.20% 
MDA-MB-231 Control 54.95±1.08% 21.52±3.99% 23.53±5.02% 
EFV 51.91±5.79% 18.81±5.74% 29.28±6.01% 
BT-549 Control 58.84±2.29% 19.46±3.46% 21.70±2.17% 
EFV 58.06±3.93% 15.70±0.17% 25.80±4.32% 
BT-20 Control  61.87±2.29% 12.61±2.35% 25.52±3.33% 
EFV 53.48±5.01% 9.86±1.51% 36.66±5.05%* 
T47D Control  60.45±6.18% 11.52±1.23% 28.02±5.00% 
EFV 49.51±8.29% 7.65±2.12% 42.84±6.17%* 
(* p<0.05, ** p<0.01) 
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Figure S 3-3 Cell cycle patterns of untreated-control and SPV-treated cells in MCF10A, 
MCF10AT, MCF10CA1α and MDA-MB-231 cell lines 
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Figure S 3-4 Cell cycle and subG1 patterns of untreated-control and EFV-treated cells in 
MCF10A, MCF10AT, MCF10CA1α and MDA-MB-231 cell lines 
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Figure S 3-5 The cell morphologies in EFV-treated and untreated cells  
This figure compared the morphologies of EFV-treated and untreated cells in MCF10AT, and 
MCF10CA1α, MDA-MB-231, MDA-MB-436, and T47D cell lines. Phalloidin (green, for detecting F-actin) 
and DAPI (blue, for detecting nucleus) was stained.  
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Figure S 3-6 Cell cycle patterns of untreated-control and EFV-treated cells in BT-549 and BT-20 
cell lines 
 
     
Figure S 3-7 The cell morphologies in EFV-treated and untreated BT-549 and BT-20 cells 
This figure compared the morphologies of EFV-treated and untreated cells in BT-549 and BT-20 cell 
lines. Phalloidin (green, for detecting F-actin), Ki-67 (red, for detecting cell proliferation), and DAPI 
(blue, for detecting nucleus) were stained. 
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Table S4-1 EFV down regulation gene set 
Gene Name FC.EF Gene Name FC.EF Gene Name FC.EF 
SCD -3.79101 RCSD1 -1.63876 MSRB1 -1.44253 
ALPP -3.06442 KLF9 -1.63675 CTSD -1.43345 
PDK4 -2.90026 APOL6 -1.61586 PSME1 -1.42149 
ELF3 -2.77384 MXD4 -1.59885 ACOT2 -1.41899 
METTL7A -2.39208 ATOH8 -1.59694 MAN2B2 -1.41881 
GBP7 -2.30187 ASAP3 -1.59268 SYT8 -1.41833 
SREBF1 -2.29244 PLEKHA7 -1.58839 TGFB2 -1.41469 
C3 -2.27458 NCOA7 -1.5818 ACSF2 -1.41449 
ACSL5 -2.20747 RHOU -1.57796 TACSTD2 -1.41328 
TMEM135 -2.15772 TFAP2C -1.57301 HPGD -1.41211 
CYP4B1 -2.15538 IKZF2 -1.57055 SNN -1.40395 
CD14 -2.15152 PRR15 -1.56494 SORT1 -1.40333 
FBXO32 -2.13288 TIMP3 -1.56241 DHCR24 -1.39932 
RARRES1 -2.07921 SCNN1A -1.54595 C16orf93 -1.39026 
CLIC3 -2.07591 C9orf116 -1.54478 IGFBP4 -1.38172 
SGK1 -2.06754 FBLN1 -1.54045 LIPA -1.37985 
KRT13 -1.97777 TIMP3 -1.53326 ZNF362 -1.37266 
IFIT3 -1.96808 YPEL3 -1.53273 PDCD4 -1.36833 
ETNK2 -1.93086 TLR3 -1.52539 KRT80 -1.36829 
BCL6 -1.91379 KCNIP3 -1.52531 PPL -1.36793 
ALDH3A1 -1.89056 ACYP2 -1.51934 VGLL4 -1.36762 
TNFAIP2 -1.87149 LINC00511 -1.511 TMEM106C -1.36037 
GRAMD2 -1.84152 LPCAT3 -1.50868 SLC44A2 -1.35994 
KLK5 -1.8101 VGLL3 -1.50522 PPAP2B -1.35529 
S100P -1.80977 SRR -1.50497 MKL2 -1.35396 
SUSD2 -1.7896 A4GALT -1.49958 CDON -1.35342 
C10orf54 -1.78556 CFH -1.49874 ABHD8 -1.35018 
PLK2 -1.7815 PDK2 -1.47652 YS049_HUMAN -1.34924 
ROM1 -1.75078 FADS1 -1.47548 PSMB8 -1.3482 
FASN -1.73691 CAPS -1.47507 DDR1 -1.34556 
FAM43A -1.73266 PSCA -1.47275 SCPEP1 -1.34353 
PSMB9 -1.72357 PTPRS -1.47252 PTPLB -1.34318 
PLA2G16 -1.71928 SLPI -1.47209 FAM214A -1.34173 
MAP3K8 -1.71266 LPIN1 -1.47064 MIF4GD -1.33976 
NEBL -1.71162 RAC3 -1.46824 ACACA -1.33821 
ACSL3 -1.69856 SELENBP1 -1.46642 KCNK5 -1.3344 
HIST1H3E -1.67543 SYTL2 -1.46226 C11orf71 -1.33136 
NTN4 -1.6714 AC093323.3 -1.45957 RCAN1 -1.33058 
PLAC8 -1.66569 PIK3R3 -1.45636 DUSP23 -1.33049 
PRSS23 -1.66283 BCL3 -1.45603 LATS2 -1.3235 
TSC22D3 -1.65614 VAV3 -1.45298 FXYD3 -1.32013 
GLUL -1.65016 FOXO1 -1.4524 MGAT5B -1.31981 
HERC6 -1.65015 C18orf56 -1.44833 CHMP4B -1.31691 
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Table S4-2 continue 
Gene Name FC.EF Gene Name FC.EF Gene Name FC.EF 
PLEKHA2 -1.31666 ASAH1 -1.27268 CTAGE5 -1.24209 
DBI -1.31366 CLN5 -1.27167 DNAJC15 -1.24204 
FBXO17 -1.31164 TOB1 -1.27093 ZFYVE28 -1.24193 
SRD5A1 -1.31083 TSPYL2 -1.27006 DAB2IP -1.24078 
TP53 -1.30911 CXXC5 -1.26741 PPTC7 -1.24072 
CAT -1.3087 ST20 -1.26684 GPX2 -1.24053 
RPP25L -1.30777 UBL7 -1.26675 NDRG3 -1.23791 
PROS1 -1.30758 MADD -1.26645 MSX2 -1.23779 
CDKN2D -1.30699 NPEPPS -1.26631 TMEM160 -1.23575 
ANAPC16 -1.30322 FAIM -1.26598 SEMA3F -1.23573 
ARHGEF37 -1.30192 SDPR -1.26424 PARD6B -1.2355 
SLC25A23 -1.30105 LGALS3 -1.26387 TAF4B -1.23501 
ITFG3 -1.29977 CDC42BPG -1.2635 DNASE2 -1.23388 
ING3 -1.29914 KRT8 -1.25956 ADAT3 -1.22786 
OBSL1 -1.29853 TMEM87A -1.25851 FZD1 -1.22705 
KRCC1 -1.29843 ZNF318 -1.25779 BCL7B -1.2258 
COX14 -1.29573 PCCA -1.2575 MID1IP1 -1.22465 
FLYWCH2 -1.2957 CYB5D2 -1.25671 RABL5 -1.22344 
DAG1 -1.29469 DHX40 -1.25655 PLEKHA2 -1.21899 
MR1 -1.29308 CCDC64 -1.25577 MAML2 -1.21823 
FOSL2 -1.28909 ROGDI -1.2552 VAMP8 -1.21815 
DRAM1 -1.28692 ETFDH -1.25457 PTPRK -1.21686 
PNPLA2 -1.28648 USB1 -1.25352 LAPTM4A -1.2168 
DAPK1 -1.28564 HINT2 -1.25199 IL1R1 -1.21429 
GAA -1.28482 CRAT -1.25146 MBTPS2 -1.2123 
BTN3A2 -1.28264 FRK -1.25133 STS -1.20988 
ERV3-1 -1.28134 BCL9 -1.25056 IL6ST -1.20881 
NRDE2 -1.28121 FUNDC2 -1.24984 TMEM59 -1.20727 
CHP1 -1.28043 NUMA1 -1.24887 LUC7L2 -1.20686 
RBPMS -1.27961 C3orf37 -1.24871 PPM1L -1.20605 
SETMAR -1.27953 PIP5K1C -1.2474 TLK1 -1.20531 
SLC2A6 -1.27906 ALDH9A1 -1.2454 GCNT2 -1.20367 
TSPAN9 -1.27881 MARCH02 -1.24465 PKM -1.20353 
B4GALT1 -1.27743 WWP1 -1.24426 PSMB3 -1.20121 
IFITM3 -1.27524 HDAC11 -1.24413 TRAPPC13 -1.20115 
GCNT1 -1.27455 ADAM12 -1.24271 GIPC1 -1.20063 
(FC.EF: fold-change after EFV treatment)  
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Table S4-2 SPV down regulation gene set 
Gene Name FC.SP Gene Name FC.SP Gene Name FC.SP 
SCD -3.6878 PDK4 -1.78511 ATOH8 -1.52911 
IFIT3 -2.98949 TLR3 -1.77924 NTN4 -1.5276 
ELF3 -2.77005 FAM43A -1.73073 CTRL -1.52536 
ALPP -2.74202 TNFSF10 -1.73011 GPR1 -1.52397 
RARRES1 -2.60428 MAP2 -1.72985 GLUL -1.52288 
IGFL1 -2.59129 FASN -1.72564 LIPA -1.52028 
KLK10 -2.57056 C10orf54 -1.72038 IFI35 -1.51973 
CD14 -2.48819 APOL6 -1.71969 C9orf3 -1.51958 
IFIT2 -2.44074 PRSS23 -1.71253 IGFBP7 -1.5117 
GBP7 -2.42212 IFITM2 -1.71252 TSPAN15 -1.5062 
METTL7A -2.42009 PADI2 -1.71227 CCDC64 -1.50211 
ISG15 -2.36524 MAP3K8 -1.70926 PARP9 -1.49909 
SGK1 -2.36219 PIK3R3 -1.70897 AMOTL2 -1.49801 
IFIT1 -2.33476 S100P -1.69768 FBLN1 -1.49643 
TMEM135 -2.32002 ETNK2 -1.69524 PSMB8 -1.49617 
ACSL5 -2.31741 SMAD6 -1.68708 TACSTD2 -1.49471 
IFI44 -2.26114 IFIH1 -1.66837 NMI -1.49395 
GRAMD2 -2.1697 PRR15 -1.66735 SEPP1 -1.49162 
SREBF1 -2.14993 SYTL2 -1.6652 SLC29A3 -1.48672 
FBXO32 -2.11818 PLA2G16 -1.65845 GPR110 -1.48293 
CYP4B1 -2.06861 TSC22D3 -1.65598 ZNF362 -1.48195 
SUSD2 -2.0487 TJP3 -1.65129 VGLL3 -1.48128 
PRR15L -2.01957 SLC43A2 -1.63461 RAC3 -1.48089 
PLK2 -2.01621 UTY -1.60041 ALDH1A3 -1.4795 
BCL6 -1.99203 KRT80 -1.59894 BAMBI -1.47946 
NNMT -1.97731 USP18 -1.59562 SORT1 -1.47944 
ID2 -1.96357 KLK6 -1.59059 PSME2 -1.4794 
PSMB9 -1.95852 TFAP2C -1.58136 A4GALT -1.47784 
KRT13 -1.92367 PSME1 -1.57191 BAG1 -1.46806 
RIPK4 -1.90997 PROM2 -1.57031 DHCR24 -1.46721 
KLK5 -1.89975 KLF9 -1.56828 PDZK1IP1 -1.46637 
EFEMP1 -1.89496 SCNN1A -1.56822 MMP7 -1.46534 
HERC6 -1.8633 WISP2 -1.56584 HS6ST1 -1.46415 
ALDH3A1 -1.86046 SLPI -1.55702 FAM214A -1.46372 
AZGP1 -1.84724 SYT8 -1.54988 LIMCH1 -1.46351 
ACSL1 -1.83568 LINC00511 -1.54754 CDKN2C -1.46327 
IRF1 -1.83428 PLAC8 -1.54727 FAIM -1.4623 
LCN2 -1.82883 GINS3 -1.54017 ACYP2 -1.46153 
CSF1 -1.82685 RCSD1 -1.53784 IFNGR1 -1.46099 
NCOA7 -1.82412 PLLP -1.53776 LRRK1 -1.45507 
BCL3 -1.8088 CTGF -1.53734 ACAT2 -1.45303 
TNFAIP2 -1.79212 KRT15 -1.53155 MOB3B -1.44954 
GBP1 -1.78716 NEBL -1.53139 FADS2 -1.44379 
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Table S4-2 continue 
Gene Name FC.SP Gene Name FC.SP Gene Name FC.SP 
TSKU -1.44323 DCN -1.36781 PDK2 -1.31152 
IFITM3 -1.43886 SRSF6 -1.36504 TRAFD1 -1.3104 
FXYD3 -1.43408 ING3 -1.36486 TRAF4 -1.3102 
TGFBR3 -1.43403 FRAT2 -1.36241 PTPRS -1.30952 
S100A9 -1.43287 ARHGEF37 -1.36052 BST2 -1.30857 
MAN2B2 -1.43215 PPAP2B -1.35692 ACSF2 -1.30819 
SMAD1 -1.43062 ASB9 -1.35688 ZC3HAV1 -1.3069 
OGFRL1 -1.42692 KCNIP3 -1.3518 ITGAE -1.30627 
ACSL3 -1.42534 SLC25A23 -1.35066 HIST1H4J -1.30485 
OGFRL1 -1.42437 TXNDC16 -1.35025 ARSD -1.30387 
C10orf112 -1.42248 PLEKHA7 -1.34879 TGFB2 -1.3025 
HLA-B -1.42159 ARRB1 -1.34775 HIST1H2AC -1.3021 
MARCKSL1 -1.419 TIMP3 -1.34645 OBSL1 -1.30084 
B9D2 -1.41414 LATS2 -1.3421 PTPRK -1.30057 
FRS2 -1.4121 DTX3L -1.34026 GSDMD -1.3003 
AS3MT -1.41081 GNRHR2 -1.3394 CTSD -1.29861 
DTWD2 -1.40681 FKBP7 -1.33802 ITGB6 -1.29778 
CASP1 -1.40337 GCH1 -1.33709 BCL9 -1.29727 
UBE2L6 -1.39911 DUSP23 -1.33627 CDC42BPG -1.29648 
TNFSF13 -1.39869 ATXN7L1 -1.33622 COL2A1 -1.29526 
MXD4 -1.39839 PPL -1.33447 ZNF689 -1.29524 
ALG14 -1.39724 TOB1 -1.33437 ASPSCR1 -1.29329 
SCPEP1 -1.39137 PLSCR1 -1.33392 SELENBP1 -1.29179 
TNS3 -1.39127 DSEL -1.33244 DTX4 -1.29125 
TRIM26 -1.39102 RCAN1 -1.33152 ASAH1 -1.28781 
MFAP3L -1.38965 ZNF628 -1.32781 NSF -1.28715 
TRIM22 -1.38531 NRDE2 -1.32605 HIST4H4 -1.28547 
UGT1A3 -1.38479 ARSK -1.32484 ANXA8L1 -1.28544 
CAPS -1.38358 HIST2H2AA3 -1.32418 TP53 -1.28527 
CXCL16 -1.38277 SLC2A8 -1.32262 PLEKHA2 -1.28523 
VAV3 -1.38128 SETMAR -1.32259 HLA-F -1.28487 
FLYWCH2 -1.38004 HIST2H2AC -1.32235 LANCL2 -1.28473 
TP53I3 -1.37954 CFI -1.3217 WWP1 -1.28448 
C9orf116 -1.37946 GLB1L2 -1.32143 SLC25A25 -1.2837 
COX14 -1.37711 ST20 -1.32047 DDX58 -1.28356 
ACACA -1.37692 PPCDC -1.31999 WWC1 -1.28308 
PRRG4 -1.37665 FOXO1 -1.31998 CYP2U1 -1.28162 
SLC44A2 -1.37658 TUSC1 -1.31738 MSRB1 -1.28039 
MRPL54 -1.3751 FAM98B -1.31705 DBI -1.28011 
PTPLB -1.37442 DRAM1 -1.31437 ANAPC15 -1.27982 
ZBTB22 -1.37285 C21orf2 -1.31347 LYRM2 -1.279 
SNN -1.37064 USB1 -1.31292 STS -1.27789 
CREG1 -1.36792 SLC2A6 -1.3126 GLA -1.27766 
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Table S4-2 continue 
Gene Name FC.SP Gene Name FC.SP Gene Name FC.SP 
MID1IP1 -1.27689 LIMK2 -1.24578 TRIM29 -1.22188 
KEAP1 -1.27668 B2M -1.24553 KAT5 -1.22176 
DAG1 -1.27504 PROS1 -1.24519 C3orf37 -1.22151 
HIST2H2BE -1.27363 ARHGDIB -1.24482 ACLY -1.22103 
DHRS4 -1.27226 TMCO4 -1.24463 LAPTM4A -1.21989 
HINT2 -1.27184 C5orf38 -1.24427 IRAK1BP1 -1.2187 
ASAP3 -1.26953 USP14 -1.24248 PPM1D -1.21804 
RBPMS -1.26908 ALDH9A1 -1.24236 C6orf106 -1.21678 
CHMP4B -1.26856 NCBP2 -1.24171 KRT5 -1.21666 
KRT8 -1.2683 ECI1 -1.24112 IL1R1 -1.21638 
LGALS3 -1.26809 ACOT2 -1.24106 C14orf142 -1.21534 
MRPL49 -1.26719 HIST1H2BK -1.24051 DAB2IP -1.21466 
ATXN10 -1.2655 GBA -1.2404 PIP5K1C -1.21357 
CSRP2BP -1.2646 MICB -1.24027 BTN3A2 -1.21136 
SDPR -1.263 B4GALT1 -1.24018 ARSD -1.21076 
C4orf46 -1.25975 CXXC5 -1.23755 VPS26A -1.21036 
ICK -1.25937 UBL7 -1.23729 IREB2 -1.20863 
LPCAT3 -1.25935 FBXO17 -1.23728 BLOC1S1 -1.20832 
SIPA1L3 -1.25915 YS049_HUMAN -1.237 CTD-2228K2.5 -1.20823 
FZD1 -1.25864 PNPLA2 -1.23624 CHST14 -1.20812 
FADS1 -1.25845 GPRC5C -1.23615 SYNC -1.20797 
MGMT -1.25741 LGALS3BP -1.23614 EID2 -1.20728 
TCF4 -1.25719 CARD6 -1.23513 DDX5 -1.20707 
HADH -1.25688 TSPYL2 -1.23385 IL6ST -1.20643 
CKMT1B -1.25671 SEMA3C -1.23334 LINC00610 -1.20583 
RFX5 -1.25655 ROGDI -1.23332 MBTPS2 -1.20558 
GOLM1 -1.25456 RILPL2 -1.2324 PKIG -1.20529 
TFDP2 -1.25274 GRWD1 -1.23193 RAET1G -1.20527 
FOXN3 -1.25233 GCNT2 -1.23059 CYB5D2 -1.20487 
CNP -1.25155 FRK -1.23051 MBIP -1.20428 
CTAGE5 -1.25038 EMC10 -1.23003 RCN1 -1.20404 
DPYSL2 -1.2492 ETFDH -1.22911 PARVA -1.20386 
RHOU -1.24844 TTC39C -1.22815 SCP2 -1.20327 
TDG -1.24835 RBBP6 -1.22655 FAM171B -1.20289 
MYEOV2 -1.24813 SH3BGRL -1.22651 TMEM87A -1.20188 
CCDC94 -1.24737 BID -1.22638 ADNP -1.2013 
SP2 -1.24728 TPRA1 -1.2258 PKM -1.20125 
SOCS5 -1.24725 TOR1A -1.22455 SSNA1 -1.20118 
CHP1 -1.24656 STRA13 -1.22406 ZNF16 -1.20035 
RCC2 -1.24625 FAM185A -1.22281   
THAP11 -1.24613 LIN52 -1.22254   
(FC.SP: fold-change after SPV treatment) 
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Table S4-3 EFV up regulation gene set  
Gene Name FC.EF Gene Name FC.EF Gene Name FC.EF 
HMGA2 2.203766 FSCN1 1.486728 NOM1 1.347823 
SH2D5 2.153474 OAF 1.472202 FUOM 1.347748 
LINC00269 2.014562 FERMT1 1.46415 OCIAD2 1.347692 
SMTN 1.980879 ARNTL2 1.460193 GFPT2 1.34698 
KDELR3 1.899312 FGFR1 1.459194 HK2 1.3465 
PAQR5 1.878873 AC016831.7 1.459101 ICAM3 1.344682 
RP11-77I22.3 1.84185 PLEC 1.456763 PLA2G4B 1.342894 
HS3ST3A1 1.821999 SEL1L3 1.451235 OSBPL6 1.342822 
AXL 1.820712 ERCC1 1.437069 MPP3 1.342511 
PLEK2 1.817137 RIN1 1.425565 KIAA0922 1.341844 
ARG2 1.811428 TMEM161B-AS1 1.425068 S100A16 1.338613 
VIM 1.785889 KLHL17 1.424825 SLC39A13 1.33779 
FOXQ1 1.770345 FTL 1.422334 TRMT6 1.335205 
FOSL1 1.760571 SMURF2 1.421686 YIPF2 1.335065 
LETM2 1.736731 EFNB1 1.416984 LYAR 1.333862 
PROCR 1.729174 POFUT2 1.414175 DRAP1 1.333558 
SLCO4A1 1.729052 TMEM39A 1.409175 SLC4A3 1.33304 
ARHGAP22 1.722266 MLTK 1.404412 MYO10 1.332926 
DOCK4 1.702998 OBSCN 1.403007 YS049_HUMAN 1.33207 
AC016831.7 1.671331 NAB2 1.397623 MLK4 1.330144 
SEC24D 1.667706 IKBIP 1.392482 GCN1L1 1.327157 
S100A2 1.653627 ATG16L2 1.391393 ZRSR2 1.326972 
STEAP1 1.644226 CCDC112 1.388897 MLKL 1.326049 
SLC20A1 1.624318 PKP2 1.388386 KNTC1 1.325738 
SDC1 1.592091 ARF4 1.387102 GLS 1.322638 
IL15RA 1.590758 COG6 1.380512 SRGAP1 1.321252 
RAP1GAP2 1.589534 YS049_HUMAN 1.377235 ATP13A3 1.320405 
HYI 1.586216 BCAN 1.375952 L3MBTL3 1.319775 
C6orf141 1.584748 SLC29A1 1.375546 TBC1D25 1.314103 
HMGA1 1.58358 STON2 1.372851 CALU 1.312283 
FLRT2 1.583218 FGFRL1 1.372219 SSR3 1.311618 
PID1 1.573859 ITPR3 1.372131 IGF1R 1.310546 
DUSP7 1.566578 MAPRE3 1.368488 POLR3D 1.308272 
DYRK3 1.547145 DVL1 1.364649 TSC1 1.305009 
UAP1 1.539652 FAM135A 1.362991 RMI2 1.303703 
ODC1 1.527796 SLC4A7 1.360676 CD274 1.302276 
TMEM194B 1.524812 CEP170 1.360516 FBXO22 1.30004 
ZBTB14 1.517357 SEC24A 1.359369 GOLGA2 1.297534 
AC016831.7 1.511181 B4GALT6 1.355342 ZCCHC6 1.297078 
POLR3G 1.505405 SKA1 1.355151 SNAP23 1.297004 
HES7 1.503565 MAPKAPK3 1.352218 OVOL2 1.29664 
E2F5 1.497455 HES2 1.351096 PFDN2 1.296482 
ECM1 1.492682 CD44 1.349677 NAPRT1 1.294557 
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Table S4-3 continue 
Gene Name FC.EF Gene Name FC.EF Gene Name FC.EF 
MED8 1.29387 TTL 1.257991 RRBP1 1.228391 
MSTO1 1.292491 ATM 1.257887 ZNF83 1.228033 
GM2A 1.291962 PIBF1 1.25779 GALE 1.227444 
FAM83G 1.291807 DICER1 1.257408 CERS2 1.22611 
EPHB2 1.291595 KCTD21 1.256589 SACS 1.223408 
TTC14 1.291463 ZCCHC7 1.256488 SLC9A3R2 1.223368 
YS039_HUMAN 1.289468 ABCC4 1.25638 CMTM7 1.222058 
DEPDC1 1.287548 PJA1 1.25629 GAS2L3 1.221804 
GINS2 1.286417 LEPREL4 1.254293 ZNF562 1.221443 
STIM2 1.28432 POPDC3 1.253956 RAB21 1.218739 
INPP4B 1.283642 GREB1L 1.253735 ATXN2L 1.218199 
WDR27 1.283417 EBLN1 1.253607 LAD1 1.216748 
GFPT1 1.282795 BDKRB2 1.252392 PPIL4 1.216377 
RP11-640M9.2 1.282666 MAP7D3 1.252236 AASS 1.216155 
PIK3CA 1.280802 FXYD5 1.252208 DPY19L4 1.215643 
RP11-319G6.1 1.280419 CAMSAP2 1.252085 SCLY 1.215479 
ALAS1 1.27808 MMP1 1.250558 WDR35 1.214325 
CORO1C 1.277469 CBWD6 1.250514 DNMT3A 1.212779 
FKBP10 1.275518 EIF4EBP1 1.249676 RALB 1.212321 
ARFGAP1 1.275248 COG3 1.249182 SIRT7 1.211955 
CTSC 1.273337 FARSB 1.248906 SURF4 1.211857 
PAQR3 1.272657 FANCB 1.248838 COPA 1.2095 
AGO2 1.271307 SOWAHC 1.246658 P4HB 1.209468 
PLXNA2 1.270281 WDR24 1.246377 DGKE 1.20937 
BCDIN3D 1.26979 ELP2 1.246321 FAM98A 1.209233 
MACROD1 1.268196 CNTROB 1.244822 MAP3K9 1.209142 
DUS4L 1.267882 STRIP2 1.241882 COPB2 1.207597 
YIF1A 1.267764 Shc1 1.240892 KIAA0020 1.207252 
LIN1_NYCCO 1.267615 SLC15A4 1.240253 UTP6 1.207213 
FRAS1 1.266537 SH3D21 1.239871 PTPDC1 1.206412 
CCDC144B 1.266015 RTTN 1.23973 MON2 1.205943 
ZDHHC8 1.265395 GTPBP10 1.238081 RGS10 1.205577 
QSOX2 1.264585 SLC30A5 1.237782 MGEA5 1.205509 
LARP1B 1.263485 ZNF280C 1.237242 ZNF37A 1.204914 
PPAPDC1B 1.263242 SETX 1.236806 DNAH14 1.204586 
MAPKBP1 1.26304 LRRC8E 1.23658 ZNF7 1.203814 
ACBD3 1.262892 MAP7D1 1.234634 UBA6 1.203583 
KCTD12 1.262795 ERCC5 1.233921 UFL1 1.203487 
AC004980.7 1.262483 CDK17 1.2338 YG039_HUMAN 1.203381 
BRI3 1.26089 SHARPIN 1.232926 NCS1 1.203188 
LRP8 1.259807 TTC3 1.23093 STEAP3 1.203123 
UHRF2 1.259199 ATG12 1.230763 DIS3 1.203102 
ZNF860 1.259025 RBM28 1.2303 ZNF841 1.202662 
MDM4 1.258134 NXPH4 1.228813 FBXO45 1.202094 
 
  
                                                                                                                                                                      Appendix 
175 
 
Table S4-4 SPV up regulaiton gene set 
Gene Name FC.SP Gene Name FC.SP Gene Name FC.SP 
ANGPTL4 2.77369 SH2D5 1.663312 MXRA8 1.491749 
CAPRIN2 2.428073 SEC24D 1.661752 UBR4 1.486684 
RPSAP52 2.33773 SCNN1D 1.657144 UACA 1.485385 
SERPINE1 2.300503 PROCR 1.657094 EMP3 1.484684 
VIM 2.255324 RP11-290L1.3 1.641563 LRP1 1.48436 
HMGA2 2.214457 LETM2 1.635522 DENND4B 1.483972 
PAQR5 2.203174 UTY 1.616979 FLRT2 1.483867 
IL13RA2 2.164794 WDR27 1.611014 RIN1 1.481809 
C9orf85 2.162859 ENO3 1.602986 BMS1 1.476621 
CREB5 2.094372 AC016831.7 1.601013 AHSA2 1.472717 
SMTN 2.072298 ARHGAP22 1.59936 GPR153 1.471915 
RP11-77I22.3 2.032499 DZIP1L 1.59334 YS049_HUMAN 1.468911 
HS3ST3A1 2.022767 PID1 1.591747 DBN1 1.46542 
RTEL1 2.014424 GG6L5_HUMAN 1.584375 LARP6 1.463662 
SLCO4A1 1.999081 MSH5 1.566028 C11orf68 1.46196 
C6orf141 1.994882 DGKA 1.562121 DUSP7 1.45896 
FOXQ1 1.977663 SDC1 1.561437 LRRC27 1.458848 
AXL 1.969879 PTK2B 1.557532 OAF 1.458728 
DUSP6 1.962258 ITGA3 1.552132 POLG2 1.456494 
MTMR11 1.906216 PLEC 1.549832 ANXA5 1.451464 
AGPAT9 1.882447 HYI 1.548615 RAP1GAP2 1.446288 
FOSL1 1.878668 ENTPD2 1.547297 FSCN1 1.439189 
SEMA3B 1.856047 NRG1 1.546116 SPTB 1.433211 
UBE3D 1.819088 RP11-253M7.1 1.539064 SFN 1.431464 
SERPINE2 1.791818 CCDC88A 1.536684 UBXN11 1.429667 
HES7 1.783064 EFNB1 1.535182 GPSM1 1.427929 
FAM196B 1.771963 PLXNA3 1.53406 POLM 1.425913 
NLRP1 1.768953 YS049_HUMAN 1.53038 MBOAT2 1.425401 
PLEK2 1.765578 PLCH2 1.529903 DYRK3 1.423515 
VGF 1.763073 FMNL2 1.528466 GFPT2 1.42227 
SLC20A1 1.754769 ARHGEF2 1.524077 FTL 1.421658 
S100A2 1.740106 FGFR1 1.517815 ABLIM3 1.419424 
KDELR3 1.738288 DOCK4 1.517081 C7orf41 1.417534 
PLEKHG5 1.725315 TMEM194B 1.510499 PI4KAP2 1.413476 
AHNAK2 1.714634 AC016831.7 1.507974 JRK 1.409942 
S100A6 1.712042 ECM1 1.50755 ADAT2 1.409909 
HMGA1 1.704836 ZNF485 1.506275 PGM3 1.408842 
CDKL1 1.698651 ZNF506 1.499848 CCDC41 1.408263 
ATG16L2 1.694391 RAC2 1.499239 AC016831.7 1.40751 
AC016831.7 1.68458 DPP3 1.495876 UAP1 1.40726 
STEAP1 1.683758 S100A6 1.49576 BCAN 1.407103 
C16orf89 1.683289 SLCO4A1 1.494883 DVL1 1.406629 
FAM83A 1.681807 TEP1 1.494317 LTBP4 1.405844 
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Table S4-4 continue 
Gene Name FC.SP Gene Name FC.SP Gene Name FC.SP 
IER2 1.404662 DEPDC1 1.362589 CBWD5 1.32714 
LPXN 1.403281 TPD52L2 1.361281 THBS3 1.326592 
ENO4 1.400903 C15orf52 1.360169 LINC00269 1.326539 
RP11-319G6.1 1.400839 GCN1L1 1.359618 TMEM120A 1.326063 
MST1R 1.399882 LIN1_NYCCO 1.3596 ACAD10 1.325066 
Gtf2i 1.398289 LIN1_NYCCO 1.359154 SLC4A7 1.324964 
CLMP 1.397945 ZNF333 1.357919 TMEM136 1.323455 
ERCC1 1.397625 ZNF516 1.357314 KATNAL1 1.323271 
SPAG9 1.396749 RP11-640M9.2 1.357198 FAM135A 1.323096 
CEP170 1.396561 GOLGA8A 1.357097 FAM83G 1.322955 
SH3D21 1.395901 SLC4A3 1.353571 PLXNA2 1.322211 
MCTP1 1.39533 ZNF860 1.353334 UTRN 1.321851 
IL15RA 1.394598 PTK6 1.353084 PLA2G4B 1.320935 
CCDC144B 1.39321 SRGAP1 1.351688 GDI1 1.320748 
KLHL17 1.391468 FAM86DP 1.351417 TMEM161B-AS1 1.320602 
B4GALT6 1.390726 SDHAP1 1.350897 S100A16 1.320417 
C9orf72 1.38869 NPHP3 1.350837 N4BP2 1.318962 
CDC25B 1.387614 ACAP3 1.349888 GLS 1.318457 
DOCK6 1.387181 MAR09 1.349686 CDRT4 1.318273 
APAF1 1.386312 SEL1L3 1.349042 TNRC6B 1.317297 
LYST 1.382528 PAX8 1.348035 MAPKBP1 1.317209 
ARNTL2 1.380779 DGKQ 1.347359 HEMK1 1.317069 
WSB1 1.380566 POFUT2 1.347282 YS039_HUMAN 1.316903 
SZT2 1.380501 CCZ1 1.345921 SMURF2 1.316462 
Fv1 1.37986 DUSP22 1.344925 ZNF160 1.316066 
ITPR3 1.379608 RGS20 1.343286 C16orf89 1.315541 
IGF2BP2 1.379079 NDE1 1.342362 GOLGA2 1.315492 
ATP8B3 1.378308 HK2 1.34222 ENO4 1.315056 
FGFRL1 1.376544 VAT1 1.342065 PPP1R13L 1.314353 
C9orf85 1.376017 MPP3 1.340909 TMEM39A 1.314285 
NAB2 1.373861 ELMO3 1.340509 C5orf54 1.314208 
FOXD1 1.373238 DMTF1 1.339711 PPP2R2C 1.314145 
WDR60 1.372969 IQGAP3 1.337453 DUS4L 1.313615 
MYO10 1.372665 PVRL1 1.336414 KIF27 1.313429 
MNT 1.372274 NOM1 1.3363 NFAT5 1.313277 
SEMA4B 1.37098 DUOX1 1.334319 NBPF9 1.313132 
DRAP1 1.370899 CCDC112 1.332931 FCHSD1 1.312741 
MYADM 1.37039 TTC14 1.332313 FERMT1 1.311019 
MLTK 1.36813 MACROD1 1.331366 ANKRD36C 1.310788 
MAPKAPK3 1.367452 ZCCHC6 1.3304 AGO2 1.310733 
SNX29P2 1.365968 DNMT3A 1.328232 KCNAB2 1.310494 
ANKRD36 1.364055 KLC3 1.327846 GLI4 1.309809 
ESPL1 1.363538 TLDC1 1.327695 CMTM7 1.309568 
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Table S4-4 continue 
Gene Name FC.SP Gene Name FC.SP Gene Name FC.SP 
CCBL1 1.30901 PTPDC1 1.284203 MTPN 1.258185 
LRP8 1.307025 CD44 1.283369 CD276 1.257955 
LINC00704 1.30622 MSTO1 1.282942 CALU 1.256646 
FKBP10 1.304481 AMOTL1 1.282537 ASPHD1 1.256227 
DMXL2 1.304291 ZNF330 1.282214 MORN1 1.256089 
SEC24A 1.304204 ALAS1 1.281455 STRIP2 1.254393 
IKBIP 1.303851 OSBPL6 1.281395 ODC1 1.253856 
RMI2 1.302999 RIOK3 1.281275 SLFN13 1.253364 
NBPF20 1.302606 UHRF2 1.279618 EPHA2 1.253147 
E2F5 1.302514 SSR3 1.279338 AP4B1 1.252445 
NAPRT1 1.302225 STK32C 1.279304 MAP3K10 1.25167 
PAK1 1.301141 FUOM 1.278153 NFRKB 1.250699 
DPAGT1 1.301037 LONRF1 1.277813 Shc1 1.250116 
LRRFIP1 1.300555 PTGR1 1.277694 LIFR 1.250041 
CPNE8 1.300375 MLK4 1.276749 DDHD1 1.249984 
PHF7 1.299924 NKTR 1.275888 CERS2 1.249646 
DLG4 1.299042 MALAT1 1.274934 CBWD6 1.248852 
DDHD2 1.298854 DYNC1H1 1.274726 TTC3 1.24864 
DENND3 1.298064 L3MBTL3 1.274369 YEATS2 1.247727 
Csnk1e 1.297921 BRI3 1.274272 NBPF24 1.247528 
ATP13A3 1.297723 CBLC 1.273868 PAQR3 1.245976 
RASA3 1.296506 C1orf132 1.273303 SENP7 1.245506 
MDM4 1.295934 RGL3 1.272768 GLYCTK 1.243998 
POLR3G 1.295764 MEX3C 1.272689 YG039_HUMAN 1.243829 
SLC45A3 1.294726 ZNF431 1.272322 ZCCHC7 1.242925 
LRRC37B 1.294163 FBXO22 1.272054 CNTROB 1.242798 
CCDC180 1.294027 NT5C 1.271479 PPP5D1 1.242328 
NFKBID 1.29375 CAMK2D 1.269319 ANKRD36B 1.242252 
ECI2 1.292831 MON2 1.268876 MICAL1 1.242165 
C9orf40 1.292207 SLC15A4 1.268524 GMPPA 1.241443 
TMEM55A 1.290954 RALB 1.267795 NPIPB5 1.241417 
NOC3L 1.290138 COG1 1.267699 KATNBL1 1.240862 
CTTNBP2NL 1.289566 GFPT1 1.267283 ATM 1.240315 
RTTN 1.288938 CD97 1.267232 USP4 1.239806 
YIPF2 1.288812 RFFL 1.267156 SLCO1B3 1.239638 
GINS2 1.288613 RASA2 1.267149 PNISR 1.239514 
AC004980.7 1.288493 C12orf23 1.266577 AMT 1.238918 
CEP290 1.287922 CYP2R1 1.265165 CXorf57 1.237152 
GPR161 1.287295 ZNF200 1.264983 FAM157C 1.237131 
OBSCN 1.286841 PIBF1 1.262176 MYEOV 1.236623 
FRAS1 1.285284 OCIAD2 1.261651 ZNF337 1.236607 
CYP26B1 1.284592 ZNF841 1.260813 GALE 1.236446 
SIM2 1.284504 HAUS6 1.260064 ASUN 1.236339 
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Table S4-4 continue 
Gene Name FC.SP Gene Name FC.SP Gene Name FC.SP 
THAP3 1.236292 ZDHHC8 1.225524 LRIG2 1.211889 
GPSM2 1.23623 EPHB2 1.224218 ZNF529 1.211425 
ZNF550 1.235739 ACADVL 1.223617 LINC00269 1.209953 
PJA1 1.235374 ZRSR2 1.223342 SESTD1 1.209208 
FAM219A 1.234886 C16orf58 1.222856 SETX 1.209072 
MAP3K9 1.23481 ACBD3 1.222784 COG3 1.208857 
RRBP1 1.23463 C20orf194 1.222524 COTL1 1.208726 
GM2A 1.234194 FAM73A 1.222482 FBXL4 1.208502 
RBM26 1.234137 MAN2C1 1.222348 GON4L 1.208195 
PPAPDC1B 1.234054 PIP4K2A 1.222317 MYO9B 1.20798 
RP11-395B7.7 1.233964 RRNAD1 1.22227 CEP72 1.207678 
UVSSA 1.23349 NF1 1.221505 YIF1A 1.20736 
PTAR1 1.233271 SHARPIN 1.2214 MPRIP 1.207189 
ASPH 1.233185 TRMT6 1.221335 CEP135 1.20677 
KCMF1 1.233037 PLEKHA8 1.221237 SMG1 1.205199 
LEPREL4 1.23269 CBL 1.22102 RECQL 1.205057 
PRRC1 1.232556 ARHGEF35 1.220941 JPH1 1.205054 
RNF214 1.232418 CASC5 1.220047 HDDC3 1.204835 
TNKS 1.23221 MNT 1.218489 ZNF83 1.204662 
CEP120 1.232049 LARP1B 1.218237 AP1S1 1.204553 
UBA6 1.231855 SLC9A3R2 1.218201 TAZ 1.204546 
SGTB 1.23179 GLUD1 1.217669 TSC1 1.203925 
ODF2L 1.231696 CERK 1.217254 MAP7D3 1.203677 
TTL 1.231333 ATG12 1.21708 NCOA3 1.203155 
UTP6 1.230092 POLE4 1.216742 L3MBTL1 1.20306 
GREB1L 1.22986 ODF2 1.216712 UGGT2 1.202528 
PFDN2 1.22937 RCOR1 1.215978 RILPL1 1.20244 
LMAN1 1.22932 MLH3 1.215939 DGKE 1.202275 
AAED1 1.228838 NAT9 1.214909 TAOK3 1.202115 
TUBG2 1.228637 UFL1 1.214888 ATP11A 1.202111 
SNAP23 1.228627 KIFAP3 1.214678 BTAF1 1.20179 
RTCA 1.228067 GTF3C3 1.214499 RFNG 1.201537 
SLC39A13 1.227137 GALNT3 1.21404 KIAA1549 1.201203 
TRAF5 1.226961 FAT1 1.213614 SCRN1 1.201192 
RSBN1 1.226587 NET1 1.213223 TTBK2 1.200982 
SIRT7 1.225741 LINC00269 1.213217 FAM126B 1.200614 
FAM200B 1.225737 DHRS7 1.21297 RP9 1.200425 
HACE1 1.225543 CTSC 1.212947   
PRKAA2 1.225529 FARSB 1.212084   
(FC.SP: fold-change after SPV treatment) 
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Figure S4-1 The STRING-DB gene network for SPV-treatment induced up regulated and down 
regulated genes in TNBCs 
 
 
 
Table S4-5 Highlighted KEGG pathways in SPV regulated gene sets using STRING-DB 
Pathway ID Pathway description Count network q-value 
01212 Fatty acid metabolism 7 9.93x10-5 
00071 Fatty acid degradation 9 0.00534 
00561 Glycerolipid metabolism 10 0.0534 
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Figure S4-2 Specific pathways being highlighted in different TNBC-only network analysis 
modules  
Midnightblue module
Darkorange module
Orangered4 module
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Figure S4-3 Bar Plot of ANOVA q-values for module eigengenes in the network analysis 
(TNBCs+MCF7) 
 
 
 
Table S4-6 ANOVA q-values for module eigengenes in the network analysis (TNBCs+MCF7) 
Module name p-value 
MEpurple 0.02445472 
MEantiquewhite4 0.03491513 
MEplum1 0.03491513 
MEmaroon    0.03764551 
MEskyblue2 0.03764551 
MEdarkred 0.03764551 
MEpalevioletred3 0.04421653 
MEblue   0.04997094 
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Figure S4-4 Specific pathways being highlighted in different TNBC+MCF7 network analysis 
modules  
  
Purple module
Darkred module
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Table S4-7 Mitochondria-related genes in network analysis 
Gene Name FC.EF FC.SP Gene Name FC.EF FC.SP 
ABCD3 -1.1386 -1.14812 MFN1 1.17084 1.14744 
ACN9 -1.15719 -1.10682 MICU1 -1.03522 -1.07097 
ACOT9 1.17204 1.17915 MRPL3 1.05854 -1.00796 
ADSL 1.12105 1.04844 MRPS22 -1.00912 1.02331 
ANXA1 1.10793 1.1234 MRPS27 -1.01285 -1.01285 
ATP5F1 -1.0012 -1.06734 MRS2 1.01629 -1.05724 
ATP5G1 1.04382 -1.04646 MTIF2 1.00186 1.00748 
AURKAIP1 1.0188 -1.00069 NDUFA8 1.02355 -1.02442 
BCAT2 1.09678 1.03948 NDUFAF7 1.09973 1.05501 
C10orf10 1.376 1.60306 NDUFS4 1.08402 -1.01554 
CAPRIN2 1.84355 2.05798 NDUFS7 -1.01483 -1.07597 
CCDC58 1.08177 1.0672 NUDT13 -1.18834 -1.01491 
CHCHD2 -1.00637 -1.06191 NUDT6 1.05245 -1.06933 
CISD3 1.0866 1.01239 OAT -1.07609 -1.12787 
CLPP 1.05066 -1.02805 OCIAD2 1.17902 1.09682 
COA3 -1.0176 -1.02064 P4HA1 1.01299 1.14766 
COASY 1.02873 1.00908 PARL -1.06503 -1.11942 
DHX32 -1.01648 -1.03279 PCCB -1.00389 -1.01368 
DLAT 1.00326 -1.04379 PDHB -1.07431 -1.08912 
DNAJC11 1.03761 -1.05997 PDK1 1.08806 1.13691 
ECSIT -1.05042 -1.12539 PHB2 -1.00531 -1.01183 
ELK3 1.22842 1.26687 PNPT1 -1.0155 -1.06202 
ETFB -1.11341 -1.03465 PRELID2 1.18676 1.27161 
GATM -1.26724 -1.18385 PSMB3 -1.14617 -1.15775 
GCAT 1.10026 1.13098 PTS 1.06382 1.02226 
GFM1 -1.02747 -1.06987 RAB32 1.06249 1.00269 
GLS 1.27994 1.28803 RAI14 1.05627 1.22371 
GLYCTK 1.0942 1.19769 RAP1GDS1 1.11381 1.06734 
GUF1 1.08906 1.04166 SFXN4 1.00284 -1.01034 
HEMK1 1.23966 1.34036 SHMT1 -1.10275 -1.1961 
LDHA -1.06593 -1.03196 SRI 1.03843 -1.01021 
LETM2 1.59791 1.46854 TFB1M 1.20072 1.16305 
LIG3 1.10457 1.02883 TMEM70 1.03425 -1.07544 
LRPPRC 1.04112 -1.01491 TOMM70A 1.04083 -1.01414 
LYN 1.03942 -1.02029 TRAK1 1.10276 1.17932 
LYRM4 1.16338 1.04836 TRMT10C 1.06115 -1.0453 
MAP2K1 1.19618 1.1732 UROS 1.03531 -1.02063 
MCU 1.03248 -1.01273 USMG5 1.06013 1.02589 
MFF 1.07091 1.02748 VDAC1 1.04226 1.0086 
(FC.EF: fold-change after EFV treatment; FC.SP: fold-change after SPV treatment) 
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Figure S5-1 The ALDHhigh cells were detected via ALDEFLUOR assay in untreated- and SPV-
treated MCF10A, MCF10AT, MCF10CA1α, MDA-MB-231, and T47D cells 
The dots inside the frame lines represent the cells with high ALDH activities. The frame lines were set 
based on their ALDH suppression controls. 
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Figure S5-2 The CD44+/ CD24- cells were detected in untreated- and SPV-treated MCF10AT, 
MCF10CA1α, and MDA-MB-231 cells 
The dots in the up-left corner represent the CD44+/CD24- mesenchymal-like CSCs. The frame lines were 
set based on their unstained controls. 
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Figure S5-3 Side populations detected via the Hoechst 33342 staining method in MCF10A, 
MCF10AT, MCF10CA1α, MDA-MB-231, and T47D cells                    
The dots inside the frame lines represent the cells with high dye efflux abilities. 
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Figure S5-4 Morphological changes in MCF10AT and MCF10CA1α cells were observed after 
treating cells with antiretroviral drugs for 4 days 
Scale bar: 100 µm 
 
 
Figure S5-5 The phenotypes of sorted-CD44+/CD24- cells after 24 hours of drug treatment 
Sorted CD44+/CD24- cells were re-cultured in the normal culture medium. When cells attached and 
re-grew, the cells were treated with antiretroviral drugs. After 24 hours of drug treatments, most of 
the drug-treated cells died. The small black dots were the dead cells (Scale bar: 500 µm) 
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Table S5-1 The numbers of tumorspheres being formed after 7 days of EFV treatment 
Number of spheres 
/104 cell-seeded 60-100 µm 100-200 µm 200-400 µm >400 µm total 
MCF10A control 9.5 5 14 14 7 16 6 2 7 1 1 1 30.5 15 38 
EFV 7.5 5 22 3.5 3 7 0.5 4 1 0 1 0 11.5 13 30 
MCF10AT control 36 47 19 27 46 46 11 11 15 9 7 3 83 111 83 
EFV 6 4 6 8 5 0 4 0 0 0 0 0 18 9 6 
MCF10CA1α control 95 79 45 91 115 53 37 33 27 3 9 8 226 236 133 
EFV 5 6 4 29 4 2 5 0 0 0 0 0 39 10 6 
MDA-MB-
231 
control 90 93 126 179 336 315 160 92 112 63 0 9 402 428 436 
EFV 10 37 5 6 17 0 2 0 0 0 0 0 8 17 0 
BT-549 control 12 27 45 38 20 50 31 24 22 34 30 32 115 101 149 
EFV 13 2 44 27 5 34 8 2 7 0 0 0 48 9 85 
BT-20 control 76 129 108 105 158 174 57 50 57 25 3 4 187 211 235 
EFV 23 47 26 70 43 22 12 0 0 0 0 0 82 43 22 
T47D control 43.5 57 46 61 119 90 40 54 43 30 27 10 131 200 143 
EFV 7 3 30 7 9 16 0.5 0 0 0 0 0 7.5 9 16 
 
 
Table S5-2 The Student t-test results for analysing the changes of antiretroviral drug-treated 
tumorspheres 
T-Test 60-100 µm 100-200 µm 200-400 µm >400 µm total 
MCF10A 0.28996 0.02877* 0.17280 0.091752 0.095816 
MCF10AT 0.04042* 0.02546* 0.02068* 0.03478* 0.00829** 
MCF10CA1α 0.02092* 0.02797* 0.00182** 0.03476* 0.01232* 
MDA-MB-231 0.02287* 0.01521* 0.0126* 0.17340 0.00167** 
BT-549 0.21179 0.00585** 0.00773** 0.00065** 0.00700** 
BT-20 0.00870** 0.05013 0.00234** 0.13767 0.01417* 
T47D 0.04191* 0.02005* 0.00455** 0.03486* 0.01705* 
(one-tail, paired Student’s t-test, *p<0.05; **p<0.0
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